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Abstract 
A third of patients with critical limb ischaemia (CLI) eventually require amputation.  
Inconsistencies between successful revascularisation and functional outcomes exist, 
and underlying musculopathy in CLI patients has been identified.  Erythropoietin 
(EPO) has tissue-protective effects in response to ischaemic injury, but its clinical use 
is often precluded by thromboembolic side effects.   
Non-haematopoietic EPO-derivatives have been designed to retain only tissue-
protective functions of EPO.  We hypothesised that ARA-290 (EPO-derivative) may 
have tissue-protective potential that could represent a novel therapeutic adjunct in 
patients with CLI. 
The effect of EPO and ARA-290 in mediating cytoprotection in an in vitro simulated 
ischaemia model of skeletal muscle was assessed firstly in the immortalised murine 
C2C12 myoblast cell line and subsequently in skeletal myoblasts isolated from CLI 
and control donors.  In human and murine cells, simulated ischaemia alone 
demonstrated a detrimental effect on cell function and survival.  Addition of EPO or 
ARA-290 demonstrated significant improvements in function and survival and utilised 
JAK2/STAT3, PI3k/Akt and NF!B signalling molecules. 
Isolation of human skeletal myoblasts from CLI patients has not previously been 
described.  Comparison of CLI and control myoblasts elucidated significant 
differences in their function and survival under both normoxic and simulated 
ischaemic conditions.  CLI myoblasts and myotubes exhibited increased proliferative 
capacity but reduced migratory and contractile function and importantly a reduced 
susceptibility to a second ischaemic-insult compared with control myoblasts and 
myotubes. 
Evaluation of several variations in the hindlimb ischaemia model allowed the creation 
of a model which closely recapitulated the muscular pathology observed in human CLI 
patients.  ARA-290 demonstrated improved functional, histological and perfusion 
outcomes compared to EPO or vehicle-control treated animals.   
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These studies demonstrate the potential of ARA-290 to protect tissues and cells from 
ischaemic-injury and encourages the development of novel pharmacological therapies 
for use in patients with “no option” CLI or severe functional deficit. 
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CHAPTER 1  
General Introduction 
1.1 Peripheral Arterial Disease 
Peripheral arterial disease (PAD) encompasses a continuum of disease states that result 
from the narrowing or obstruction of any artery excluding the coronary or intra-cranial 
vessels.  Most often, narrowing or obstruction of these vessels is due to build up of 
atherosclerotic plaques, which perturbs and eventually prohibits blood flow.   
1.1.1 Epidemiology, risk factors and natural history 
PAD is a significant healthcare problem in the Western world, where prevalence 
increases sharply with age.  PAD will affect less than 5% of the general population 60 
years of age and less [1, 2], however in those aged over 75 years, prevalence will have 
risen to 20% of the population [1-3].  It is estimated however that the true prevalence 
of PAD may be three or four times higher, when taking into account those individuals 
who are asymptomatic [4].  The age-adjusted prevalence of PAD is approximately 
12% [5], which equates to approximately 27 million individuals with PAD in Europe 
and North America [6].  Although male gender is a well-recognised risk factor for 
atherosclerosis, some disparity exists in the literature to exact rates of PAD affliction, 
at all stages of disease, with regards to gender.  Various reports will suggest higher 
prevalence in one or other gender, as well as both genders being equally affected with 
PAD [1, 2, 5, 7, 8].   
As a result of population aging, increased life expectancy, better management of 
traditional cardiovascular risk factors (discussed below) and the increasing prevalence 
of diabetes mellitus, it is likely that the burden of PAD will increase in the coming 
years [9]. 
Risk factors 
Atherosclerotic lesions of limb arteries are the most common factor underpinning 
development of PAD.  Various risk factors for developing and accelerating the 
formation of atherosclerotic plaques have been identified, and these are almost 
identical to the risk factors for developing PAD.  They include increasing age (over 40 
 20 
years), diabetes mellitus, dyslipidaemia, hypertension [10, 11], and cigarette smoking 
[12-17].  Other associations for developing PAD include hyperhomocysteinaemia, 
raised C-reactive protein, chronic renal insufficiency and hyperviscosity and 
hypercoagulable states [14, 18].  Considering the numerous shared risk factors for 
PAD and coronary artery disease (CAD), as well as the similarities in disease 
pathogenesis, there is a significant association between PAD and CAD, with 
approximately 21–33% of patients undergoing surgical management of CAD found to 
have PAD [14, 19] and conversely, between 60–92% of PAD patients who have 
concomitant CAD [20-24].  
Natural history 
The natural history of PAD is a slow progression of symptoms over time.  This is due 
in part to the nature of atherosclerotic development and evolution.  As an 
atherosclerotic plaque continues to accumulate, narrowing of the artery becomes 
critical until the entire lumen may become occluded.  This explains the diversity in the 
spectrum of PAD, where it is estimated the prevalence is underestimated due to the 
initial asymptomatic nature of PAD [15].  Even after symptoms begin to present, the 
time-course of progression tends to be highly variable, and can be prolonged 
significantly on strict modification of risk factors.  The spectrum of PAD therefore 
ranges from asymptomatic disease to intermittent claudication (IC) to critical limb 
ischaemia (CLI).  One third of patients with PAD in the lower limbs will have IC.  
Within this group, approximately 30% of patients will have disease progression 
towards CLI.  The incidence of CLI is estimated at between 500–1000 per million 
population per year in Europe and North America [25].  Of those patients who 
progress to CLI, 40% will require an amputation within 6 months, due to various 
reasons (discussed below) including patient co-morbidities, or anatomical lesion 
difficulties, and 20% will have died within a year [4].  There is a cumulative 
amputation rate of approximately 10% at 10 years [26]. 
1.1.2 Clinical presentation and classification 
Approximately one third of patients with PAD will present with typical symptoms of 
IC, which is defined as “leg pain sufficient to cause the patient to stop walking, which 
is produced by exercise and relieved by rest, and is caused by arterial occlusive 
disease” [5, 27].  Limb pain will often be localised to the calf muscle; however the 
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affected muscle group will depend on the distribution of the atherosclerotic lesion.  
Disease of the abdominal aorta or iliac arteries can result in calf, thigh or buttock 
claudication, whereas disease of the superficial femoral artery in the thigh will present 
with calf pain. 
In those individuals who are initially asymptomatic and manage to escape detection of 
IC and progress onto CLI, the first presentation will be with constant and intractable 
pain at rest, with tissue loss of non-healing ulcers.  Approximately 2% of patients will 
have an initial presentation with symptoms of CLI without previous IC symptoms [4].  
The clinical definition of CLI is “chronic ischaemic rest pain, ulcers or gangrene 
attributable to objectively proven arterial occlusive disease” [27, 28].   
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Figure 1.1: Typical features of PAD 
Early features of PAD include intermittent claudication, causing pain on exertion (A).  
As PAD progresses to CLI, patients will often suffer from chronic ulcers and gangrene 
(B and C), occasionally requiring amputation (D and E). 
 
  
A B 
C D 
E 
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Classification  
Classification of PAD is most commonly represented by the Fontaine stages and the 
Rutherford categories (Table 1.1).  The Fontaine classification was introduced in 1954 
by René Fontaine for ischaemia [29].  A more recent classification system, the 
Rutherford categories, was developed in 1997 [30].  Both classification systems are 
used clinically to determine improvements following treatment.  An upward shift of at 
least one category is required to denote symptomatic improvement, the exception 
being patients with tissue loss, who must improve to a stage of claudication for 
treatment to be considered as improved.  
Table 1.1: Classification of PAD: Fontaine’s stages and Rutherford’s categories 
Fontaine’s Stages  Rutherford’s Categories 
Stage Clinical description  Grade Category Clinical description 
I Asymptomatic  0 0 Asymptomatic 
IIa Mild claudication  I 1 Mild claudication 
IIb Moderate to severe claudication  I 2 Moderate claudication 
   I 3 Severe claudication 
III Ischaemic rest pain  II 4 Ischaemic rest pain 
   III 5 Minor tissue loss 
IV Ulceration or gangrene  IV 6 Ulceration or gangrene 
Mild claudication is described as the distance moved before symptoms of claudication 
(claudication distance) > 50m.  Moderate claudication = claudication distance < 50m or 
completion of treadmill test with ankle pressures post-test > 50mmHg.  Severe claudication = 
unable to complete treadmill test or ankle pressure post-test < 50mmHg.  
 
1.1.3 Diagnostic modalities 
Differentiating between symptoms of claudication and other mechanical (e.g. hip 
arthritis) or medical (e.g. nerve root compression or spinal stenosis) leg conditions is 
essential for the prompt and accurate diagnosis of PAD necessary to ensure 
appropriate management of PAD symptoms and risk factors.  A comprehensive and 
detailed clinical history and examination will usually identify those individuals with 
classical symptomatic IC who refer to a history of pain on exertion, relieved by rest.  
Similarly, symptomatic CLI individuals will complain of pain at rest with or without 
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the presence of gangrene, ulcers or tissue loss.  In addition, both groups on 
examination may reveal a pale limb with absent distal pulses.   
Systematic history-taking and thorough clinical examination is usually adequate to 
give a diagnosis of PAD, however often further objective testing is required to either 
confirm the presence or reveal the location and severity of disease.  This will usually 
fall into two categories: 1. Non-invasive, surrogate markers of blood flow or 2. 
Imaging of the peripheral vasculature, which can be both invasive and non-invasive.   
1.1.3.1 Surrogate markers of blood flow 
Simple diagnostic tests which allow easy measurement of haemodynamics and 
therefore underlying limb perfusion are useful to identify those patients at risk, with 
disease, as well as providing an indicator of disease location and severity.  Included in 
these tests are the ankle-brachial pressure index (ABPI), toe-brachial pressure index 
(TBPI), segmental limb pressures and transcutaneous oxygen pressure (TcPO2). 
ABPI and TBPI: The ABPI is an important and commonly used diagnostic tool in the 
evaluation of PAD, which is inexpensive and simple to perform in the majority of 
clinical settings.  It is measured using a handheld continuous-wave Doppler ultrasound 
probe and a blood pressure cuff: the highest systolic pressure reading from either the 
dorsalis pedis or posterior tibial artery (in each leg) is divided by the highest brachial 
artery pressure reading taken from both arms, with the patient lying in a supine 
position.  The ABPI is useful in providing a measure of the severity of PAD, as well as 
excluding individuals with other exercise-related leg pain (e.g. osteoarthritis), and for 
the detection of PAD of the contralateral limb, which may be masked by more severe 
symptoms in the symptomatic leg.  The normal range of ABPI is between 0.91–1.31 
[31, 32].  ABPI values between 0.41 and 0.90 are usually indicative of mild to 
moderate claudication disease, whilst values less than 0.40 tend to correlate with 
patients who have CLI with ischaemic rest pain [33].  In patients who have a ratio 
greater than 1.31, PAD cannot be excluded, as this is likely to be due to the presence 
of incompressible, calcified arteries, which tends to be more prevalent in patients with 
concomitant PAD and diabetes or end-stage renal disease [3, 34].  In these patients, the 
toe-brachial pressure index provides a more accurate measure as the digital vessels are 
usually spared from calcification [35, 36].   
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Toe-brachial pressure index (TBPI) utilises small occlusive cuffs, placed around 
usually, the proximal portion of the 1st and 2nd digits, to provide a more accurate 
systolic pressure reading.  TBPI should be greater than 0.75 in healthy individuals.  A 
TBPI value of less than 0.7 is considered abnormal and a value less than 0.25 is 
suggestive of CLI in patients [37]. 
The ease of ABPI measurement, as well as the high sensitivity (80–95%) and 
specificity (95–100%) of ABPI has established its role in the initial evaluation of PAD 
patients [28, 38].   
Segmental limb pressures: Information on the anatomical location of disease can be 
gained using segmental limb pressures.  Based upon the same methodology as ABPI, 
the blood pressure cuff is used to take a brachial blood pressure reading, and then 
sequential leg pressures.  Measurement by Doppler ultrasound is taken at the most 
obvious ankle arterial signal as the blood pressure cuff is placed at various points from 
the upper thigh down to the lower thigh, upper calf, ankle and metatarsal.  A 
comparison of the pressures obtained at different levels allows initial detection of the 
location of arterial occlusion [33].  Whilst this technique is useful to localise lesions, it 
is less sensitive and specific when there is multi-level disease, calcified arteries or 
long-segment lesions.  In addition artefacts may occur due to inappropriate cuff sizes 
or positioning [26, 39]. 
Both ABPI and segmental limb pressures are useful for the first-line identification of 
disease severity and general location, but tend to need supplementation with more 
advanced laboratory imaging such as duplex ultrasound (DUS). 
Transcutaneous oxygen pressure (TcPO2): is performed using small electrodes 
consisting of a central platinum cathode surrounded by a circular silver-silver chloride 
anode which are placed directly onto the skin of the lower limbs.  Oxygen that diffuses 
to the skin is reduced at the cathode to produce a current proportional to the partial 
pressure of oxygen (PO2) within the sensor [33].  TcPO2 is usually measured on the 
dorsum of the foot or anteromedial aspect of the calf.  A TcPO2 of <30mmHg is used 
as an indication of CLI according to TASC II guidelines [4].  Measurement of TcPO2 
is useful in assessing the severity of limb ischaemia and to identify those with ulcers 
that would benefit from revascularisation.  It is not routinely performed however, due 
to the sensitive and time-consuming nature of the test, which is easily influenced and 
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affected by numerous factors, including skin temperature, sympathetic tone, metabolic 
activity, cellulitis, hyperkeratosis and oedema [33]. 
1.1.3.2 Imaging of the peripheral vasculature 
Due to the often complex nature of disease in patients with CLI, it is useful to image 
the vascular tree from the renal arteries to the pedal arch, in order to identify precise 
anatomical location and extent of disease, and the amenability of obstructions to 
revascularisation therapies and to guide treatment. 
Duplex ultrasound (DUS): DUS is useful in identifying and delineating the 
anatomical location, as well as the degree of disease.  It combines a B-mode 
ultrasound with a colour Doppler ultrasound in order to assess narrowings in the vessel 
and the impact on blood flow.  The B-mode ultrasound allows visualisation of vessel 
architecture, and therefore shows the direct interaction of a plaque with the vessel in 
areas with narrowings or obstruction.  The colour Doppler then adds to this image by 
allowing visualisation of blood flow through the artery.  Blood flow velocity tends to 
increase in areas of stricture, and this allows correlation of increased velocity with an 
area of narrowing.  This is also the cause of certain limitations of DUS in multi-level 
disease analysis where the detection of downstream stenoses is less sensitive, as the 
more proximal lesions tend to slow onward flow [40].  It is also a highly operator-
dependent imaging modality, with artefact also prominent in supra-inguinal lesions 
when patients are of certain body habitus, or due to overlying bowel gas [41].  DUS is 
useful in identifying the anatomical location, which can help decide on the feasibility 
of different interventions, and is non-invasive and less expensive than other imaging 
techniques.  It is also frequently used for post-revascularisation surveillance of bypass 
grafts and endovascular stents [42, 43]. 
Computed tomography angiography (CTA): CTA enables scanning of the entire 
vascular tree at high spatial resolution within a very short period of time.  This reduces 
the amount of contrast medium required, as well as radiation exposure.  However, the 
requirement for iodinated contrast media is associated with a 16.8% risk of contrast-
induced nephropathy in high-risk patients (including those with underlying renal 
impairment or diabetes).  Fortunately only 1% of these progress to require renal 
replacement therapy [44].  Exposure to radiation is estimated as approximately 
7.47mSv, though some centres have reported higher doses, but it has been suggested 
 27 
that the risk of radiation dose in patients with advance PAD is of less concern due to 
their already shortened life expectancy.  However physicians need to be aware of CTA 
use in younger patients, where the latent-period of radiation-induced malignancy is 
within their life expectancy.  Meta-analysis of CTA has shown its utility with high 
sensitivity (95%) and specificity (96%) for greater than 50% stenosis, as well as 
excellent inter-observer agreement [45]. 
Magnetic resonance angiography (MRA): In similar fashion to both DUS and CTA, 
MRA of the peripheral vasculature is useful in the anatomical localisation as well as 
investigating the extent of PAD.  Technological advances have also enabled multiple 
imaging platforms such as 2-dimensional time of flight, 3-dimensional with or without 
contrast-enhanced visualisation of the vascular system amongst others.  These imaging 
techniques can also be used in combination, allowing fairly robust and accurate 
imaging of the lower extremity vascular system, and any disease which may be present 
[46].  3D contrast-enhanced MRA (ceMRA) has been extensively reviewed and 
compared within the MRA umbrella to other MRA techniques, as well as to other 
imaging techniques, such as CTA.  MRA showed superior sensitivity and specificity, 
95% and 97% respectively, when compared to other imaging modalities [47].  In 
addition the potential side effects tend to be lower – less than 1% of all patients had 
anaphylactic reactions to the gadolinium contrast [48], and MRA avoids the use of 
radiation.  MRA can also be performed in the outpatient setting, unlike CTA, which 
requires a short in-patient stay.  Certain scenarios prevent the use of MRA however, 
such as individuals with pacemakers, implantable cardiac defibrillators or aneurysm 
clips where the magnetic force used makes it unsafe to scan patients [49, 50]. 
In patients with severe renal impairment care should be taken to optimise individuals 
prior to gadolinium contrast-enhanced MRA due to the rare, but serious complication 
of nephrogenic systemic fibrosis (NSF).  Recent studies have suggested a causal 
relationship between gadolinium-based contrast agents and NSF in patients with 
chronic kidney disease stage 4 or 5, between 3–7% [51].  In patients on dialysis, some 
recent studies have reported 30% who receive gadolinium-based contrast agents 
developed NSF [52].  Patients with NSF develop rapidly progressive, widespread 
tissue fibrosis, affecting the skin, joints and internal organs (including the heart, lung, 
diaphragm, oesophagus and skeletal muscle).  The risk of developing NSF can be 
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reduced in patients with severe renal disease by increased hydration prior to 
administration of contrast, and prompt initiation of dialysis.   
Intra-arterial angiography: Digital subtraction angiography (DSA) has been a gold-
standard imaging investigation in PAD diagnosis against which many of the more 
modern imaging modalities is often compared with.  The technique is more invasive 
than a lot of the newer techniques, and involves administration of contrast to enhance 
visualisation of vessels, as well as exposure to radiation.   
Angiography carries a 0.1% risk of severe reaction to contrast medium, and a 0.16% 
mortality risk [4]. 
1.1.4 Medical and Interventional treatment and prognosis 
The highly progressive nature of PAD, a growing ability for primary care detection 
and the increased morbidity and mortality associated with disease have highlighted the 
importance of treating those with disease immediately and with multiple approaches.  
The majority of treatments can be categorised into medical or interventional 
management.  The requirement for more invasive intervention is usually reserved for 
those at the more severe end of the PAD spectrum, and those who are unresponsive to 
conservative medical management. 
1.1.4.1 Medical management 
The principal approach for treating patients with PAD is the aggressive modification 
of the risk factors of atherosclerosis, to slow the progression of PAD as well as the 
underlying atherosclerotic process.  In addition, treatment to provide symptomatic 
relief (pain and tissue loss) may also be required.  Risk factor modification is an 
absolute requirement due to the significant risk to patients with PAD of developing 
severe cardiovascular complications.  As described previously, greater than 60% 
patients with PAD will often have CAD.  As PAD progresses (and ABPI value 
decreases) risk of a major cardiovascular event – myocardial infarction or ischaemic 
stroke – as well as risk of mortality, increases [53-55]. 
The primary aim of cardiovascular risk factor management includes smoking 
cessation, treatment of dysplipidaemia using medical therapy as well as lifestyle and 
dietary modifications, and aggressive management of hypertension and diabetes.   
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Smoking cessation advice should be offered to patients with PAD due to the 
correlation of cigarette smoking with disease severity rates, mortality, graft-patency 
and rates of lower limb amputation [16, 56, 57].  In addition, meta-analysis has shown 
decreased patency rates of bypass grafts in smokers, but the ability to ameliorate 
patency rates when smoking is significantly reduced or stopped [58, 59]. 
Evidence for managing dyslipidaemia in PAD is in vast abundance.  A Cochrane 
review of 18 randomised control trials (RCTs) involving patients with PAD 
demonstrated a significantly reduced risk of cardiovascular events, especially coronary 
events whilst receiving statin therapy (odds ratio [OR]: 0.8; 95% confidence interval 
[CI]: 0.7-0.9) [60].  In patients with PAD and hypertension, current guidelines 
recommend a target blood pressure of $140/90 mmHg, or $130/80 mmHg if patients 
also have concomitant diabetes or renal insufficiency [61, 62]. 
In patients with concomitant diabetes, rigorous blood glucose control is key to 
preventing the known microvascular complications.  In comparison however, the 
effect of strict blood glucose control on improving the risk of macrovascular 
complications is less well evidenced.  The aim in diabetic PAD patients is currently to 
achieve a glycated haemoglobin (HbA1c) of <7% (53mmol/mol), or as close to 
normal, <6% (42mmol/mol), as an individual patient can achieve.  In addition, multi-
disciplinary involvement of podiatric services, to ensure adequate foot care and advice 
can help minimise the risk of developing diabetic foot complications.  The United 
Kingdom Prospective Diabetes Study, compared intensive pharmacological treatment 
with sulphonylureas or insulin with diet control alone, and showed a significant 
reduction in MI, but no significant reduction with regards to risk of death or 
amputation rate due to PAD (relative risk [RR]: 0.6; 95% CI 0.4-1.2) [63].    
Medical therapy for other PAD risk factors and earlier stages of disease is also 
advocated.  In patients who are not at risk of bleeding, and also have evidence of other 
atherosclerotic processes, anti-platelet therapy should be deliberated, as well as in 
those individuals undergoing infra-inguinal endovascular stenting, drug-eluting 
balloon angioplasty or below the knee open bypass surgery [53].  A meta-analysis of 
trials assessing the efficacy of anti-platelet therapy in patients with high-risk vascular 
disease demonstrated a 23% reduction in adverse cardiovascular incidents, including 
MI, stroke and vascular death.  Similar beneficial results were seen in patients with IC, 
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or those who had already undergone revascularisation therapies (angioplasty or bypass 
grafts) [64, 65]. 
Although no pharmacological agent has proved significantly efficacious alone to 
supersede surgical revascularisation, a number of drugs have been investigated, and 
are commonly used as an adjunctive therapy (in combination with revascularisation) or 
to aid in symptomatic relief where procedures have failed, or as a therapeutic 
alternative in patients not suitable for revascularisation [66].  The majority of the 
adjunctive therapies utilised in the treatment of PAD patients rely upon their ability to 
modulate the vasculature – so called ‘vasoactive’ drugs.  These include prostaglandin 
analogues (iloprost) and phosphodiesterase inhibitors (cilostazol and pentoxifylline).  
Iloprost, and other prostanoid-derived drugs demonstrated efficacy in treating rest pain 
(RR: 1.32, 95% CI 1.10 to 1.57) and ulcer healing (RR: 1.54, 95% CI 1.22 to 1.96), 
and iloprost treatment showed a reduction in major amputations (RR: 0.69, 95% CI 
0.52 to 0.93) in recent meta-analysis and systematic review [67].  The use of cilostazol 
in the treatment of PAD symptoms has been demonstrated to improve microvascular 
circulation [68], as well as improve rates of amputation-free survival but not overall 
survival or the need for repeat revascularisation [69]. 
In patients with claudication, the principal non-pharmacological treatment is a formal 
exercise-training program.  A Cochrane review of 22 trials with PAD patients with IC 
demonstrated that exercise programs conferred significant benefit in terms of walking 
distance and time for up to two years in comparison to routine medical therapy [70].  
However, exercise programs need to be supervised for the benefit to be observed, and 
last for a minimum of 6 months [28]. 
1.1.4.2 Interventional Management 
As peripheral arterial lesions progress and blood flow to the peripheries becomes 
compromised, vascular intervention is required to preserve both limb function as well 
as the limb itself.  Surgical intervention has two purposes therefore, firstly, to 
revascularise the limb, using various endovascular, surgical or hybrid techniques, and 
secondly, when vascular supply to the limb goes beyond a critical life-threatening 
stage, amputation of the limb to preserve life and remove non-viable tissue. 
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Revascularisation 
The decision to revascularise PAD patients is based on a number of factors including 
disease location and morphology, as well as the amenability of individuals to undergo 
revascularisation intervention.  With the constantly improving endovascular as well as 
hybrid fields, greater numbers of patients are suitable.  Determining the best method of 
revascularisation therapy to treat symptomatic PAD patients can loosely be modelled 
upon the TransAtlantic Intersociety Consensus II (TASC II) classification guidelines 
[18] summarised in tables 1.2 and 1.3 and figure 1.2 and 1.3.  In general, TASC ‘A’ 
lesions are deemed the most amenable to treatment using endovascular procedures; ‘B’ 
type lesions would benefit from endovascular treatment, unless concomitant open 
procedure is required for other lesions in the same anatomical region (e.g. 
endarterectomy); ‘C’ type lesions are best treated with open surgical revascularisation, 
with endovascular techniques reserved for patients at high-risk for open repair; ‘D’ 
type lesions should not primarily be treated with endovascular techniques, as it does 
not yield adequate results compared to open surgical treatment. 
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Table 1.2: TASC II classification of aorto-iliac lesions  
Lesion type Characteristic features 
A • Unilateral or bilateral stenosis of CIA 
• Unilateral or bilateral single short EIA stenosis ($3cm) 
B • Short stenosis of infrarenal aorta ($3cm) 
• Unilateral CIA occlusion 
• Single or multiple stenosis (3–10 cm) involving EIA, not 
extending into CFA 
• Unilateral EIA occlusion not involving origins of IIA or CFA 
C • Bilateral CIA occlusions 
• Bilateral EIA stenosis (3–10 cm) not extending into CFA 
• Unilateral EIA stenosis extending into the CFA 
• Unilateral EIA occlusion involving origins of IIA and / or CFA 
• Heavily calcified unilateral EIA occlusion with or without 
involvement of IIA and / or CFA origin 
D • Infra-renal aortic occlusion 
• Diffuse disease involving the aorta an both iliac arteries 
• Multiple, diffuse stenoses involving unilateral CIA, EIA and CFA 
• Unilateral occlusions of both CIA and EIA 
• Bilateral occlusions of EIA 
• Iliac stenoses in patients with AAA requiring treatment not 
amenable to endovascular stent grafting, or other lesions requiring 
open surgery 
CIA – common iliac artery, EIA – external iliac artery, CFA – common femoral artery, IIA – 
internal iliac artery, AAA – abdominal aortic aneurysm.  Modified from [4]. 
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Figure 1.2: Diagram of TASC II classification of aorto-iliac lesions 
Type A lesions are most amenable to endovascular techniques.  Type D lesions are 
most amenable to surgical interventions.  Type B and C lesions can be managed using 
either endovascular or open surgical techniques depending on the requirements and 
risk factors of individual patients.  
Type A 
lesions 
Type B 
lesions 
Type C 
lesions 
Type D 
lesions 
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Table 1.3: TASC II classification of femoral-popliteal lesions  
Lesion type Characteristic features 
A • Single stenosis $ 10cm in length 
• Single occlusion $ 5cm in length 
B • Multiple lesions (stenoses or occlusions) each $5cm 
• Single stenosis or occlusion $15cm not involving the popliteal 
artery below the knee 
• Single or multiple lesions in the absence of continuous tibial 
vessels to improve inflow for a distal bypass 
• Heavily calcified occlusion $5cm in length 
• Single popliteal lesion 
C • Multiple stenoses or occlusions totalling > 15 cm with or without 
heavy calcification 
• Recurrent stenosis or occlusions that require treatment following 
two endovascular interventions 
D • Chronic total occlusion of CFA or SFA (>20cm involving the 
popliteal artery) 
• Chronic total occlusion of popliteal artery and proximal 
trifurcation vessels  
CFA – common femoral artery, SFA – superficial femoral artery.  Modified from [4]. 
 35 
 
Figure 1.3: Diagram of TASC II classification of femoral popliteal lesions 
Type A lesions are most amenable to endovascular techniques.  Type D lesions are 
most amenable to surgical interventions.  Type B and C lesions can be managed using 
either endovascular or open surgical techniques depending on the requirements and 
risk factors of individual patients. 
The decision to treat patients, based on TASC II classification, has limitations as the 
majority of PAD patients have multi-level disease lesions, which may not be 
represented by the classification system. 
Advances in endovascular techniques have increased the treatment options for patients 
to undergo minimally invasive percutaneous therapies.  Currently available 
endovascular revascularisation techniques include percutaneous transluminal 
angioplasty with balloon dilatation, subintimal angioplasty, stenting (using bare metal 
Type A 
lesions 
Type B 
lesions 
Type C 
lesions 
Type D 
lesions 
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or drug-eluting stents), laser atherectomy, cryoplasty and thermal angioplasty [71].  
Whilst early and mid-term outcomes demonstrate highly promising limb salvage rates 
of greater than 80%, substantial evidence of outcomes has also demonstrated a high 
proportion of restenosis and need for re-intervention [72-74].  Currently the only, 
multi-centre prospective randomised trial comparing traditional surgical bypass with 
endovascular angioplasty, the BASIL (Bypass versus Angioplasty in Severe Ischaemia 
of the Limb) trial, has demonstrated that at both 3 and 7-year follow-up, bypass 
surgery using autologous vein provides the best long-term amputation-free survival 
[75, 76]. 
Traditional surgical techniques – endarterectomy or bypass – are more commonly 
required to treat patients with significant symptoms despite medical management and 
where anatomy of arterial lesions is amenable to bypass surgery.  Where possible, 
when performing infra-inguinal bypasses, autologous vein is used as the bypass 
conduit.  Synthetic grafts have a higher risk of graft occlusion and lower patency rates 
in comparison, and are therefore not recommended [28].  Meta-analysis of CLI 
patients undergoing infra-inguinal bypass reported 5-year primary graft patency at 
64%, secondary patency rate of 71% and limb salvage as 78% [77]. 
Hybrid interventions – a combination of endovascular and open surgical techniques – 
are being used more frequently for complex multi-level arterial lesions of the lower 
limb in specialist centres, with excellent technical success rates.  However long-term 
outcomes are less clear at present.  Early reporting on mid-term outcomes following 
hybrid procedure have suggested patency rates of greater than 70% at 1 year and 60% 
at 5 years, as well as limb salvage rates greater than 83% [78-82]. 
Amputation 
Despite advances in endovascular and hybrid techniques, many patients will still go on 
to require lower limb amputation for non-viable limbs or where the arterial disease is 
not amenable to revascularisation.  Indications that identify patients requiring 
amputation include unreconstructable peripheral vascular disease, usually due to the 
lack of runoff vessels distally, fixed flexion deformities or extensive tissue loss [83].  
The incidence of major lower limb amputation varies from 120–500 per million/year, 
with almost equal rates of above-knee or below-knee amputations [18, 84].   
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1.1.4.3 Prognosis 
The natural history of PAD is a slow progression of symptoms over time; however the 
time-course of progression is highly variable, and can be prolonged significantly on 
strict modification of risk factors.  Limb-loss in patients suffering from claudication 
symptoms is a major fear, however in these patients, the risk of suffering from an 
adverse cardiovascular or cerebrovascular event is much greater.  Recent studies have 
suggested a 5-year risk of major amputation in IC patients of only 1–3.3% [4].  In 
contrast however, once symptoms of CLI appear (rest pain, frank tissue-loss, gangrene 
and non-healing ulcers), prospects become far bleaker, with approximately 40% 
requiring major amputation and a mortality rate of up to 20% within 6 months [4].  
The prognosis following amputation continues to deteriorate.  The peri-operative 
mortality for below-knee and above-knee amputation is between 5–10%, and 15–20%, 
respectively.  Of those who survive the post-operative period, less than half of 
amputees will have regained full mobility by two years, approximately 40% will die 
within 2 years of their amputation and 30% will require a second amputation [85-87].   
Whilst clinical, or physician-orientated outcomes, demonstrate successful 
revascularisation therapy, evidence details that patients do not observe functional 
benefits, and continue to show deterioration in their quality of life, and independence, 
and limitations in activities of daily living when surveyed.  This suggests a disparity 
between clinical and patient-orientated outcomes, which has been previously described 
[88-94].  These findings indicate that the underlying cause of the functional impedance 
patients with PAD describe may be due to more than haemodynamic compromise to 
the limb alone.   Attempts to improve muscle function and survival especially in 
ischaemic conditions may provide an additional avenue of treatment that could 
increase patient-orientated outcomes. 
1.1.5 Pathology of muscle dysfunction 
Although it is widely accepted that PAD is a manifestation of systemic atherosclerotic 
disease – and the narrowing and obstruction of vessels is the primary catalyst that 
leads to an impairment of blood flow to tissues – the resultant haemodynamic 
alteration does not entirely explain the pathophysiology or mechanisms of functional 
impairment in PAD patients [95, 96].    
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Research conducted in the last decade has implicated ischaemia-related pathological 
changes within various limb muscle groups, and in particular calf muscle, which may 
contribute to the functional decline patients’ experience including functional changes, 
histomorphological changes such as muscle fibre type shift, mitochondrial dysfunction 
and metabolic alterations, oxidative stress and neuropathy in PAD skeletal muscle. 
1.1.5.1 Functional changes 
The functional impairment experienced by PAD patients usually manifests as 
claudication, either intermittently or also experienced at rest.  This results in 
significantly reduced walking speed and distance as well as pain in muscle groups – 
either at rest or during exercise.  Whilst the obvious explanation would appear to be 
the effect of poor blood flow and therefore oxygen delivery to tissues, various groups 
have established that there is very little correlation between haemodynamic flow 
limitations in the limb and claudication-associated functional disability [39, 97-99].  In 
addition, various invasive revascularisation therapies do not completely improve 
exercise performance (a measure of functional benefit) despite observable 
improvement in haemodynamic capacity [100, 101], whereas conversely, prescribed 
exercise rehabilitation has some amount of established efficacy [102-104]. 
Measurement of muscle strength in PAD patients using a 5-second maximal isometric 
strength assessment – a test which is entirely blood flow-independent – demonstrated 
significantly reduced muscle strength in PAD patients suggesting that there was in 
addition an intrinsic muscle weakness unaffected by any acute haemodynamic 
restriction [105].  
1.1.5.2 Histomorphological changes and muscle fibre type shift 
Examination of PAD skeletal muscle using both light and electron microscopic 
evaluation has revealed numerous myopathic and neuropathic changes that appear to 
correlate with disease severity.  Characteristic alterations observed in PAD muscle 
tissue include fibre size diversity, central nuclei, endomysial fibrosis, apoptosis and 
necrosis, phagocytosis and type II muscle fibre atrophy [106-110].   
Adult skeletal muscle is composed of repeated sarcomeres – a basic functional unit 
that contains the protein filaments actin and myosin that gives skeletal muscle its 
characteristic striated appearance.  These two components then interact when 
necessary to allow contraction.  Skeletal muscle can be categorised depending on the 
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type of myosin present in the muscle fibres.  Broadly speaking there are two categories 
of myosin heavy chain (MHC) classes: type I and type II [111].  They differ in terms 
of appearance as well as activity.  Type I fibres appear red due to a greater presence of 
myoglobin – an oxygen binding protein, that therefore makes type I fibres well-
adapted to a role in oxidative or aerobic metabolism in order to generate adenosine 
triphosphate (ATP) an “energy unit” utilised by muscle, that can provide prolonged 
muscle contractions.  On the other hand, type II muscle fibres (of which there are 3 
isoforms) [112] appear white due to the relative absence of myoglobin, which means 
they are better at very intense, fast or powerful movements, which are short lasting, 
through anaerobic glycolysis in order to provide ATP.  These fibres tend also to 
fatigue much faster.  Skeletal muscle fibres have a great capability to change both size 
and fibre type composition in order to meet with changing demands.   
A variety of methods now exist in order to determine fibre type, each stain exploiting 
one of the differences between the two fibre types.  These include myofibrillar ATPase 
staining – which exploits the difference in ATP generation by type I and II fibres, 
succinate dehydrogenase – which takes advantage of differences in oxidative potential, 
and #-glycerophosphate dehydrogenase which depends on differences in glycolytic 
activity.  In addition antibodies against specific MHC isoforms have also been 
developed with some finding popular commercial use [113]. 
In human skeletal muscle, though it varies depending upon the exact muscle under 
analysis, both muscle fibre types will be present.  In the majority of muscle groups 
there tends to be a roughly equal distribution of both fibre types, however some 
muscles will have a more polarised representation by one fibre type.   
In addition to generalised variation in muscle fibre diameter and atrophy, various 
groups have demonstrated a shift in muscle fibre type in chronic PAD sufferers 
towards type I fibres [108, 114-116].  Although these differences have been noted, it is 
not entirely understood whether the plasticity in muscle fibre type is as a consequence 
of PAD cellular pathology (especially the notable mitochondrial and metabolic 
dysfunction), or whether it results from the simple deconditioning that often occurs as 
PAD severity and patient inactivity increases. 
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1.1.5.3 Mitochondrial dysfunction and metabolic alterations 
Evidence of abnormal mitochondrial activity was suggested as far back as 1975 when 
a study into the effects of carbohydrate supplementation on exercise time in 
claudication PAD patients demonstrated a significant increase in the glycogen content 
of their muscle, as well as increased exercise tolerance.  Leading on from this work, 
various groups have since demonstrated that the mitochondria from chronically 
ischaemic leg muscle have an aberrant dysregulation of a number of metabolic 
processes.  Isolation of mitochondria from the calf muscle of claudicants demonstrated 
that the rates of pyruvate dehydrogenase-dependent oxidation of carbohydrates was 
positively correlated with walking performance and increased with exercise training 
[117].  This suggested that although mitochondrial carbohydrate oxidation is abnormal 
in claudication PAD, the mitochondrial function is not entirely impaired, and is 
amenable to exercise-training. 
Further studies into the mitochondrial ability to oxidise other metabolites (including 
lipids, proteins and carbohydrates) by examining acylcarnitine levels also established 
an imbalance in PAD patients.  In normal states, fat, protein and carbohydrate 
substrates will first be converted into acyl-coenzymeA (acyl-CoA) intermediates 
before entering into and undergoing complete catabolism through a series of oxidative 
steps which make up the Kreb’s cycle.  When mitochondrial metabolism is interrupted, 
incomplete oxidation of acyl-CoAs occurs, causing their accumulation, which acts in a 
negative-feedback fashion to inhibit their continued production.  However, the 
presence of the carnitine system, which acts as a buffer for acyl-CoAs, allows the 
existence of excess acyl-CoAs by collecting their acyl groups to become acylcarnitine.  
This in turn causes a rise in acylcarnitine concentration, which can be measured in 
both tissue and plasma, and acts as a biomarker for poor mitochondrial uptake and 
oxidation of acyl-CoA in PAD [118].  Other groups have also demonstrated that 
acylcarnitine levels are associated with walking performance in PAD patients, and are 
amenable to exercise training [119-121]. 
In vivo analysis looking for evidence of a mitochondriopathy uses techniques of 31P 
nuclear magnetic resonance spectroscopy (MRS).  31P MRS is a non-invasive tool that 
provides information on the relative intracellular concentrations of various 
phosphorous metabolites (including ATP, adenosine diphosphate (ADP) and 
phosphocreatine) as well as pH in order to allow the calculation of the rate of 
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phosphoenergetic reactions, which gives an indication as to the bioenergetics 
occurring.  Various pathological conditions can therefore be characterised by their 
different metabolic signatures.  In PAD patients after maximal exercise testing, 
31PMRS has displayed a prolonged rate of recovery suggestive of alterations in the 
oxidative phosphorylation processes, as well as evidence in support of a genuine 
dysfunction of mitochondria.  In addition, evaluation of human PAD limbs with 
different severity of ischaemic disease revealed the greatest level of mitochondrial 
dysfunction in the most severely affected limbs [118, 122]. 
1.1.5.4 Oxidative stress 
In addition to the specialised role mitochondria play in ATP-production, mitochondria 
also produce reactive oxygen species (ROS), which can directly and indirectly affect 
other cellular activity.  In normal resting state, more than 90% of the ROS found in a 
cell is produced by mitochondria [123] at 2 main sites – electron transport chain (ETC) 
complexes I and III [124, 125].  However, if damage occurs at these sites, ROS 
generation is exponentially enhanced [126, 127].   Various groups, using various 
techniques to study the different aspects of ROS generation, as well as clearance by 
intracellular antioxidants (such as manganese superoxide dismutase (MnSOD)) have 
shown that in PAD patients, there is a deficiency of electron transport chain (ETC) 
complexes I, III and IV [123, 128].  Coupled with the potential increase of ROS 
production due to damaged complexes, PAD patients also exhibit a scarcity of the 
antioxidant MnSOD [129].  Evidence of these two imbalanced forces being present in 
the mitochondria was also shown by analysis of ROS damage to lipids and proteins in 
PAD muscle, which demonstrated consistently increased protein oxidation and lipid 
peroxidation products [124]. 
1.1.5.5 Neuropathy  
Whilst the most noticeable symptom for patients with CLI is pain, this can often mask 
the presence of a general leg weakness, suggestive of an insidious neuromuscular 
dysfunction.  In addition to the histological changes mentioned above, muscle of PAD 
patients also demonstrates features of focal denervation of the muscle fibres (seen as 
muscle fibre group atrophy), and denervation-reinnervation characteristics (seen as 
grouping of fibre types).  Muscle fibre group atrophy occurs when a motor neuron 
becomes incapable of supplying a muscle fibre with its required excitatory and trophic 
stimuli, so that after a period of denervation, the muscle fibres become locked in the 
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flaccid state, and without stimuli from a nearby motor neuron begins to lose the 
majority of their contractile apparatus seen as a muscle fibre atrophy.  If however, the 
muscle fibre is ‘rescued’ by a neighbouring, healthy motor neuron, then the 
reinnervated fibre will begin to function like the new motor neuron which supplies it.  
This gives rise to the characteristic denervation-reinnervation morphology of fibre type 
grouping. 
Objective testing using nerve conduction and electromyographic techniques also 
identified a number of similar issues in muscle function in PAD patients including 
axonal neuropathy, demyelination and denervation-reinnervation.  The neuropathy 
observed in PAD whilst appearing predominantly to be motor neuropathy, has also 
been identified as causing a sensory deficit [118, 130]. 
 
1.2 Erythropoietin and erythropoietin-derivative  
 (ARA-290) 
In 1906 Carnot and Deflandre first postulated the idea of a hormone that was secreted 
into the blood stream that was responsible for the regulation of erythropoiesis [131] 
with its particular name, erythropoietin, introduced in 1948 [132]. EPO was first 
purified from the urine of patients suffering from aplastic anaemia [133].  With the 
purified urinary hormone, it was possible to partially identify the amino acid sequence, 
which was a major step forward in the process of producing recombinant human EPO 
(rHuEpo).  However, it took almost 8 decades before the gene encoding erythropoietin 
(EPO) was identified, cloned and expressed in 1985 [134, 135].   
Since Food and Drug Administration (FDA) approval was granted in 1989 for the use 
of erythropoietin in the treatment of renal anaemia, over several million patients with 
chronic kidney disease have benefitted from the numerous erythropoiesis stimulating 
agents (ESAs) available for correcting haemoglobin levels, reducing the requirement 
for transfusions, and improving quality of life and symptoms of anaemia, in particular 
fatigue [136].  Since then, a multitude of alternative actions of EPO have been 
discovered.  Amongst these novel roles, the cytoprotective properties of EPO in 
situations of ischaemia and metabolic stress have gathered significant interest from a 
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variety of different clinical specialities, linked via a common interest in ischaemia-
induced injury, such as ischaemic stroke and myocardial infarction [137-140]. 
Cells in the mammalian body have a requirement for oxygen when undergoing 
oxidative respiration, as well as many other biochemical reactions.  However oxygen 
concentrations in cells need to be finely balanced, as excessive oxygen can lead to 
undesirable oxidative damage of numerous cellular components, resulting in cell 
death.  Haemoglobin, contained within erythrocytes is responsible for oxygen delivery 
to tissues.  Usually, in healthy individuals, the fine balance between oxygen demand 
and delivery to all the tissues of the body will be maintained within strict parameters 
by the number of circulating erythrocytes.  The average life of a red blood cell is 
approximately 120 days, and each day approximately 1% of the circulating pool of 
erythrocytes will be removed [141], and replaced by an equal number of reticulocytes 
(immature erythrocytes).  As the increased numbers of reticulocytes replete the 
circulating numbers of erythrocytes, the rate of new reticulocyte production is retarded 
so that a rebound polycythaemia may not occur.  EPO is the principal mediator of this 
delicately tuned homeostatic process. 
1.2.1 Structure and expression of erythropoietin and erythropoietin receptor 
Erythropoietin 
The glycoprotein hormone EPO is a member of the type I cytokine superfamily.  Other 
members of the type I cytokine superfamily include interleukin (IL) –2, –3, –4, –5 and 
–6, granulocyte colony stimulating factor and granulocyte – macrophage colony 
stimulating factor (GM-CSF), leukaemia inhibitory factor and ciliary neurotrophic 
factor.  EPO is able to promote the growth, differentiation and survival of erythroid 
progenitors in the bone marrow, for the purposes of regulating red blood cell mass in 
circulation.  In embryonic development, hepatocytes and stellate cells within the liver 
are the primary site of EPO production.  Slowly after birth, hepatic production of EPO 
decreases until in the adult human, the peritubular fibroblasts of the renal cortex 
almost exclusively produce erythropoietin [142, 143].  However, EPO mRNA is also 
detectable in the brain, retina, heart, liver, spleen, lung and testis, confirming the 
presence of locally produced EPO [144-147].  Indeed, upregulation of hepatic EPO 
production can be as great as 20 – 50% of total EPO production, when stimulated by 
hypoxia [148, 149]. 
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The human EPO gene is located on the long arm of chromosome 7 (q11–q22) and 
contains 5 exons and 4 introns.  The exons encode a 193-amino acid prohormone that 
undergoes cleavage of a 27 amino acid leader sequence prior to secretion.  The 
secreted EPO hormone has a molecular mass of 30.4kDa.  This is composed of a 
peptide core and a glycosylated carbohydrate portion.  The carbohydrate portion of 
EPO accounts for approximately 40% of the mass of circulating EPO, and contains 4 
glycosylated chains [150], including 3 N-linked oligosaccharides at asparagines 24, 38 
and 83 and 1 O-linked oligosaccharide chain at serine 126 [151, 152].  The 
carbohydrate composition is necessary to increase the solubility and stability of the 
EPO glycoprotein in vivo [153, 154].  The peptide portion of the EPO protein is 
composed of approximately 165 amino acids arranged into a compact globular 
structure, due to its hydrophobic 4 #-helices (named A through D), which are 
responsible for receptor-binding.  Nuclear magnetic resonance spectroscopy has 
revealed that, like many other members of the type I cytokine superfamily, EPO shares 
the typical structure represented by four anti-parallel #-helices [155]. 
The coding region of the EPO gene, on analysis of both nucleotide and amino acid 
sequence, appears to be well conserved across mammalian species [156], with 91% 
sequence homology with monkeys [157], 85% identical with cats and dogs, and 80 – 
82% homology with mice, rats pigs and sheep [158, 159].  It is not surprising, 
therefore that there is a marked cross-reactivity between mammalian EPOs.   
Erythropoietin receptor 
The erythropoietin receptor (EPOR), like its cognate ligand, is part of the type I 
cytokine receptor superfamily.  Classically, this superfamily of receptors is composed 
of an extracellular domain, with highly conserved regions, a single hydrophobic 
transmembrane spanning region, and a highly variable cytoplasmic portion, with 
constitutively bound Janus kinases (JAK), due to the lack of intrinsic kinase activity, 
characteristic of this superfamily.  Mature human EPOR contains 484 amino acid 
residues, and has a calculated weight of 52.6kDa, which increases to approximately 
59kDa due to glycosylation and phosphorylation [160]. 
The extracellular domain of the EPOR is composed of approximately 230 amino acids.  
In addition, in keeping with other type I cytokine receptors, the extracellular domain 
contains four conserved cysteine residues and the WSXWS motif.  In the EPOR, this 
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corresponds to WSAWS.  The extracellular portion is also composed of 2 major 
fibronectin type III subdomains, which form a hinge-like structure where the two 
domains interact at 90° [161, 162].  Crystallographic analysis has demonstrated that 
the EPOR homodimerises through the hinge domain [161, 163], where they are 
separated by 73Å.  Ligand binding causes conformational alterations, which bring the 
two domains to within 39Å, crucial for subsequent signal transduction [164]. 
The intracellular, or cytoplasmic domain of the EPOR, like the majority of receptors 
within its superfamily, lacks enzymatic activity.  Comparison of the cytoplasmic 
domain sequence within the superfamily of receptors identifies regions within the 
proximal portion of the cytoplasmic domain that are conserved.  These regions – 
named box 1, box 2 and a region between box 1 and 2 are thought to be areas of EPOR 
association with JAK2, to compensate for the lack of kinase activity [164, 165].  
The presence of the EPOR outside of erythroid precursor cells has been detailed.  
EPOR mRNA and protein expression has been described in various tissues, many of 
which have already been noted above, due to the concomitant expression of EPO 
mRNA.  Additional regions demonstrating EPOR expression are pancreatic islet cells, 
renal mesangial and epithelial cells, skeletal muscle and the placenta [166-172].   
1.2.2 Hypoxic regulation of erythropoietin 
Hypoxia – a reduction in oxygen tension below the body’s needs – is the primary 
physiological stimulus of EPO gene expression in humans.  This is mediated via a 
family of transcription factors; known as hypoxia inducible factors (HIFs), which are 
specific DNA-binding transcription factors.  HIFs are responsible for oxygen 
homeostasis by utilising a spectrum of genes capable of providing hypoxic adaptation 
including angiogenesis, apoptosis, erythropoiesis, energy metabolism and vasomotor 
control [173, 174].  HIF is comprised of an oxygen-labile #-subunit and a 
constitutively expressed "-subunit.  In conditions of normal oxygen tensions, these 
subunits are found individually, but will form a heterodimer under conditions of low 
oxygen tension.  Three HIF-# splice variants exist, each targeting different 
transcriptional targets, although HIF-1 and HIF-2 share many common targets. The 
vast majority of present knowledge regarding EPO regulation is based on in vitro 
studies using human hepatoma cell lines (HepG2 and Hep3B) [143], but work is now 
moving into looking at the regulation of EPO synthesis in the kidneys.  Until quite 
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recently it was believed that HIF-1 was entirely responsible for the regulation of EPO 
production, but HIF-2 has since emerged as the principal regulator of EPO production 
in adults [175-179]. 
Under conditions of normal oxygen tension, the oxygen-sensitive HIF-# subunits 
undergo hydroxylation of conserved proline residues by prolyl-4-hydroxylase domain 
(PHD) containing enzymes [180-182].  Oxygen is required as a co-factor for PHDs 
catalytic activity.  This marks them for rapid proteasomal degradation by the von 
Hippel-Lindau tumour suppressor protein (pVHL).  pVHL acts as a substrate for E3-
ubiquitin ligase, and hence the subsequent ubiquitylation of HIF-#, in complex with 
pVHL, targets it for degradation by the 26S proteasome [183, 184].  In conditions of 
hypoxia, the lack of oxygen restricts the ability of PHDs to hydroxylate HIF-#, 
preventing their recognition by pVHL, and allowing the stabilised HIF-# to 
accumulate and associate with HIF-" in the nucleus [185].  Following the 
heterodimerisation of the two molecules, they are then capable of binding with 
hypoxia responsive elements (HRE), which are contained in various hypoxic 
adaptation genes, including the EPO gene.  Interestingly, some of the PHDs (PHD2 
and 3) are themselves under the regulation of HIF.  During chronic hypoxic exposure, 
as the expression of PHDs increases, HIF-1# levels decline [143]. 
Besides the HRE, other regulatory components exist within the EPO gene, including 
GATA sites.  In conditions of normoxia, EPO gene upregulation is suppressed by 
GATA-2 [186].  GATA-2 levels are then reduced in hypoxic conditions [187]. 
1.2.3 Erythropoietin mode of action 
Erythrocyte precursor cells, so called erythrocyte-blast forming and colony forming 
units (BFU-E and CFU-E), located within the bone marrow are the principal targets of 
EPO.  Under healthy physiological conditions, the replenishment of the red blood cell 
circulating pool is held under tight regulation by the low concentration of EPO 
available.  This allows for only a small number of BFU-E to differentiate and give rise 
to CFU-E and only a small number of CFU-E to undergo maturation and become 
erythrocytes.  The remaining erythrocyte progenitor cells undergo apoptosis.  The 
primary mechanism therefore, whereby EPO maintains haematopoiesis is by the 
prevention of programmed cell death, or apoptosis, of erythroid progenitor cells.  The 
binding of the EPO ligand to its cognate receptor, as described previously, induces 
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homodimerisation of EPOR [188, 189] and causes a conformational change within the 
(EPOR)2 homodimer, which allows the constitutively associated JAK2 to 
phosphorylate itself, as well as 8 tyrosine kinase residues within the cytoplasmic 
portion of the EPOR [190].  This creates docking sites for various kinase substrates 
with Src homology-2 (SH2) domains, including signal transducer and activator of 
transcription 1, 3 and 5 a/b (STAT), mitogen-associated protein kinase/extracellular 
signal-related kinase (MAPK/ERK), phosphatidyl-inositol-3 kinase (PI-3K/Akt) and 
protein kinase C, which are some of the signal transduction pathways, proposed to 
have a role in the EPO-mediated prevention of apoptosis [162, 191-195]. 
1.2.4 EPO-derivatives 
The major step towards the production of EPO-derivatives first occurred in 1983 when 
the EPO gene was cloned for the first time, and then followed a few years later with 
the subsequent production of the EPO glycoprotein.  Since then, with the aid of many 
modern technologies, the EPO protein has been studied in-depth, with particular 
emphasis on structure-activity relationships.  The focus of both industry and academia 
has been the potential to improve or re-engineer EPO, with the result being the advent 
of many EPO-derivatives, produced by investigating the EPO molecule from different 
perspectives.  Although initially the focus was the generation of EPO-derivatives that 
could stimulate production of red blood cells for the treatment of anaemia, once 
cytoprotective effects were observed, there has been a shift towards the development 
of non-haematopoietic EPO-derivatives.  EPO-derivatives have been crafted by 
altering glycosylation sites, chemically modifying or adding peptides to the EPO 
glycoprotein, as well as looking at the primary, secondary and tertiary structure of 
EPO to generate derivatives based on certain parts of the EPO molecule.  
Recombinant DNA derived-human EPO 
The development of recombinant human EPO (rHuEPO) was made possible by the 
identification of the EPO gene.  It allowed a biotechnological advance, which has, and 
still continues to, revolutionise the treatment and prognosis of anaemia associated with 
chronic kidney disease, as well as other chronic diseases.  This group of EPO-
derivatives are also known as erythropoiesis stimulating agents (ESAs) and treatment 
with any rHuEPO is intended to drastically reduce the number of allogeneic blood 
transfusions required by stimulating the body’s own infant reticulocytes into mature 
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erythrocytes.  It therefore also reduced the risk in these patients over time of having a 
transfusion reaction.   
Many commercial forms of rHuEPO are now available, produced and marketed by 
different pharmaceutical companies under different trade names.  They are generally 
classified into epoetin alpha (Darbepoetin, Epogen, Eprex), beta (NeoRecormon), delta 
(Dynepo), omega (Epomax) and zeta (Retacrit).  Similarities between the different 
forms of rHuEPO include their amino acid sequence (except Darbepoetin) and 
production through recombinant-DNA cell culture.   Epoetin alpha and beta utilise 
Chinese hamster ovary cell lines to produce the recombinant protein, but epoetin 
omega is produced in baby hamster kidney cells.  Epoetin delta utilises a human 
fibrosarcoma cell line to produce the recombinant protein [196], with the result that 
glycosylation of the protein is more characteristic of human cells.   In addition, a dimer 
of EPO, linked by a 17 amino acid chain, has been produced, demonstrating 8-fold 
more effective erythropoietic ability, with a prolonged half-life (approximately 8 
hours) [197].   
All ESAs have the same mechanism of action in terms of EPOR activation, but tend to 
differ in their receptor binding affinity, plasma half-life, bioavailability, in vivo 
potency and clearance, with the aim of altering certain aspects of their 
pharmacokinetic or pharmacodynamics profile. Most commonly, the different 
isoforms of rHuEPO created are able to guarantee market share in the treatment of 
anaemia due to the subtle differences, which alter the functional profile, mainly by 
increasing plasma half-life, and therefore are seen as more patient-friendly by reducing 
the number of doses required each week.  There is however potential that the 
prolonged time of stimulation from newer-generation ESAs can lead to unrequited 
side-effects of EPO over-stimulation, and therefore all patients on ESAs will have 
strict monitoring of their haemoglobin and haematocrit levels. 
Chemically altered EPO 
When it was noted that EPO had potential as a tissue-protective cytokine there was an 
instant surge in the attempts of different groups to identify novel EPO-derivatives.  
The aim was to create a derivative that could retain and mediate tissue-protective 
effects, whilst abolishing the haematopoietic effects, which due to the doses required 
would often lead to thrombotic side effects.   
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Even before the protective effects were observed, asialo-EPO was detailed in the 
literature [198].  EPO is composed of various N-linked and O-linked carbohydrate 
groups.  14 sialic acid residues mask the galactose residues that make up the terminal 
residues in each of these branched carbohydrate chains.  Nowadays, complete 
enzymatic desialylation (typically using neuraminidase) yields asialo-EPO.  Due to the 
desialylation, the terminal residue becomes galactose.  With terminal galactose 
residues available, the asialo-EPO is able to bind to galactose receptors in the liver.  
This hepatic clearance in part explains the very short plasma half-life of asialo-EPO 
(approximately 1.4 minutes).  The lack of modification to the protein backbone of the 
molecule means that binding and affinity to the EPOR remains unchanged, but the 
very rapid rate of elimination means there is not sustained stimulation of the EPOR 
and therefore no haematopoietic effect.  Asialo-EPO is however, capable of activating 
signalling pathways involved in tissue-protection, due to the dynamic nature required 
in activation of the tissue-protective receptor. 
Whilst chemical modification of the EPO molecule can involve any of the lysine, 
arginine, tyrosine or carboxyl terminals, not all of these have been exploited yet.  
Modification of lysine residues has however been investigated, and led to the 
development of another well-known EPO-derivative: carbamylated EPO (CEPO).  
Under normal physiological conditions in humans, it is possible to find partially 
carbamylated EPO molecules.  This occurs when urea within the plasma is converted 
to cyanate, which is then able to react with EPO to create partially carbamylated EPO 
molecules.  It can also be produced via the carbamylation of all seven lysine residues 
in EPO to homocitrulline, with the effect of more than 1000-fold lower binding 
affinity for the EPOR, and subsequently 1000-fold lower effect in haematopoiesis 
stimulation assays. 
Alterations in EPO primary structure to create Mutant EPO (MEPO) 
Following careful examination of the EPO gene, in conjunction with its structure, to 
identify the areas responsible for erythropoiesis, various groups are now in the process 
of creating mutant EPO-derivatives.  These EPO-derivatives have been carefully 
constructed using site-directed mutagenesis to cause single amino acid mutations 
within the erythropoietic motif.  The result is a MEPO that lacks its former 
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erythropoietic activity due to a reduction in affinity for the EPOR, but retains its 
desired tissue-protective effects. 
Numerous MEPOs can be found in the literature, and below is a table (Table 1.4) 
summarising their site of mutation, amino acid change and the arena in which they 
have been identified for potential therapeutic benefit.  In general, following site-
directed mutagenesis, the mutant gene will be subcloned into a plasmid, and then 
either inserted to create a recombinant viral vector and injected for in vivo analysis or 
inserted into a competent cell line which will express sufficient volumes of the MEPO 
to conduct in vitro and in vivo analysis. 
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Table 1.4: Mutant erythropoietin (MEPO) derivatives 
NMDA: N-methyl-D-aspartate, MCA: middle cerebral artery, MPTP: 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine. 
 
Peptide addition  
Following on from the discovery that EPO-derivatives with additional glycosylation 
sites had increased plasma half-life, investigators have looked at other ways of 
increasing plasma half-life by the addition of other moieties.  The rationale for 
pursuing peptide addition to the EPO molecule came from observed increases in 
plasma half-life (and a resultant increase in bioactivity) when the carboxy terminal 
peptide of the " subunit of human chorionic gonadotrophin (hCG) was added to other 
glycoproteins (e.g. thyrotropin) [208].  Progressing with this idea, successful Epo-
fusion peptides have included the use of peptide-derivatives of the carboxy-terminal 
region of hCG [209-211] and human thrombopoietin (hTpo).  The fusion of these 
selected peptides to the EPO molecule saw the advent of chimeric EPO-derivatives 
with 28 additional amino acids when hCG peptide was added and either 17 or 178 
additional amino acids when hTpo carboxy terminal (or a shortened form) was added.  
MEPO 
name 
Amino acid 
residue 
Initial ! mutated  
amino acid 
Tissue-protection area 
EPO-
R76E 
76 
Arginine ! Glutamic 
acid 
In vivo MPTP-induced Parkinsonism [199] 
In vivo optic nerve crush [200] 
In vivo photoreceptor cell damage [201] 
EPO-
R103E 
103 
Arginine ! Glutamic 
acid 
In vitro NMDA-neuron toxicity [202] 
In vivo retinal degeneration [203, 204] 
EPO-
S71E 
71 Serine !Glutamic acid In vivo MPTP-induced Parkinsonism [199] 
EPO-
S100E 
100 Serine ! Glutamic acid 
In vitro NMDA-neuron toxicity [202] 
In vivo MCA occlusion [205] 
In vivo photoreceptor cell damage [203, 
206] 
In vivo retinal degeneration [200] 
S104I-
EPO 
104 Serine ! Isoleucine 
In vitro NMDA-neuron toxicity [202] 
In vivo MCA occlusion [207] 
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All of these chimeric proteins demonstrated prolonged plasma half-life, and marked 
improvement in haematopoietic activity, compared to commercially available EPO-
derivatives [209]. 
Thus far, the resultant EPO-peptide fusion derivatives have mainly been concerned 
with creating EPO-derivatives that maintain and prolong their haematopoietic activity 
via increased plasma half-life, and in some cases even further protracted efficacy due 
to decreased clearance as well.  They have not yet been investigated for a role in 
tissue-protection, but this is likely to follow soon, as well as the potential to create 
other tissue-protective chimeric fusion proteins using EPO-derivatives that already 
exhibit solitary tissue-protective functions. 
EPO-derivatives based on tertiary structure 
Analysis of the tertiary structure of EPO using x-ray crystallography or nuclear 
magnetic resonance tools has provided a vast quantity of knowledge about the protein 
structure, and also interaction with its receptor to provide structure-function clues.  
Analysis of EPO tertiary structure has also given rise to EPO-derivatives.  An EPO-
derivative based on the helix-C motif has been created (Epotris) and trialled as a 
neuroprotective agent in an in vivo model of kainic acid-induced neurotoxicity [212]. 
Epotris demonstrated better cytoprotective survival and regenerative profiles compared 
to EPO, but no evidence of erythropoietic ability.  Epotris has subsequently been 
trialled in a second neurological setting, in an in vivo electrically–induced status 
epilepticus model where it demonstrated more modest cellular protective capability, 
but did attenuate cellular consequences of status epilepticus [213]. 
Further scrutiny of the tertiary structure of EPO and structure-function analysis gave 
rise to an EPO-derivative based on helix-B of EPO.  This molecule is discussed in 
chapter 1.2.6 in further detail. 
1.2.5 Erythropoietin and EPO-derivatives as pleiotropic cytokines 
The theory that EPO may possess roles outside of the promotion of haematopoiesis 
and red blood cell maturation was suggested more than 2 decades ago.  In the well-
designed study, Anagnostou et al demonstrated first, using radio-iodinated-labelled 
EPO, binding of the ligand to a receptor of approximately 79kDa (subtraction of 
EPOR molecular mass then gave a molecular mass of 45kDa for the putative receptor).  
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EPO was then observed to stimulate migration as well as proliferation in two 
endothelial cell types (human umbilical vein and bovine adrenal capillary endothelial 
cells) [214]. This first report of the non-haematopoietic effects of EPO was followed 
shortly with numerous publications reporting either presence of the EPOR or a non-
haematopoietic effect of EPO in several organ systems.  Of note, the presence of 
functional EPOR or EPOR mRNA was demonstrated in the brain, heart, lung [215], 
liver stromal cells [216], bone marrow, adrenal cortex, megakaryocytes [217], spleen 
and testis [218].  Pleiotropic effects of EPO demonstrated in these various tissues, in 
addition to chemotactic and mitotic promotion noted above, include stimulation of 
differentiation, increased DNA synthesis [219, 220] as well as neurotropic effects 
supporting the survival of injured neurons [221]. 
Unfortunately, the ability of EPO to stimulate red blood cell production has proven to 
be the limiting factor in its clinical application.  In clinical scenarios of ischaemic 
tissue injury, there is evidence that EPO administration can lead to negative side 
effects caused by a rise in haemoglobin and haematocrit causing adverse 
cardiovascular thrombotic events [222, 223].  However structure-function analysis of 
EPO binding to the EPOR identified specific areas of the EPO molecule essential for 
stimulating erythrocyte maturation.  In addition, studies of EPO-derivatives that have 
lacked haematopoietic effect have shown the ability to retain previous observed tissue-
protective effects [202].  Taken together, these two pieces of information suggest not 
only that different regions of the EPO molecule have different functional roles, but 
also, there may be alternative receptors through which EPO mediates tissue protection. 
Tissue-protective receptor 
The cytokine common beta receptor ("cR) subunit, is so named due to its mutual role 
as the signal transducing component of many cytokine receptors, including GM-CSF, 
IL-3R and IL-5R.  All of these cytokine receptors are composed of a cytokine-specific 
#-subunit, and share the "cR subunit [224, 225].  Hence alternative names for the "cR 
include IL-3R", IL-5R" or CD131.  Importantly for functionality, it is required that 
two of the "cR subunits are brought together in order to autophosphorylate JAK2, 
which similar to the EPOR, is constitutively bound to the cytoplasmic domains of the 
"cR subunit [226]. 
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Typically, members of the type I cytokine family of receptors are known for forming 
heteroreceptors, making EPOR unique due to its homodimer conformation.  However, 
EPOR and "cR have previously demonstrated associations in vitro [227].  
Confirmation of the two receptors forming heterodimers in a tissue-protective setting 
was provided in a variety of tissues enriched by passage across CEPO – an EPO 
derivative that does not display any haematopoietic functionality.  EPOR / "cR 
heterodimer complex was demonstrated in preparations of brain, heart, liver and 
kidney tissue [228].  
Identification of a proposed tissue-protective receptor has largely sought to refocus 
attention back on to EPO and EPO-derivatives, and their pleiotropic capabilities. The 
use of EPO, and more recently EPO-derivatives, is far-reaching in terms of its clinical 
potential, and a summary of current clinical applications is delivered below.  The 
initial discovery of EPO inducing mitosis and migration, has been replicated time and 
again in many different cell types, including stem cells (endothelial, neuronal, renal 
progenitor cells and mesenchymal stem cells) [229-232]. 
Further pleiotropic functions of EPO have been demonstrated including anti-apoptotic 
effects, beyond simply erythroid precursor stem cells, in numerous other cell types, 
including astrocytes, cardiomyocytes, endothelial cells, epidermal cells, glial cells, 
neurons, renal tubular epithelial cells, retinal ganglion cells and skeletal myotubes 
[200, 231, 233-238]. 
Other lesser-described pleiotropic effects of EPO include improved contractility 
witnessed in vascular smooth muscle cells and cardiac myocytes [239-241] and an 
anti-inflammatory effect, by modulating pro-inflammatory cytokines, of which, IL-6 
and TNF-# have been the most publicised.   
1.2.6 Discovery of ARA-290  
Analysis of the tertiary structure of EPO and the interaction of EPO with the 
erythropoietin receptor (EPOR)2 revealed significant information about the regions of 
the EPO molecule which are required to bind with the (EPOR)2 in order to initiate 
haematopoiesis.  These regions include helices A, C and D as well as the loop 
connecting helices A and B [155, 242, 243].  Interestingly, chemical modification of 
amino acid residues located within any of those regions eliminated binding of the EPO 
ligand to the (EPOR)2 and therefore saw a reduction in the haematopoietic effect.  
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Modification did not however, eliminate the tissue-protective properties of the 
molecule [202].  This led to intensive analysis of the other regions of the EPO 
molecule in the search for potent tissue-protective molecules.  The remaining portions 
of the EPO molecule (helix B and parts of the loops between helices A/B and C/D) 
came under scrutiny.  When EPO is bound to (EPOR)2 these regions face the aqueous 
medium, away from the homodimer binding site.  Initial work using a 24 amino acid 
synthetic peptide composed of the peptide sequence of helix B (amino acids 58 – 82) 
revealed that the EPO-derivative was not capable of promoting the growth of 
erythrocytes in the UT-7 EPO cell assay.  It was however still able to offer 
neuroprotection (comparable to EPO) in a rat motor neuron in vitro model [244] as 
well as in vivo, in a model of ischaemic stroke by reducing infarct size [245].   
Further crystallographic study of EPO binding to its homodimer receptor offered 
guidance as to the exact residues in helix B (8 residues at the surface of the aqueous 
medium) which may possess specific tissue-protective biological activity.  In addition, 
observation of the amphipathic nature of helix B, as well as other surface amino acids 
of the B/C loop (exposed due to the rigid structure of the associated A, C and D 
helices) led to the generation of a new 11 amino acid peptide, called helix B surface 
peptide (HBSP) [245].  HBSP, due to the incorporation of three additional residues 
from the B/C loop, is dissimilar in primary sequence to EPO, however, as intended, 
mimics the 3-dimensional structure of the EPO molecule believed to be cytoprotective.  
This compound again showed no erythropoietic activity in vitro or in vivo, but tissue-
protective activity in a model of sciatic nerve injury, comparable to EPO and other 
EPO-derivatives [245]. 
 Spontaneous cyclisation of N-terminal glutamine residues into pyroglutamate, even at 
room temperature, occurs [246].  Analysis of the HBSP product revealed it consisted 
of a mixture of two peptides – around 90% of the product had a free N-terminal, whilst 
the remaining 10% had cyclised into what is now known as ARA-290 – pyroglutamate 
HBSP (pHBSP) [245].  Initial studies using ARA-290 exhibited no haematopoietic 
activity.  ARA-290 was used in vivo in a murine model of renal ischaemia-reperfusion 
injury and demonstrated a dose-dependent renoprotective effect, similar to prior 
investigation using EPO as the tissue-protective modality [245, 247].  Its role in a 
model of ischaemic stroke injury also revealed significant reduction in infarct volume, 
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even when administered 24 hours post stroke induction, as well as improved 
neurological function.   
ARA-290 synthetic peptide, is now manufactured using standard F-moc solid phase 
peptide synthesis and purified by HPLC and ion exchange chromatography [248]. 
1.2.7 ARA-290 in animal models 
Evolving analysis of the utility of ARA-290 in the treatment of a wide-ranging number 
of conditions has relied upon pre-clinical animal models of those various diseases to 
assess both safety and efficacy. 
Cardioprotection 
In a rat model of myocardial infarction (MI) – through ligation of the left anterior 
descending artery – ARA-290 was able to attenuate a number of important features, 
such as apoptosis, inflammation, cardiac failure and ventricular remodelling.  ARA-
290 significantly reduced the degree of apoptosis and inflammatory infiltrate within 
the myocardial area at risk.  Echocardiography of the animals 4 weeks after induction 
of MI also demonstrated greater ejection fractions compared to untreated controls, and 
a lesser degree of ventricular dilatation [233]. 
Using a hamster strain of dilated cardiomyopathy  (J2N-k), ARA-290 was assessed for 
its ability to protect cardiomyocytes from TNF-# induced apoptosis.  ARA-290 
significantly prevented apoptosis, and was shown to do so via activation of the Akt and 
ERK1/2 pathways.  Creatine kinase (released during muscle injury) and atrial 
natriuretic peptide (a prognostic marker for cardiac failure) were both significantly 
reduced with ARA-290 treatment [234]. 
ARA-290 has also been trialled at an earlier stage of cardiac disease, to assess whether 
or not it has potential to delay progression of coronary atherosclerosis.  Using a rabbit 
model of heritable hyperlipidaemic spontaneous MI, ARA-290 was capable of 
significantly supressing the progression of coronary atherosclerotic lesions and 
prevented apoptosis of coronary artery endothelial cells, again utilising the Akt 
pathway.  In addition ARA-290 facilitated a reduction in TNF-# as well as the pro-
inflammatory (M1) phenotype of macrophages.  Interestingly though, M2 (anti-
inflammatory) macrophage numbers were not altered, there was also a significant 
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reduction in the M1/M2 ratio, suggesting a positive effect of ARA-290 on pro-
inflammatory cytokines [249]. 
Diabetic neuropathy and retinopathy 
Using the Akita murine model of diabetic autonomic neuropathy, ARA-290 was 
employed to determine its ability to reverse established, well-described features of 
neuritic dystrophy and neuronopathy classical to this model.  Akita mice reproducibly 
develop severe diabetes at 3-4 weeks of age following "-islet cell death, followed by 
disturbances in blood glucose, HbA1c levels and body weight [250].  Although ARA-
290 was unable to demonstrate any positive effect on the described metabolic features 
or ongoing neuronopathy, it significantly reduced neuritic dystrophy compared to 
controls [250]. 
Using the streptozotocin-induced diabetes model, the potential of ARA-290 to 
ameliorate features of diabetic retinopathy was explored.  ARA-290 was able to 
significantly reduce glial fibrillary acidic protein expression, the concentration of pro-
inflammatory cytokines (TNF-# and IL-6) and diabetes-induced DNA damage [251].  
Using the same streptozotocin diabetic model, another group demonstrated the 
potential of ARA-290 to reduce retinal leakage [245]. 
Neuroprotection 
EPO has demonstrated many neuroprotective functions within the brain, following 
exogenous administration, as well as after local, endogenously produced EPO has been 
demonstrated to increase.  ARA-290 has similarly shown a wide-ranging effect of 
neuroprotective characteristics in several settings.  ARA-290 has shown benefit in 
modulating pain originating from a variety of causes, including diabetes, 
inflammation, neuropathic pain and sarcoidosis where it led to improved functional 
and behavioural pain testing measures [250, 252-254].   
In models of traumatic brain injury, ARA-290 administration was capable of 
significantly reducing contusion volume and improving functional outcome 
assessments in rats [255, 256]. 
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Using electrical stimulation to initiate a self-sustained status epilepticus episode, ARA-
290 intervention demonstrated a significant neurogenic effect as well as improvement 
in cognitive deficits and functional outcomes [257]. 
Renal protection 
Acute kidney injury due to ischaemia reperfusion of the renal pedicle in rats was 
created to assess the ability of ARA-290 to reduce glomerular and tubular dysfunction, 
and prevent renal injury.  Renal ischaemia reperfusion injury (IRI) was created by 
clamping the renal pedicle (renal artery, vein and nerve) for a 30-minute period before 
releasing the clamp.  ARA-290 was able to significantly improve glomerular and 
tubular dysfunction, measured by serum creatinine and urea, creatinine clearance and 
excretion of sodium, compared to controls.  In addition plasma biomarkers of renal 
injury (clusterin and osteopontin) were reduced by ARA-290 administration.  
Subsequent analysis of numerous signalling pathways identified that this amelioration 
in tissue injury was likely to have involved Akt, GSK-3" and NF!B signalling 
pathways [258, 259].  Another examination of renal IRI in a larger animal model, 
using pigs, described similar findings of improved renal function (using glomerular 
filtration rate as the marker) with ARA-290 treatment.  In addition, ARA-290 was able 
to reduce mRNA expression of the pro-inflammatory cytokines IL-6 and monocyte 
chemotactic protein-1 (MCP-1), and improve morphological changes of interstitial 
fibrosis following injury [260].   
Further assessment of the signalling pathways utilised in mediating tissue-protection in 
renal IRI has been undertaken.  Using a murine model of IRI, ARA-290 conferred 
similar anti-apoptotic effects as already described.  However, concomitant 
administration of the PI-3k inhibitor wortmannin, abolished the reduction in apoptosis 
observed, and additionally worsened serum markers of renal injury, suggesting a key 
role of the PI-3k signalling pathway [261].   
Wound healing 
Assessment of thermally induced wounds and the ability of ARA-290 to improve 
outcomes was assessed by subjecting mice to a partial thickness burn.  The partial 
thickness burn converted into a full-thickness burn within 48 hours due to necrosis of 
the surrounding tissue, in untreated controls.  However, ARA-290 treated animals 
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were able to maintain microvasculature, and therefore tissue integrity, and 
demonstrated once again a dampening effect on raised pro-inflammatory cytokines, 
especially TNF-# [262]. 
Wounds of both non-ischaemic and recurrent ischaemic origin have also been treated 
with ARA-290, and each demonstrated a positive role of ARA-290 in ameliorating 
wound features.  In the non-ischaemic wound model, the wound size of ARA-290 
treated mice was significantly reduced compared to control.  In the recurrent ischaemic 
wound model (a pre-clinical model for ulcers), ARA-290 reduced the initial wound 
lesion size, but did not demonstrate a prolonged effect on reducing wound size.  This 
may have been due to experimental procedure, where only 2 doses of ARA-290 were 
administered on days 1 and 2 of a 14 day total end-point experiment [248]. 
1.2.8 Current human clinical applications of ARA-290   
The role of ARA-290 in a pre-clinical setting, using both in vitro and in vivo methods, 
has been complemented with its admittance into clinical trials in multiple fields 
including inflammatory and rheumatological diseases, neuropathic pain and 
neuropathic pain in the setting of type 2 diabetes.  The current enrolment of ARA-290 
for human clinical application will be described below.  
Completed clinical trials 
Initial safety and toxicity studies on humans were performed by Araim 
Pharmaceuticals Inc. and revealed no safety concerns at supra-clinical doses in healthy 
volunteers as well as patients with end-stage renal disease, or sarcoidosis [263]. 
Investigators in the Netherlands performed a trial to assess the pharmacokinetics of 
ARA-290 in healthy volunteers.  A variety of doses were administered subcutaneously 
(SC) and a single dose intravenously (IV).  SC administrations demonstrated a dose-
dependent peak increase in plasma concentration occurring at 6 minutes post-injection.  
The elimination half-life (t1/2) was estimated at approximately 20 minutes [263].  In 
comparison, IV administration led to peak plasma concentrations within 1 minute, and 
a t1/2 = 2 minutes [263]. 
The same group of investigators went on to perform a phase IIa and phase IIb clinical 
trial assessing the use of ARA-290 for small fibre neuropathy (SFN) in a disease 
setting of sarcoidosis.  Both trials are listed as completed, but only one has been 
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published thus far.  22 patients with sarcoidosis and symptoms of SFN were enrolled 
in a double-blind, randomised, placebo-controlled study.  Primary outcome was pain 
relief as assessed by SFN screening list.  Other outcomes included quality of life, brief 
pain inventory, depressive symptoms and fatigue.  Patients in the ARA-290 treatment 
group demonstrated significant improvement in SFN screening list scores as well as 
significant change from baseline pain and physical functioning scores [252].  
Clinical trials currently active/recruiting 
Numerous clinical trials involving ARA-290 have been registered with the 
Netherlands trial register (NTR) or the European clinical trials register (EU-CTR).  
These trials cover a variety of clinical fields, and are at different stages of their clinical 
trial assessment.  The variety of studies therefore involves both healthy volunteers and 
patients with different disease manifestations [264, 265]. Table 1.5 describes clinical 
trials currently registered with either EU-CTR or NTR, and their clinical setting.
Table 1.5: Currently active clinical trials investigating clinical applications of ARA-290
Trial 
Registry 
Identifier 
Scientific Title Study Group / 
Study Attributes 
Intervention Primary Outcomes Secondary Outcomes 
2010-023469-
22 / NTR2577 
[266] 
A phase II study of ARA 
290 as therapeutic strategy 
in rheumatoid arthritis 
Rheumatoid arthritis 
Randomised, control 
study  
2mg ARA-290; 1 or 
3x/week; IV 
administration  
Disease activity, functional 
ability, systemic 
inflammatory markers 
(ESR, CRP) 
Drug tolerance 
2010-018584-
41 / NTR2685 
[267] 
A phase II study of ARA-
290 as therapeutic strategy 
in no-option critical limb 
ischaemia patients 
CLI 
Interventional study 
3x/week for 4 weeks Drug safety and 
tolerability, pain scores and 
analgesic use diary, wound 
healing, inflammatory 
markers, quality of life 
N/A 
NTR3575 
[268] 
Effects of ARA-290 on the 
regrowth of epidermal 
nerve fibres in patients with 
sarcoidosis 
Sarcoidosis and SFN 
Randomised, double-
blind, placebo control 
study 
ARA-290 or placebo 
SC for 28 days 
Changes in epidermal nerve 
fibre density, cutaneous 
sensitivity, visual tests 
Changes in SFN score,  
pain inventory,  
6 minute walk test 
2012-005590-
32 / NTR3858 
[269] 
A double blind, placebo 
controlled Phase II study 
comparing the effects of 
ARA-290 on neuropathic 
symptoms of patients with 
type 2 diabetes. 
Diabetes mellitus type 
2 
Randomised, double-
blind, placebo control 
study 
ARA-290 or placebo 
SC for 28 days 
Drug safety,  
changes in HbA1c,  
pain and physical function 
scores 
Changes in sensory testing, 
epidermal nerve fibre 
density, 6 minute walk test, 
visual acuity, heart rate, 
retinal thickness, glucose 
control, CRP and 
microalbuminuria 
NTR3131 
[270] 
ARA-290 and the 
ventilatory response to 
hypoxia and pain responses 
in healthy volunteers 
Healthy volunteers 
Randomised, placebo-
control, crossover 
study 
ARA-290, placebo 
or EPO IV at time of 
hypoxic induction 
Hypoxic ventilatory 
response, 
Pulmonary artery pressure 
Systolic and diastolic cardiac 
function, vital and ventilatory 
parameters, pain threshold 
under hypoxia 
CRP – C-reactive protein, ESR – erythrocyte sedimentation rate, IV – intravenous, SC – subcutaneous, SFN – small fibre neuropathy 
1.3 Hypotheses 
PAD is a disease of complex pathophysiology and multiple aetiologies.  The 
underlying interplay between haemodynamic compromise and musculopathy has 
proven the need to better understand the lasting effects of chronic ischaemia on the 
muscle end-organ, in order to improve current as well as future novel adjunctive 
treatment options with the aim of improving functional benefit for patients.   
Many novel therapeutic agents are brought into the tissue-protective arena, but their 
utility often needs to be proved via extensive in vitro or in vivo animal analysis before 
they can be safely and efficaciously prescribed to patients.  EPO has previously been 
trialled in other hypoxic or ischaemic injury settings, but often its use is prevented 
due to its pro-thrombotic tendencies following prolonged dosing in people with 
normal haemoglobin levels.  ARA-290 is one of several EPO-derivatives which have 
since been created which initial studies have suggested retains the tissue-protective 
properties of EPO but lack any haematopoietic potential. 
In terms of the lack of functional benefit often reported by patients following 
successful revascularisation, it is likely that satellite cells, the principal progenitor 
component of muscle, may hold the key to elucidating pathological differences due to 
chronic exposure to a hypoxic environment.  For the purposes of this work however, 
the myogenic differentiated form of satellite cells, myoblasts and myotubes, were 
isolated and utilised. 
This thesis addresses the hypothesis that EPO and the EPO-derivative ARA-290 are 
capable of mediating cytoprotection when skeletal muscle is subjected to hypoxic 
insult emulating that seen in critical limb ischaemia.   
Experimental approach: 
Two experimental approaches were employed to test this hypothesis: initially using 
an established in vitro model of skeletal muscle (derived from mouse) and 
subsequently primary human skeletal muscle cells, in conjunction with an established 
model of simulated ischaemia.  This provided a useful platform to assess the EPO and 
ARA-290 compounds ability to reconcile ischaemia-induced apoptosis, as well as 
determining potential signalling axes being utilised. 
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Following on from in vitro studies, an in vivo model of hindlimb ischaemia was used 
to assess both compounds in a pre-clinical model, with assessment of functional, 
histological and perfusion outcomes. 
1.4 Aims 
The aim of this study was to investigate the cytoprotective ability of EPO and the 
EPO-derivative, ARA-290, in ischaemia-induced injury.  In order to achieve this, it 
was necessary to achieve the following: 
1. Demonstrate expression of the tissue-protective receptor in human skeletal 
muscle. 
2. Assess the ability of EPO and ARA-290 to enhance C2C12 myoblast and 
myotubes function and survival in an in vitro simulated ischaemia model. 
3. Investigate the functional differences in CLI and control myoblasts and 
myotubes, and their suitability to form a primary human in vitro skeletal muscle 
model. 
4. Assess the ability of EPO and ARA-290 to enhance observed differences in CLI 
and control myoblast and myotubes function and survival in an in vitro simulated 
ischaemia model. 
5. Develop a suitable murine model of hindlimb ischaemia in order to study the 
ability of EPO and ARA-290 to protect skeletal muscle from ischaemic injury. 
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CHAPTER 2  
Materials and methods 
2.1 Patients 
Following study approval by the Local Research Ethics Committee (Royal Free and 
University College Medical School, Hampstead, London) and The Heart Hospital, 
University College London Hospitals NHS Trust, tissue samples were taken from 2 
groups of patients: 
Critical Limb Ischaemia group: Patients with CLI 
Control group: Patients with no clinical evidence of PAD 
Consultations were conducted with patients prior to operative procedure, written and 
verbal information was provided, and informed consent was obtained from all 
participants. 
CLI Group 
Seventeen patients with CLI requiring major lower limb amputation, (i.e. above knee 
or below knee amputation), were recruited.  The Trans-Atlantic Inter-Society 
Consensus for the management of PAD (TASC guidelines) definition of CLI was 
used, where patients had chronic ischaemic rest pain for at least two weeks, with or 
without ulcers or gangrene, attributable to objectively proven arterial disease (e.g. 
ABPI <0.3).  Patients undergoing major lower limb amputation for pathology other 
than CLI were excluded from the study. 
Control Group 
Control samples were taken from patients undergoing coronary artery bypass graft 
(CABG) surgery for coronary artery disease, in which the long saphenous vein was 
harvested.  Patients were assessed pre-operatively by clinical history, physical 
examination and ABPI measurement to exclude significant PAD.  Patients with 
symptoms and, or, signs of PAD or in whom ABPI measurement was less than 0.9 
were excluded from recruitment.   
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As described in the previous chapter, different muscle groups contain different 
proportions of myosin heavy chain fibre type.  Therefore in order to try and 
standardise muscle sample collection we obtained all biopsies from the deep belly of 
the gastrocnemius muscle in both groups of patients.  The gastrocnemius muscle is 
also easily accessible in the control group, and in the CLI group is usually a suitable 
distance from any infected, ulcerating or gangrenous areas, which were avoided when 
collecting samples, in order to reduce the confounding effects of concurrent 
inflammation or infection on our data.  The gastrocnemius muscle in CLI patients has 
been demonstrated to be ischaemic, through presence of HIF-1 as well as by near-
infrared spectroscopy in the literature [271].  Demographic details, prevalence of 
cardiovascular risk factors and information on current medication were also collected 
from both groups. 
2.1.1 Sample collection and preparation 
CLI group 
Following surgeon-devised operative amputation protocol, the amputated remnant 
limb was provided to us for access to muscle biopsies.  The gastrocnemius muscle 
was identified, and open muscle biopsies excised. 
Excised muscle biopsies were divided into 4 portions.  One portion was placed in a 
microcentrifuge tube and immediately snap frozen in liquid nitrogen, and then stored 
at –80°C for protein analysis.  A second part was collected into RNAlater™ RNA 
stabilisation reagent (Ambion, Austin, Tx) and stored according to manufacturer’s 
guidelines for later RNA quantitation.  A third portion was immersed in 10% formal 
saline containing 4% formaldehyde (CellPath, UK) for histological processing.  The 
final remaining portion was collected into solution A (30mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 130mM sodium chloride, 3mM potassium 
chloride and 10.1mM glucose) for isolation of myoblasts.   
Control group 
Individuals undergoing long saphenous vein harvest for CABG had the medial aspect 
of either left or right calf exposed.  Once saphenous vein harvest was completed, the 
gastrocnemius muscle was identified, and an incision in the deep fascia (fascia 
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cruris) was made.  Open muscle biopsies (approximately 0.5 cm x 0.5 cm x 0.5 cm) 
were taken from the surgically exposed gastrocnemius muscle. 
Once the muscle sample was excised, the muscle was collected in the same manner as 
CLI muscle above. 
2.2 Tissue analyses 
2.2.1 Histological analysis 
Preparation of samples collected for histological analysis allowed the muscle biopsy 
to fix in 10% formal saline containing 4% formaldehyde (CellPath, UK).  Samples 
were allowed to remain in fixing solution for up to 10 days.  Fixed tissues were 
processed and dehydrated overnight and embedded in molten paraffin wax to 
generate the formalin-fixed paraffin embedded (FFPE) samples.  When required, 3µm 
sections were cut using a microtome (Leica, UK) and mounted onto polylysine-
coated slides (VWR, UK) from the FFPE muscle samples.  Sections were heated 
overnight at 42°C and then used to perform staining. 
Histology 
FFPE sections were dewaxed in xylene (Genta Medical, York, UK) and passed 
through a series of graded ethanols and then transferred to water.  To ensure correct 
cross-sectional orientation of the embedded muscle tissue, and also to assess tissue 
architecture, haematoxylin and eosin (H&E) staining was performed using standard 
protocol.  Briefly, FFPE sections were dewaxed and prepared as above.  After 
immersion in running tap water sections were immersed in Harris’ haematoxylin for 5 
minutes before differentiating by dipping in a weak acid alcohol solution (20mM HCl 
in 70% ethanol).  Sections were then rinsed in running tap water before immersion in 
eosin for 1 minute.  Sections were then rinsed and dehydrated by passing through 
graded alcohols, cleared in xylene, and then mounted in permanent DePeX mountant 
(VWR, UK).  
Immunohistochemistry 
All immunohistochemistry undertaken was performed on FFPE sections.  After 
dewaxing sections, slides were immersed in 0.5% hydrogen peroxide (v/v) in 
methanol for 10 minutes to quench endogenous peroxidase activity.  Antigen retrieval 
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was performed according to manufacturer’s guidelines, but usually entailed either 
heat-mediated or enzymatic antigen retrieval.  Heat-mediated antigen retrieval was 
achieved by microwave heating of sections submersed in either 10mM Citrate buffer 
(pH 6.0) or Tris-EDTA (10mM Tris base, 1mM EDTA) buffer (pH 9.0) for 10 – 20 
minutes.  Alternatively, enzymatic antigen retrieval was performed using either 0.5% 
trypsin (w/v) or 20µg/ml proteinase k applied directly to the slide for 15-20 minutes.  
Antigen retrieval protocols were optimised for each antibody used individually. 
To reduce nonspecific background staining as a result of binding to non-
immunological antigenic sites a blocking step was performed.  This involved pre-
incubating sections with normal whole serum against the species in which the 
secondary antibody was raised.  Isotype matched control serum (Vector Laboratories, 
Burlingame, CA) was diluted 1:10 in phosphate-buffered saline (PBS, pH 7.4) and 
applied to sections for 30 minutes.  Endogenous biotin activity was blocked using a 
commercially available kit (Vector Laboratories) according to manufacturer’s 
instructions.  Primary antibodies, dilutions and manufacturer’s details were as 
follows: 
Table 2.1: Primary antibodies used for immunohistochemistry 
Antibody Dilution Manufacturer 
Rabbit anti-IL3RB (!cR) 1:250 Abcam 
Rabbit anti-IL3RB (!cR) 1:250 Santa Cruz biotechnology 
Mouse anti-EPOR 1:40 Abcam 
Rabbit anti-EPOR (C-20) 1:500 Santa Cruz Biotechnology 
Rabbit anti-EPOR (M-20) 1:500 Santa Cruz Biotechnology 
Mouse anti-Pax-7 1:100 Abcam 
Rabbit anti-Ki-67 1:100 Abcam 
Rabbit anti-CD34 1:100 Abcam 
 
Optimisation of treatment conditions including antibody dilution, length and ambient 
temperature during staining treatment was performed for each antibody used.  An 
appropriate biotin-conjugated IgG antibody (Vector Laboratories) at 1:200 dilution 
was applied for 30 minutes at room temperature.  Binding was detected using either 
peroxidase or alkaline phosphatase-based standard immunohistochemical ABC 
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method (VectaStain, Vector Laboratories).  Sections were developed using the 
corresponding peroxidase-linked chromagen DAB (3,3’diaminobenzidene) or 
alkaline phosphatase substrate in Tris-HCl (pH 8.2) buffer.  In the case of double 
staining, both DAB and alkaline phosphatase substrates were used following a 
sequential staining series.  Sections were counterstained in Mayer’s haematoxylin, 
and dehydrated in ethanol, cleared in xylene and mounted using the permanent 
mountant DePeX (VWR, UK). 
2.2.2 RNA quantitation and analysis 
RNA extraction of tissue samples  
Tissue samples were stored in RNAlater™ RNA stabilisation reagent (Ambion, 
Austin, TX).  As per manufacturer’s guidelines, samples were stored at 4!C overnight 
and the solution removed before longer-term storage at -80°C.  When required, the 
samples were thawed, on ice, and adequate weights of tissue samples (approximately 
30mg) were immersed in RNeasy RLT lysis buffer containing 10µl/ml (14.3mM) !–
mercaptoethanol (RNeasy fibrous tissue mini kit, Qiagen).  Tissues were disrupted by 
lysis for a total of 4 minutes (2 x 2 minutes) at 30 Hz in a TissueLyser (Qiagen).  To 
ensure even homogenisation, samples were rearranged throughout the TissueLyser 
reaction-tube holder after 2 minutes. After homogenisation, fibrous tissue was 
digested using proteinase K 0.011% at 55°C for 10 minutes.  Samples were 
centrifuged to remove tissue debris and the supernatant containing RNA mixed with 
half a volume of 100% ethanol as per RNeasy protocol.  RNA was bound within the 
silica spin column and washed repeatedly.  RNA was eluted in 60µl of RNase-free 
water into microcentrifuge tubes for storage at –80°C.   A 16µl aliquot was used for 
DNase I (Sigma-Aldrich, UK) digestion, to eliminate any contaminating template 
DNA. 
RNA quantification 
RNA was quantified using a Nanodrop ND-8000 spectrophotometer (Thermo-
Scientific). Briefly, 1µl of each sample was placed on the spectrophotometer and 
measured for quantity and purity, assessed by the A260:A280 and A260:A230 ratios.  
Acceptable A260:A280 ratios were between 1.9 – 2.2, and ratios of A260:A230 between 
2.0 – 2.2. 
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RNA quality was assessed using the Agilent RNA 6000 nano chips and kit with an 
Agilent 2100 Bioanalyzer (Agilent Technologies UK Limited) according to 
manufacturer’s instructions (figure 2.1).  The RNA integrity algorithm was used to 
calculate the integrity.  For PCR analysis, the minimum acceptable RNA integrity 
value was greater than 7.0.  
 
Figure 2.1: Agilent RNA 6000 Nano chip assay results for human skeletal muscle 
Representative summary of Agilent RNA 6000 nano chip assessment of RNA quality 
of RNA isolated from human skeletal muscle.  The quality of RNA isolated from 
human and mouse skeletal muscle was assessed using the Agilent RNA 6000 nano 
chip set.   
Primer design 
Primers were designed using NCBI / Primer-BLAST software and human and mouse 
accession numbers.  Human and mouse sequences were aligned to identify conserved 
areas similar to both species.  Primers were designed to span exon-exon junctions 
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common to both human and mouse.  Primers were generated to standard 
specifications of GC content of 40-50, and a melting temperature of approximately 
60!C.  All primer sequences were then subjected to BLAST analysis 
(www.ncbi.nlm.nih.gov/blast) to ensure specificity for the EPOR and !cR genes.  No 
self-annealing or primer dimers were reported on the technical data.  Primers were 
produced by Sigma-Aldrich and are listed in table 2.2. 
Table 2.2: Primers used for quantitative PCR 
Gene name Forward primer sequence (5’ – 3’) Reverse primer sequence (5’ – 3’) 
!cR CGTGGAAGGACAGCAAGACC GCTGTCCCCGAATCCTACAG 
EPOR ATCAATGAAGTAGTGCTCCT CAGCCACAGCTGGAAGTTA 
TBP AGTGACCCAGCATCACTGTTT GGCAAACCAGAAACCCTTGC 
 
cDNA synthesis 
0.5µg of total RNA was reverse transcribed using the QuantiTect reverse 
transcription kit (Qiagen).  Briefly, the first step requires the elimination of genomic 
DNA contaminants within each RNA sample.  Following this, the RNA was reverse 
transcribed using the supplied blend of random and oligo-dT primers. The completed 
cDNA reaction was diluted five-fold with nuclease-free water, giving a final 
concentration of 100ng/µl. 
Quantitative Polymerase Chain Reaction (qPCR) 
2µL (final concentration of 100ng) of diluted cDNA was used for real-time 
quantitative reverse transcription PCR (qRT-PCR) in a 12µL reaction volume using 
QuantiFast SYBR Green RT-PCR kit (Qiagen).  As per manufacturer’s guidelines, 
the reaction mixture also contained 6µL 2x QuantiFast SYBR Green RT-PCR master 
mix, 0.24µL primer mix (final concentration 1µM), and made up with nuclease-free 
water to 12µL.  A negative, or non-template control was also added into each qPCR 
cycle by replacing cDNA with nuclease-free water.  The reaction mixture was 
analysed on a Rotorgene-6000 (Corbett Life Sciences, Sydney, Australia) under the 
following conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 10 seconds, 
57°C for 15 seconds and 72°C for 5 seconds.  Primer dimers were excluded by melt 
curve analysis.  The reference gene TATA box binding protein (TBP) was analysed 
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using REST© (Relative Expression Software Tool) from Qiagen to obtain 
normalisation factors.  Gene of interest copy numbers were corrected using these 
normalisation factors.   
2.2.3 Protein quantitation and analysis 
Homogenisation of human muscle tissue 
Whole muscle samples were homogenised using TissueLyser (Qiagen).  Briefly, 
muscle samples were thawed on ice, and weighed.  Between 30 – 50mg of muscle 
tissue was placed in a 2ml round bottom microcentrifuge eppendorf tube, and 10-
volumes of radio-immunoprecipitation assay (RIPA) buffer (150mM NaCl, 1.0% 
IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50mM Tris, pH 8.0; 
Sigma-Aldrich, UK) with 1x Complete mini EDTA-free protease inhibitor (Roche) 
and 10µL/ml each of phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich, UK) 
added.  A stainless steel metal ball was added, and the samples arranged in the 
TissueLyser.  Tissue was disrupted by mechanical homogenisation for a total of 6 
minutes (2 x 3 minutes) at 30 Hz.  To ensure even homogenisation, samples were 
rearranged throughout the TissueLyser reaction-tube holder after 3 minutes.  
Homogenised samples were centrifuged at 15,000g for 15 minutes at 4°C.  The 
supernatant was removed and a bicinchoninic acid (BCA) protein assay 
(ThermoScientific, UK) performed according to manufacturer’s protocol to assess 
protein quantity within each sample.  Briefly, standard protein concentrations are 
created using known albumin protein concentrations, and a 7 fold-serial dilution 
performed.  Equal volumes of standard or samples are added to wells in a 96-well 
microplate in duplicate.  Protein present in the samples will mediate the reduction of 
Cu2+ to Cu1+ in a protein concentration dependent manner, which results in a 
characteristic colour change from green to purple.  The absorbance at 560nm of each 
sample was measured using a microplate reader (Mithras LB940 microplate reader, 
Berthold Technologies, Germany).  Sample protein concentrations were calculated by 
comparison with the standard curve.  Samples were then normalised to the sample 
with lowest protein concentration, and 4x lithium dodecyl sulphate (LDS sample 
buffer (Invitrogen, UK) and 50mM dithiothreitol (DTT) added to each sample before 
denaturing samples by heating at 70°C for 10 minutes.  Samples were stored at -80°C 
when not used. 
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Western blot analysis 
Identification of proteins of interest within muscle or cell lysate samples was 
performed using Western blot analysis.  Equal amounts of protein in LDS sample 
buffer were fractionated by SDS-polyacrylamide gel electrophoresis using 4-12% bis-
tris gels (Invitrogen) or various tris-glycine gradient gels, prepared when required and 
with a suitable acrylamide composition for the size of the protein of interest.  A 
reference ladder (Novex® Sharp Pre-stained Protein Standard, or SeeBlue® Plus2 
Pre-Stained Standard, both Invitrogen) was included, and samples electrophoresed at 
180V for 1 hour (bis-tris gels) or 125V for 90 minutes (tris-glycine gels).  Proteins 
were transferred by electro-blotting from each gel onto a nitrocellulose membrane 
(Hybond-C Extra, GE Healthcare Amersham, UK). 
Adequate transfer was assessed by Ponceau S solution  (0.1% (w/v) in 5% acetic 
acid) staining (Sigma-Aldrich, UK) of each membrane.  The membrane was washed 
briefly with phosphate-buffered saline with 0.1% Tween-20 (PBS-T) (Sigma-
Aldrich).   
Non-specific binding was blocked by membrane incubation with 5% (w/v) non-fat 
dry milk in PBS-T for 2 hours at room temperature.  Membranes were incubated 
overnight at 4°C with gentle agitation with primary antibodies, listed below with 
dilutions and manufacturer’s details (table 2.3).  !-tubulin was used as a loading 
control in all Western blot analysis. 
Before addition of a secondary, species-specific HRP-linked antibody, membranes 
were washed thoroughly with PBS-T.  Secondary antibodies were used at 1:1000 
dilution in 5% non-fat dry milk solution and allowed to incubate for 1 hour at room 
temperature. Signal was detected using a luminescence kit (ECL detection kit; 
Amersham) followed by exposure to photographic film (Hyperfilm ECL; Amersham) 
and manual development.  Densitometry analysis was performed using 
VisionWorkLS analysis software (UVP, CA, USA). 
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Table 2.3: Primary antibodies used for Western blot analysis 
Antibody Dilution Manufacturer 
Rabbit anti-IL3RB (!cR) 1:5000 Abcam 
Rabbit anti-IL3RB (!cR) 1:1000 Santa Cruz biotechnology 
Mouse anti-EPOR 1:500 Abcam 
Rabbit anti-EPOR (C-20) 1:1000 Santa Cruz Biotechnology 
Rabbit anti-EPOR (M-20) 1:1000 Santa Cruz Biotechnology 
Mouse anti-Pax-7 1:500 Abcam 
Mouse anti-myogenin 1:1000 Abcam 
Mouse anti-HIF-1" 1:500 Novus Biologicals 
Rabbit anti-Cleaved caspase-3 1:1000 Cell Signalling 
Rabbit anti-Akt 1:1000 Cell Signalling 
Rabbit anti-Phospho Akt (Ser 473) 1:1000 Cell Signalling 
Rabbit anti-beta-tubulin 1:50000 Abcam 
 
2.3 Materials 
Human EPO protein for all in vitro experiments was purchased from Santa-Cruz 
Biotechnology (CA, USA).  The protein was reconstituted in 10% glycerol (v/v in 
PBS (pH 7.4) at a stock concentration of 120µg ml-1.  The stock solution was 
aliquoted and stored at -20°C.  Eprex® (Janssen-Cilag, Buckinghamshire, UK), an 
erythropoietin alfa analogue, was obtained from the Royal Free Hospital Pharmacy 
for the purposes of in vivo work.   
ARA-290 synthetic peptide used in both in vitro and in vivo work was a kind gift 
from Professor Anthony Cerami, and Michael Brines of Araim Pharmaceuticals (NY, 
USA).  The peptide was reconstituted in PBS at a stock concentration of 1mg/ml, 
sterile-filtered, aliquoted and stored at 4°C for up to one month.  
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2.4 In vitro model of simulated ischaemia 
In vitro cell culture models are an abundantly used tool to study various signalling 
pathways, as well as pharmacological interventions and their impact on cellular 
function.  They also provide a useful platform for the initial extensive assessment of 
novel therapeutic agents.   
In order to investigate the effect of ischaemia on a murine myoblast cell line, as well 
as primary isolated human cells a reproducible model of ischaemia was required.  Our 
group has previously investigated the use of several gas mixtures to find the optimum 
gas mixture to simulate many of the conditions typically found in the ischaemic limb 
of CLI patients.  Parameters that were similar included pH, partial pressures of 
oxygen and carbon dioxide as well as lactate dehydrogenase release and induction of 
HIF-1" and apoptosis of myotubes [238].   
A modular incubator (MIC-101, Billups-Rothenberg Inc., Del Mar, CA, USA), and 
the previously described 20% carbon dioxide balanced in 80% nitrogen (BOC 
Limited, Guildford, UK) was used in order to simulate aspects of human skeletal 
muscle ischaemia seen in CLI patients, within our in vitro model. 
2.4.1 Culture of C2C12 myoblast cell line 
C2C12 is an established, immortalised, myoblast cell line of murine origin.  The C2 
line was first isolated in 1977 by Yaffe and Saxel from the thigh muscles of 1-2 
month old mice that had undergone crush injury.  The C3H line was then subcloned 
by H. Blau to produce the C2C12 myoblast line.  C2C12 mouse myoblast cell line 
was obtained commercially (HPA culture collection, #91031101).  C2C12 myoblasts 
were grown in growth medium containing Dulbecco’s modified Eagle’s medium 
(DMEM GlutaMAX™) (Invitrogen, Paisley, UK) supplemented with 10% foetal calf 
serum (FCS) (Gibco®, Paisley, UK), 100 units/ml penicillin and 100µg/ml 
streptomycin (Invitrogen).  The cells were then placed in a humidified incubator with 
5% CO2 atmosphere maintained at 37°C.  The medium was changed every 48 hours 
until cells reached 60 – 70% confluence.  Cells were trypsinised – 0.25% trypsin 
(w/v) in 1mM EDTA (trypsin-EDTA) (Invitrogen) when they reached confluence, 
and passaged approximately 1:10.  All cells required for experiments were used 
within 10 passages.  Following trypsinisation, if cells were required to perform 
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experiments they were counted using a haemocytometer, and resuspended to a cell 
density of approximately 25,000 cells/ml.  Cells were then seeded into 6-well plates 
(2ml/well), 24 well plates (500µl/well) or 96-well plates (100µl/well). 
Differentiation of C2C12 myoblasts 
After seeding C2C12 myoblasts into 6 well plates and allowing them to reach 70-
80% confluence, if differentiated myotubes were required, growth medium was 
exchanged for differentiation medium containing DMEM GlutaMAX™ supplemented 
with 2% horse serum (Gibco®, Paisley, UK), 100 units/ml penicillin and 100µg/ml 
streptomycin (Invitrogen).  In vitro differentiation of C2C12 myoblasts has been well 
publicised when a change from serum-rich to a less rich serum medium is performed.  
The medium was changed every 48 hours, and cultures were inspected using a phase-
contrast microscope to confirm typical myotube morphology.  Cells were maintained 
in differentiation medium for between 5 and 7 days to ensure adequate differentiation, 
before being subjected to any experimental procedure. 
Pre-treatment with EPO or ARA-290 
Stock solutions of both EPO and ARA-290 were made up as detailed above.  After 
assessing the effect of a range of doses on cleaved caspase-3 expression, experimental 
doses of EPO and ARA-290 were selected.  Doses used for EPO pre-treatment ranged 
from 0.6 – 1200ng/ml, and the optimum dose chosen for future experiments was 
60ng/ml.  For ARA-290 pre-treatment, doses ranged from 0.05 – 500ng/ml, and the 
effective dose used for all future experiments was 5ng/ml. 
Inhibitor Assessment  
Inactivation of key signalling molecules to elucidate important components of the 
EPO or ARA-290-mediated cytoprotective pathway assessed JAK2/STAT3 (SD-
1029), PI3k/Akt (LY294002 and wortmannin) and NF#B inhibitor of activation IV 
(all Calbiochem, Merck Millipore International, Germany).  All inhibitors were 
reconstituted in DMSO or purchased in solution with DMSO.  SD-1029 was used at a 
final concentration of 10µM.  LY294002 was used at a final concentration of 3µM.  
Wortmannin was used at a final concentration of 10nM and NF#B inhibitor of 
activation IV was used at a final concentration of 150nM.  Vehicle-only (DMSO) at 
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the highest concentration (1:3000) was added to ensure cell-death was not in response 
to DMSO content. 
2.4.2 Preparation of C2C12 samples for analysis 
Cell lysate samples from parallel normoxic control cell cultures, and those that were 
exposed to pharmacological pre-treatment prior to simulated ischaemia were 
collected.  Supernatant was discarded, the cell monolayer rinsed in PBS, and then 
RIPA buffer (150 nM NaCl, 1% Triton, 0.1% SDS, 50 mM Tris-HCl pH7.5, 2mM 
EDTA, protease inhibitor cocktail and 8M urea) with 1x Complete mini EDTA-free 
protease inhibitor (Roche, UK) and phosphatase inhibitor cocktails 2 and 3 (Sigma-
Aldrich, UK) were applied directly to cells.  Cells were lysed further using 
mechanical shearing by a needle and 24-gauge syringe. 
 
2.5 Isolation and culture of human myoblasts and 
myotubes 
2.5.1 Isolation of human myoblasts  
The isolation of myoblasts from human muscle tissue was achieved following a 
protocol from the MRC Centre for Neuromuscular Diseases: Myoblast isolation from 
muscle biopsy V4, kindly offered by Dr Jenny Morgan.  Briefly, at the time of muscle 
biopsy excision, a 0.2 x 0.2 x 0.2cm fragment was placed in 5ml of Solution A and 
transported on ice, before being processed on the same day.  Under aseptic conditions 
in a class II microbiological safety laminar flow hood the muscle biopsy only was 
transferred to a petri dish and washed in 5ml fresh Solution A.  The muscle biopsy 
was then placed on an empty petri dish, and all visible adipose and connective tissue 
removed, before finely mincing the tissue into smaller pieces.  5ml Solution ATE 
(10% Trypsin-EDTA, Invitrogen, UK in Solution A) was added to the finely minced 
tissue to help aspirate it into a sterile wheaton flask with a magnetic stirrer.  The petri 
dish was washed a further two times with 5ml Solution ATE to give a final volume in 
the flask of 15ml.  The flask was placed in a pre-warmed beaker of water, at 37°C, 
placed on top of a hotplate with magnetic stirrer (Stuart Scientific, Bibby Scientific 
Limited, Staffordshire, UK) and the stirring mechanism initiated to ensure the magnet 
bounced within the flask disrupting the tissue fragments further.  After 15 minutes 
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solution ATE, with dissociated cells, was aspirated and transferred into a 50ml 
centrifuge tube containing 20ml 10% FCS-DMEM, with care taken to avoid 
removing the muscle fragments.  15ml fresh solution ATE was added to the flask to 
continue the magnet stirring.  This process was repeated a third time.  Each time the 
15ml solution ATE with dissociated cells was placed into 20ml DMEM-10%FCS to 
neutralise the trypsin-EDTA before centrifuging at 400g for 5 minutes to obtain a 
pellet of dissociated cells.  Each cell pellet was resuspended in 1ml skeletal muscle 
cell growth medium (PromoCell, Heidelberg, Germany) supplemented with 
PromoCell skeletal muscle SupplementMix (containing foetal calf serum 0.05 ml/ml, 
bovine fetuin 50µg/ml, recombinant human epidermal growth factor (EGF) 10ng/ml, 
recombinant human basic fibroblast growth factor (bFGF) 10ng/ml, recombinant 
human insulin 10µg/ml, dexamethasone 0.4µg/ml), 10% FCS (Gibco®), 1x 
GlutaMAX™ (Gibco®, UK), 100 units ml-1 penicillin and 100µg ml-1 streptomycin 
(Invitrogen) (SMM complete medium).  The cells were pooled and each centrifuge 
tube rinsed with 2ml SMM complete medium to collect any remaining cells.  All 9 ml 
was filtered across a 40µm sterile cell strainer (BD Falcon™, Oxford, UK) and then 
plated into a 25cm2 tissue culture flask.  The flask was then placed in a humidified 
incubator with 5% CO2 atmosphere maintained at 37°C.  After 3 days, 3ml of fresh 
SMM complete media was added into the flask.  5 days after initial plating of cells, 
all medium was removed, and the cells washed gently with 3mls DPBS (Dulbecco’s 
phosphate buffered saline, calcium and magnesium free, Gibco, UK) and 9ml fresh 
SMM complete medium replaced into the flask.  The media was changed every 48 – 
72 hours, and cultures were inspected using a phase-contrast microscope to confirm 
typical myoblast morphology.   
2.5.1.1 Culture and differentiation of human myoblasts 
Cultures of human myoblasts were maintained in SMM complete medium until 60 – 
70% confluent.  At this point, to avoid the cells differentiating due to cell-to-cell 
contact, cells were trypsinised as described above for C2C12 myoblasts, and 
passaged approximately 1:6.  If required for future experiments, human myoblasts 
were counted using a haemocytometer and resuspended to approximately 30,000 
cells/ml.  Cells were then seeded into 6-well plate (2ml/well) 24-well plate 
(500µl/well) or 96-well plates (100µl/well).  All experiments using human myoblasts 
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and myotubes were performed between passages 2 – 5 to ensure cells did not undergo 
phenotype conversion. 
2.5.2 Human myoblast analysis 
Cultures of human myoblast isolates were used to explore the differences in function 
and response to simulated ischaemia.  Human myoblast isolates were also assessed 
for true myogenic lineage and purity.  Analysis of differences between CLI and 
control myoblasts, with regards to their proliferation, migration and contractile 
characteristics were assessed in the following ways.   
2.5.2.1 Assessment of proliferative capability 
Several techniques for assessing the proliferative capacity of cells exist.  Often these 
techniques rely upon either the viability or activity of cells in order to estimate their 
proliferative capacity [272].  In order to accurately identify the proliferative potential 
of human myoblasts under both normoxic and hypoxic conditions a number of 
techniques were used in combination. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
MTT is a tetrazolium dye that is reduced by cellular mitochondrial dehydrogenase 
enzymes present in viable cells, to produce an insoluble formazan product.  The 
formazan product can be solubilised using dimethyl sulphoxide (DMSO), and the 
absorbance of the solution measured using a spectrophotometer at absorbance 
wavelength 560nm.  As only viable cells can reduce the MTT to formazan, it is often 
used as a surrogate marker for cell proliferation.  The MTT proliferation assay was 
conducted as follows.  Following trypsinisation, cells were plated in triplicate at 
5,000 cells/well in a 96 well microplate, and allowed to adhere for 6 hours.  Medium 
was exchanged for fresh 1% FCS-DMEM.  If the effect of ARA-290 or EPO was 
under investigation, these were added to the media of the relevant wells.  One plate 
was placed in the hypoxic chamber under simulated ischaemia as detailed above for 
12 hours, and a second control plate left in a normal humidified incubator with 5% 
CO2 ambient atmosphere.  When the ischaemic period was finished, both plates had 
media exchanged with 100µl fresh media and 10µl 12mM MTT.  Both plates were 
returned to a normal humidified incubator for 4 hours.  85µl of the media-MTT mix 
was removed, and any formazan by-product produced was solubilised using DMSO, 
by adding 50µl DMSO to each well.  The plates were incubated at 37°C for 10 
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minutes, shaken gently using a plate shaker and the absorbance read at 560nm using a 
Mithras LB940 microplate reader. 
Crystal Violet assay 
In contrast to the MTT assay which is dependent on metabolic activity, crystal violet 
relies upon the DNA-dye binding [272, 273].  Its accumulation within the nuclei is 
then solubilised to indicate the relative cell number as a tool to assess cell 
proliferation.  For the purposes of cell proliferation measurement, it was used in the 
following way.  A 0.025% (w/v) crystal violet solution was dissolved in a 10% (v/v) 
methanol solution.  Cells were plated in a similar way as described for MTT 
proliferation assay, and subjected to the same simulated ischaemia and normoxic 
conditions.  Following the ischaemic period, both plates were prepared by removal of 
media, and 2 washes with PBS, with care taken not to affect the cell monolayer.  50µl 
of the working crystal violet solution was added to each well, and allowed to incubate 
at room temperature for 10 minutes.  Following the incubation period, crystal violet 
solution was removed, and the plate washed 3 times with dH2O.  Following the final 
wash, to ensure the plate was adequately dried, it was inverted and blotted on tissue 
paper, before being left inverted and allowed to air dry for 3 hours.  After ensuring 
adequate drying, crystal violet was solubilised using a 33% acetic acid solution, and 
the absorbance read at 560nm using a microplate reader (Mithras LB940). 
CyQUANT® NF Cell Proliferation assay 
CyQUANT® NF Cell Proliferation assay (Invitrogen, UK) is based on the principle of 
measuring DNA content using a proprietary fluorescent DNA-dye which will bind to 
DNA.  The extent of cell proliferation can be determined by assessing cellular DNA 
content which will be proportional to cell number [274, 275].  Assessment of cell 
proliferation using this kit was performed as follows.  Cells were plated as previously 
described for MTT assay, and subjected to the same simulated ischaemia and 
normoxic conditions.  Following the ischaemic period, both plates were prepared by 
removal of media, and 2 washes of PBS, with care taken not to disrupt the cell 
monolayer.  A 1x dye binding solution was prepared by adding 22µl of CyQUANT® 
NF dye reagent, and 11µl of dye delivery reagent to 11ml of Hank’s balanced salt 
solution.  50µl of the dye binding solution was applied to each well, and the plate 
incubated at 37°C for 30 minutes.  Fluorescence intensity was measured in each 
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sample using a microplate reader with excitation at ~485nm and emission detection at 
~530nm (Mithras LB940). 
2.5.2.2 Scratch-wound assay for the assessment of migratory potential 
Scratch or wound assays were performed to assess the ability of myoblasts to close an 
artificial gap made in a monolayer of cells, as a marker of their migratory ability.  
Preparation for this assay required cells to be plated in a 24-well plate, and allowed to 
adhere and proliferate until around 70% confluence.  An artificial scratch was made 
into a monolayer of myoblasts using a sterile p10–200 pipette tip and the lid of the 
plate as a straight-edge ruler [276-278].  The cell monolayer was then washed with 
DPBS to remove any floating cells from the edge or centre of the scratch-wound. 
Mitomycin-C (Merck Millipore, UK) was included in all wells to inhibit cell 
proliferation.  A positive control well containing DMEM supplemented with 1% FCS 
only was also included.  All other wells were treated with DMEM supplemented with 
1% FCS and 7.5µg/ml mitomycin-C (MMC) as well as EPO or ARA-290 with any 
inhibitors of interest.  All wells were visualised using phase-contrast microscopy to 
ensure integrity of scratch-wound at time 0 hours.  Images were captured after 24 
hours (Olympus CDK2 microscope) for analysis of cell migration and scratch-wound 
closure.  Closure of the scratch-wound was expressed as the percentage of cells 
migrated into the scratch wound at 24 hours. 
2.5.2.3 Floating collagen gel cultures and quantitation of gel contraction 
Assessment of contractile ability was conducted using the previously described 
floating collagen gel contraction assay [279, 280].  Briefly, 24-well tissue culture 
plates were pre-coated with 0.22µm sterile-filtered 2.5% bovine serum albumin 
(BSA) overnight.  Prior to use, the BSA was removed, and the plate washed 3 times 
with DPBS.  Trypsinised human skeletal myoblast cells were counted using a 
haemocytometer and resuspended in DMEM supplemented with 1% FCS and mixed 
with a collagen solution, containing one part of 0.2 M N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES; pH 8.0), four parts collagen (Vitrogen-100, 3 
mg/ml, Cohesion Technologies, Palo Alto, CA), and five parts of DMEM-cell 
suspension yielding a final concentration of 80,000 cells/ml and 1.2mg/ml collagen.  
1ml of the collagen-cell suspension was added to each well, and the plate replaced to 
the humidified incubator with 5% CO2 atmosphere maintained at 37°C, for 1 hour to 
allow polymerisation of the collagen gels.  After polymerisation, gels were detached 
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from wells by adding 1ml of 1% FCS-DMEM medium.  Supplementing wells with 
10% FCS-DMEM medium created a positively contracted gel for comparison.  
Contraction of the gel was quantified by loss of gel weight and decrease in gel 
diameter over a 48-hour period. 
2.5.3 Preparation of human myotube samples for analysis 
2.5.3.1 Differentiation of human myoblasts 
Following trypsinisation, human myoblasts were seeded into different tissue culture 
plates including 6, 24, and 96 well plates as described previously and in addition 4-
well chamber slides (15,000 cells/well) (BD Bioscience, Bedford, MA, USA) for 
later immunofluorescence analysis.  Myoblasts were maintained in skeletal muscle 
cell growth medium until they reached 70-80% confluence, at which point they were 
induced to differentiate by the addition of differentiation, low-serum media described 
above (DMEM GlutaMAX™ supplemented with 2% horse serum).    
2.5.3.2 Immunofluorescence-immunocytochemistry of skeletal muscle cells 
Assessment of human isolated skeletal muscle populations using 
immunofluorescence analysis was performed using markers to ensure a myogenic 
population, and also to investigate the effect of simulated ischaemia on cell apoptosis.  
Immunofluorescence analysis was performed on cells seeded into chamber slides as 
described above.  All isolated myoblasts were subjected to immunofluorescence 
analysis for the muscle-specific marker desmin (Abcam, Cambridge, UK).  
Populations that demonstrated less than 5% contamination with other cell-types were 
used for myotubes analysis.   
Immunofluorescence protocol was as follows.  Cells were fixed in 10% formal saline 
containing 4% formaldehyde (CellPath, UK) for 5 minutes at room temperature.  If 
required, a permeabilisation step was performed using 0.05% Triton-X-100 in PBS 
for 10 minutes at room temperature.  Cells were washed thoroughly with PBS and 
non-specific binding of antibody prevented by incubating samples with isotype-
matched normal whole serum against the species in which the secondary antibody 
was raised.  Primary antibody dilution, duration and ambient temperature of 
incubation were optimised for each antibody including anti-desmin (Abcam) and anti-
annexin V (Abcam), both used at 1:250 dilution.  Slides were washed and incubated 
with a suitable Alexa Fluor® fluorescent secondary antibody against primary antibody 
 82 
species IgG heavy and light chain (Invitrogen, UK) at 1:2000 dilution for 30 minutes 
at room temperature, shielded from the light.  Slides were washed and mounted with 
Vectashield mounting medium containing DAPI (Vector Laboratories).  Fluorescence 
signal was detected using AxioSkop2 fluorescence microscope and Axiovision v4.8 
software (both Carl Zeiss GmbH, Jena, Germany) 
2.5.3.3 Preparation of human myotubes cell lysates for analysis 
Following experimental procedure, conditioned supernatant media was collected and 
stored for subsequent quantification.  Cell lysates were prepared by first rinsing the 
cell monolayer using DPBS.  Subsequently, RIPA buffer with 1x Complete mini 
EDTA-free protease inhibitor (Roche, UK) and phosphatase inhibitor cocktails 2 and 
3 (Sigma-Aldrich, UK) were applied directly to cells.  Cells were lysed further using 
mechanical shearing by a needle and 24-gauge syringe.  LDS sample buffer and the 
reducing agent DTT was added before samples were heated.  Prepared samples were 
then used for Western blot analysis as previously described. 
2.5.3.4 Enzyme-linked immunosorbent assay of human myotubes supernatant 
Enzyme-linked immunosorbent assay (ELISA) was performed on conditioned 
medium of both normoxic samples and those pre-treated with EPO or ARA-290 and 
the various inhibitors, before being subjected to simulated ischaemia.  ELISA 
quantitation of the conditioned medium for the inflammatory cytokine interleukin-6 
(IL-6) was performed using a sandwich-ELISA technique using Human IL-6 Duoset 
ELISA kit (R&D Systems®, MN, USA) as per manufacturer’s protocol.  Briefly, 
100µl of IL-6 capture antibody, at a concentration of 2µg/ml, was applied to the 
appropriate number of wells in a 96 well microplate.  The microplate was sealed and 
allowed to incubate overnight at room temperature.  Following overnight incubation, 
the capture antibody was aspirated and discarded, and the wells washed carefully 3 
times, ensuring complete removal of liquid at each step.  All future washes 
throughout the ELISA protocol were performed in an identical fashion, as described 
here, with the previous incubated solution aspirated and discarded, and 3 washes 
performed, ensuring complete removal of all liquid at each step.  The microplate was 
blocked using 100µl per well of 0.2µm sterile-filtered 1% bovine serum albumin 
(BSA) in PBS (pH 7.4) for 1 hour at room temperature.  Blocking solution was 
aspirated, and the wells washed.  A seven-point standard curve, using 2-fold serial 
dilutions, with a high standard of 600pg/ml was prepared.  100µl of sample or 
 83 
standard (duplicates) was added to the appropriate well and allowed to incubate at 
room temperature for 2 hours.  Standards and samples were discarded and the wells 
washed.  Detection antibody was diluted to 50ng/ml, and 100µl applied to each well.  
The plate was covered and allowed to incubate for 2 hours at room temperature.  
Detection antibody was discarded and the wells washed.  100µl streptavidin-
horseradish peroxidase (HRP) was applied to wells for 20 minutes at room 
temperature.  Streptavidin-HRP was discarded and the wells washed.  Glo Substrate 
Reagent (R&D systems®, MN, USA) was substituted for the frequently used 
hydrogen peroxide/tetramethylbenzidine substrate for HRP, and used as directed by 
manufacturer’s protocol.  Briefly, one part of Glo substrate reagent A (luminol) is 
mixed with two parts of Glo substrate reagent B (hydrogen peroxide) and 100µl 
added to each well.  The microplate was incubated in the dark for 5 minutes before 
the luminescence of the microplate was read using Mithras LB940 microplate reader.  
IL-6 concentration of each sample was calculated by comparison with a 4-parameter 
logistic curve to create a standard curve. 
2.6 In vivo murine model of hindlimb ischaemia 
2.6.1 Animal housing 
All animals were licensed under the UK Home Office Animals (Scientific 
Procedures) Act 1986 and Home Office approval was obtained prior to commencing 
all animal procedures (project licence PPL: 70/7087).  Strict adherence to institutional 
guidelines was practiced.  All animals were obtained from Charles Rivers 
Laboratories.  Upon arrival, they were housed in a specific pathogen-free 
conventional colony, with access to food and water ad libitum, and were exposed to 
12-hour light/dark cycles. 
The planning and reporting of the in vivo experiments were done according to 
ARRIVE guidelines [213, 281]. 
2.6.2 Hindlimb ischaemia model 
Unilateral hindlimb ischaemia was induced on BALB/c mice (Charles River, UK).  
Animals were anaesthetised using Avertin (2,2,2 tri-bromoethanol) dissolved in tert-
amyl alcohol (both, Sigma-Aldrich, UK) (0.25–0.5mg/kg) prior to surgery.  Once 
anaesthetised, animals were prepared by shaving over the hindlimbs on both sides.  
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The mouse was then placed in a supine position on an isothermal heating pad, and the 
surgical area prepared using alcohol wipe to clean.  Under a magnifying glass, a 1 cm 
vertical incision was made in the groin at the level of the inguinal ligament.  The 
subcutaneous fat pad overlying the groin was repositioned to one side to reveal the 
femoral artery, vein and nerve, covered by a thin layer of fascia.  The fascia was 
divided to expose the neurovascular bundle.  The femoral artery was carefully 
mobilised, with care taken to avoid damage or injury to the surrounding vein and 
nerve structures.  The common femoral artery, just proximal to bifurcation giving rise 
to the profunda femoris, superficial femoral and superficial circumflex artery was 
ligated using a 7-0 vicryl (Ethicon, Johnson & Johnson, UK) suture passed under the 
artery, and tied with a double knot.  The popliteal artery (an extension of the femoral 
artery) proximal to the knee joint was then identified and ligated in the same way.  
The artery in between the two ligatures was excised.  Closure of the incision was 
performed using 6-0 vicryl (Ethicon, Johnson & Johnson, UK), interrupted sutures.  
Immediately after completion of surgery, mice were randomly allocated to a 
treatment group, and received treatment plus analgesic care – Temgesic 
(buprenorphine) 0.05mg/kg.  Animals in the sham group underwent the same 
anaesthetic preparation, incision and exploration of the groin area to identify and 
mobilise femoral artery, but no ligation of the artery.  Skin was closed in an identical 
fashion, and animals received analgesic care.  Following surgery, mice were observed 
until they recovered, and then returned to standard housing conditions with free 
access to food and water ad libitum. 
2.6.3 Assessment of blood flow in the ischaemic hindlimb 
Blood flow perfusion of the ischaemic hindlimb was assessed using laser Doppler 
perfusion imaging (LDPI) (Moor Instruments, UK).  Measurements were taken pre-
operatively, in $ of randomly selected animals, and immediately following induction 
of ischaemia in all animals to ensure greater than 95% blood flow reduction in the 
operated paw was achieved.  At the time of sacrifice, 3, 10 and 21 days after surgery, 
animals were anaesthetised, allowed to equilibrate in temperature on an isothermal 
heating pad, at 37°C for 15 minutes, and LDPI measurement taken.  Paw perfusion 
results were analysed using in-program software (Moor LDPI Image Processing v4.0, 
Moor Instruments, UK).  All perfusion images were analysed by an observer blinded 
to intervention.  The extent of residual ischaemia at the various end-points was 
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expressed as a ratio of perfusion in the left (ischaemic) paw versus the right (control) 
paw – known as the perfusion index. 
2.6.4 Assessment of functional outcome following hindlimb ischaemia 
Two observers, blinded to the treatment group of each mouse, assessed functional 
ability of the mice following hindlimb intervention.  Functional assessment was 
performed using a variety of well validated and detailed scoring systems, each 
assessing a different aspect of functional capacity, including generalised movement 
(Tarlov score), specific locomotor function (Basso mouse scale for locomotion 
(BMS)) and grading of visible ischaemia (Ischaemia and modified ischaemia score).   
At pre-determined time-points, all mice from all treatment groups were tested in an 
open field (30 cm x 20 cm) for 2 minutes, and assessed based on the above mentioned 
scoring systems, detailed below and in tables 2.4 and 2.5.   
2.6.4.1 Tarlov score 
The Tarlov score [282] is a widely used tool for assessing functional outcomes in a 
variety of different fields.  It contains graded scoring where at its lowest value 0 
always represents no movement.  However the Tarlov score has been modified to suit 
the requirements of different investigators, depending on the animals and scenario 
being studied.  Therefore the upper value can range from the original 6, to lesser or 
greater values [283].  For the purposes of this work, the original Tarlov score was 
used, with 0 representing no movement, and 6 indicating the normal full and fast 
movements seen in mice. A full description of characteristic movement and criteria 
related to each score can be found in Table 2.4. 
2.6.4.2 Ischaemia and Modified ischaemia score 
The ischaemia score was devised to evaluate the mobility of mice following hindlimb 
ischaemia by simple visual assessment [284].  Visual inspection of the ischaemic 
hindlimb was performed to assess the viability of the foot or whole limb, or the 
presence of any gangrenous tissue or possible auto-amputation.  The ischaemia score 
was later modified to detect less severe levels of ischaemia, as represented by 
discolouration of nails or toes [285].  The individual criteria of each score can be 
found in table 2.4, but collectively allow for the easy visual assessment of greater 
degrees of hindlimb ischaemia.  Both the original and modified ischaemia scores 
were employed and the animal assessed in the open field. 
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2.6.4.3 Basso mouse scale of locomotion (BMS) 
The BMS evolved from the previously described Basso, Beattie and Bresnahan 
(BBB) locomotor rating scale, a scale originally designed to assess locomotor 
competence in rats following spinal cord injury [286].  The BMS was introduced to 
cater specifically for mice, to be a comprehensive locomotor assessment, which, once 
assessors were trained would be highly sensitive, and easier to replicate.  The detailed 
scoring system was modified for the purposes of this work, so that evaluations 
relevant only to spinal cord injury pathology were excluded.  The modified BMS 
used can be found in table 2.5.     
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Table 2.4: Tarlov, ischaemia and modified ischaemia functional scores 
Functional assessment scoring sheet, copied from Brenes et al 2012 [287] 
Score Description 
Tarlov   
0 No movement 
1 Barely perceptible movement, non-weight-bearing 
2 Frequent movement, non-weight-bearing 
3 Supports weight, partial weight-bearing 
4 Walks with mild deficit 
5 Normal but slow walking 
6 Full and fast walking 
  
Ischaemia  
0 Auto-amputation > half lower limb 
1 Gangrenous tissue > half foot 
2 Gangrenous tissue < half foot, with lower limb muscle necrosis 
3 Gangrenous tissue < half foot, without lower limb muscle necrosis 
4 Pale foot or gait abnormalities 
5 Normal 
  
Modified Ischaemia  
0 Auto-amputation of leg 
1 Leg necrosis 
2 Foot necrosis 
3 Discolouration of > 2 toes 
4 Discolouration of 1 toe 
5 Discolouration of >2 nails 
6 Discolouration of 1 nail  
7 No necrosis 
 
Table 2.5: Basso scale for mouse locomotion 
Functional assessment score sheet, modified from [286]  
Score Description 
0 No movement in affected limb 
1 Slight movement in affected limb 
2 Extensive movement in affected limb 
3 Plantar placing of the paw with or without weight support –OR– 
Occasional, frequent or consistent dorsal stepping but no plantar 
stepping 
4 Occasional plantar stepping 
5 Frequent or consistent plantar stepping, no coordination 
6 Frequent or consistent plantar stepping, some coordination 
7 Coordinated plantar stepping (normal) 
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2.6.5 Sample collection and preparation 
2.6.5.1 Post mortem samples 
Following whole blood collection, animals were sacrificed by cervical dislocation.  
0.3 x 0.3 x 0.3 cm samples of gastrocnemius and tibialis anterior muscles from both 
right and left hindlimbs was placed in RNAlater™ RNA stabilisation reagent 
(Ambion, Austin, Tx) and stored according to manufacturer’s guidelines for later 
RNA quantitation.  The remaining muscle samples as well as whole heart, lungs, liver 
and kidney organs were immersed in 10% formal saline containing 4% formaldehyde 
(CellPath, UK) for histological processing.   
2.6.5.2 Histological analysis 
As detailed above, formalin-fixed tissues were processed and dehydrated overnight 
before being embedded in molten paraffin to generate FFPE samples.  Sections were 
cut and mounted on polylysine slides for histological analysis.   
Haematoxylin and Eosin stain 
H&E was performed on sections from all animals, to ensure correct orientation.  The 
H&E stain is also an excellent stain to display tissue architecture, and demonstrate 
any areas of muscle regeneration, denervation, necrosis or provide evidence of 
inflammatory infiltrate – all characteristic features of muscle afflicted with chronic 
periods of ischaemia.  Representative high-powered images, encompassing 3 fields of 
view per muscle group were taken using Axioscop-2 (Carl Zeiss, Germany), with the 
observer blinded to the origin of the animal.  Following image acquisition, 5 blinded 
observers were used to score all sections focusing on typical features of muscle 
pathology previously mentioned.  A scoring system based on a standard operating 
procedure for quantifying skeletal muscle pathology, developed by the neuromuscular 
diseases network, was created [288] to delineate stages of muscle injury.  
Representative scoring images can be seen below, along with their associated score, 
based upon different stages of muscle damage and repair or regeneration (figure 2.2).  
Normal, or undamaged muscle fibers scored 0.  At the other end of the muscle injury 
spectrum, muscle which showed large areas that had undergone fibro-adipocytic 
changes, as well as large areas of non-muscle tissue were given a score of 5.  A score 
of 1 was awarded if muscle showed signs of inflammatory infiltrate, with minimal 
disruption to tissue ultrastructure.  A score of 2 corresponded to necrotic myofibres, 
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showing dense inflammatory infiltrate and, or, variation in muscle fibre size due to 
hypercontracted and degenerating muscle fibres.   A score of 3 corresponded to 
recently regenerated muscle fibres, as evidenced by small myofibres with centrally 
located nuclei.  Larger diameter fibres with central nuclei was evidence of a 
regenerated myofibres, which attained a score of 4. 
 
Figure 2.2: Histological features of mouse skeletal muscle pathology stained with 
haematoxylin and eosin, copied from [288] 
A = 0 
C = 2 
E = 4 
B = 1 
D = 3 
F = 5 
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Representative images of muscle injury seen following H&E staining of muscle 
sections.   A: Normal myofibres characterised by peripheral nuclei, intact sarcoplasm 
and regular shape are mainly visible.  B: Early inflammation and necrotic myofibres 
can be seen with severe inflammatory infiltration.  There is also loss of sarcoplasm 
and variation in fibre size.  C: Degenerating, necrotic myofibres characterised by a 
fragmented sarcoplasm, myofibres with irregular shape and few peripheral 
myonuclei.  D: Recent regeneration characterised by many small-diameter myofibres 
with central nuclei.  E: Regenerated myofibres, indicated by larger-diameter 
myofibres which have retained their central nuclei.  F: Fat deposition in injured 
muscle, between myofibres in the interstitial space is common and can also include 
fibrotic changes (not shown).  
Immunohistochemical analysis to determine the degree of proliferation using the 
marker Ki-67 was performed.  In addition assessment of capillary : fibre (C:F) ratio 
was performed using CD34 staining.  CD34 is commonly utilised as a haematopoietic 
and endothelial cell surface marker, however it is also capable of identifying both 
activated and quiescent satellite cells in mice, but not human, tissue [289, 290].  
Details of immunohistochemistry methods can be found in chapter 2.2.1. 
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2.7 Data analyses 
2.7.1 Power calculation 
Selection of sample sizes was based on calculations performed using preliminary data 
from validation and optimisation experiments and from published data to provide a 
90% power of detecting a difference between the groups at the 5% significance level.  
This was based on the formula:  
N per group = 2 x (Z"/z + Z!)2 x %2/&2 
Where:  & = difference in mean values 
% = standard deviation of values in either group 
  " = probability of Type I error occurring = 0.05 
  ! = probability of Type II error occurring = 0.10 (power of 90%) 
  Z"/z = 1.96 
  Z! = 1.28 
Based on mean values and SD of preliminary EPO and ARA-290 efficacy studies in 
the literature, required sample sizes were estimated to be approximately 12 patients 
per group for human tissue analysis, 5 samples per group for human in vitro analyses 
and 6 animals per group for in vivo validation. 
Further considerations were made based on unit case-load, the time period required to 
collect adequate samples and the time and costs of laboratory analyses. 
2.7.2 Statistical analyses 
Statistical analyses were performed using GraphPad Prism version 6.0 for Mac 
(GraphPad Software).  Single comparisons between two groups were analysed using 
two-tailed Mann-Whitney test for non-parametric unpaired data.  Ordinary one-way 
ANOVA test was used for comparisons between multiple independent groups, 
followed by Tukey’s multiple comparison test.  A p-value < 0.05 was considered 
statistically significant.   
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CHAPTER 3  
Tissue protective receptor in CLI 
3.1 Introduction 
The ability of EPO to prevent apoptosis is key to its function as a haematopoietic 
hormone.  Endogenous EPO production is mediated by signals of low or impaired 
oxygen delivery to tissues.  Multiple causes of low oxygen tension exist, including 
anaemia and hypoxemia.  This hypoxic stimulates upregulates gene transcription of 
EPO, mainly in the kidneys – the primary site for EPO production in adults.  The 
main action of EPO is upon erythrocyte-colony forming units (CFU-E) contained 
within the bone marrow.  Once EPO reaches target EPO receptors on CFU-E, it is 
able to prevent apoptosis of the immature cells, allowing them to mature into 
reticulocytes and enter the circulation, maturing further into erythrocytes, increasing 
the circulating pools of erythrocytes and ultimately improve tissue oxygenation.   
This anti-apoptotic effect of EPO is what has propagated the belief that EPO could 
play a pivotal role in mediating cytoprotection in other tissues.  Its potential tissue-
protective actions have previously been investigated in organs including the brain, 
heart and kidneys, all of which have also exhibited EPOR expression.   Other tissues 
that have demonstrated EPOR expression include testes and skeletal muscle.   
More recently EPO-derivatives have also been created with the specific intention of 
retaining only those tissue-protective effects of EPO and not its haematopoietic 
effects, which can lead to thrombotic side effects.  The advent of novel EPO-
derivatives was deemed possible for numerous reasons, including structural analysis 
that demonstrated discrete portions of the EPO molecule binding with the EPO 
receptor homodimer to promote erythrocyte maturation.  Additionally, the capacity 
EPO possesses to provide tissue-protective effects are thought to be mediated via a 
heterodimer receptor composed of the EPOR in complex with a !cR, and EPO-
derivatives preserve the ability to bind with the EPOR / !cR tissue protective receptor 
complex. 
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Little published data exists describing the presence of the EPOR or the !cR in human 
skeletal muscle in detail.  Previous reports have described the presence of both 
receptors in human skeletal muscle, but not investigated their functionality [169, 
291].  In this chapter the presence of the EPOR / !cR tissue protective receptor in 
human skeletal muscle has been explored.  Recently, some controversy has arisen 
over the validity of previously published data with regards to EPOR expression in 
non-haematopoietic tissue.  Much of this debate has stemmed from the proposed lack 
of specificity of numerous commercially available EPOR antibodies [292].   
Skeletal muscle has an intrinsic ability to repair and regenerate itself in response to 
biological, chemical or mechanical injury.  This regenerative potential is largely 
fulfilled by satellite cells – small mononuclear cells, identified by their characteristic 
location between the basal lamina and sarcolemma of skeletal muscle fibres.  Often 
referred to as the principal skeletal muscle stem cell, mitotically quiescent satellite 
cells are activated in response to injury stimuli, resulting in increased proliferation.  
The new pool of satellite cell progeny giving rise to a significant increase in 
proliferation will merge with existing myofibres and help to repair or regenerate 
injured myofibres either by fusing with existing myofibres, one another or 
replenishing the satellite cell population [293, 294].   
Satellite cells in early studies were identified by observation under electron 
microscope, on the basis of their location.  Reliable markers of satellite cells have 
since been identified, but practical difficulties have arisen, mainly due to the dynamic 
state of markers in quiescent and subsequently activated cells, as well as significant 
differences in the presence of several markers between humans and animals, mainly 
mice, in which much of the current knowledge regarding satellite cells and their 
markers has ben performed.  Examples of specific molecular markers of satellite cells 
for both humans and mice include Pax7 and M-cadherin [295].  In addition, other 
commonly used markers in mice include syndecan 4, CD34 and Myf5 [295-297]. In 
CLI there is evidence of increased numbers of satellite cells and attempts at muscle 
repair [298].  
 
 
 94 
3.2 Aims 
The aims of this chapter were therefore to demonstrate the existence of both the 
EPOR and !cR and further to determine a functional role of the tissue-protective 
receptor by identifying its potential to co-localise and interact physically within 
human skeletal muscle. 
 
3.3 Methods 
Written informed consent was obtained from all patients prior to enrolment in this 
study.  Muscle biopsies from CLI patients undergoing lower limb amputation and 
control patients requiring saphenous vein harvest for CABG were collected for the 
purposes of this work.  Clinical and demographic data on all donors was also 
collected at the time of biopsy harvest.  Subsequent analysis on clinical indicators and 
patient demographics was performed. 
Western blot analysis was performed to detect the presence of the tissue protective 
heteroreceptor, EPOR and !cR, and to determine differential expression of Pax7 in 
human skeletal muscle homogenates from CLI and control biopsies.  The techniques 
of muscle homogenisation and Western blot analysis have previously been described 
in chapter 2.2.3. Protein expression of EPOR in skeletal muscle homogenates was 
assessed using two commercially available EPOR antibodies.   
Immunohistochemistry was performed on human skeletal muscle sections to assess 
the localisation of EPOR and !cR within skeletal muscle.  Subsequent co-localisation 
of the two receptors was established using immunohistochemistry and 
immunofluorescence.  Expression of the satellite cell marker Pax7 was also assessed 
on human skeletal muscle sections.  A detailed protocol of immunohistochemistry 
techniques, including double staining, can be found in chapter 2.2.  Double 
immunofluorescence labelling for EPOR and !cR required the use of Zenon Rabbit 
IgG Labelling kit (Invitrogen, UK) as per manufacturer’s protocol.  Briefly, 1µg of 
each antibody was mixed with 5µl of desired Zenon labelling reagent for 5 minutes at 
room temperature.  5µl of Zenon blocking reagent was added into the mixture and the 
complete solution incubated for a further 5 minutes at room temperature.  The 
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antibody-fluorescent probe complex was then applied to FFPE human skeletal muscle 
sections that were dewaxed, prepared using 10mM citrate buffer (pH 6.0) antigen 
retrieval, and blocked in 0.2% BSA and 5% goat serum in PBS for 30 minutes at 
room temperature.  The antibody-fluorescent probe complex was applied to sections 
for 1 hour at room temperature followed by three 5-minute washes.  A second 
fixation of the tissue sections was performed using 4% formaldehyde in PBS for 10 
minutes at room temperature followed by two 5-minute PBS washes before 
counterstaining and mounting in mounting medium with DAPI. 
3.3.1 Co-immunoprecipitation 
To directly assess heterodimerisation of the EPOR and !cR, co-immunoprecipitation 
and subsequent Western blot analysis was performed.  Immunoprecipitation is 
designed to enrich a protein within a complex mixture (as you would find in a whole 
tissue homogenate).  Co-immunoprecipitation, should, if a physical interaction is 
present, enrich both proteins of interest.  To determine the physical interaction 
between the EPOR and the !cR co-immunoprecipitation (Co-IP) was performed on 
snap frozen muscle biopsies.  Briefly, 20mg of muscle tissue was placed in a 2ml 
round-bottomed microcentrifuge tube with 600µl of IP lysis/wash buffer (150mM 
NaCl, 1% Triton X-100, 10mM Tris pH7.4, 1mM EDTA, 1mM EGTA pH8.0, 1x 
Complete mini EDTA-free protease inhibitor (Roche), 1% phosphatase-inhibitor 
cocktail 2 and 3 (Sigma-Aldrich)).  The muscle was homogenised using a 5mm 
stainless steel bead with TissueLyser (both, QIAGEN GmbH, Hilden, Germany) for 2 
x 2 minutes at 30 Hz.  The steel bead was removed, and samples centrifuged at 
13,000 rpm for 15 minutes at 4°C.  The supernatant was removed and applied to the 
pre-clearing antibody-Sepharose bead complex, prepared below. 
Antibody-bead preparation 
The antibodies of interest were each cross-linked to the protein A-Sepharose beads 
(Sigma-Aldrich, UK) and in addition a pre-clearing antibody-Sepharose bead 
complex was also prepared.  For the purposes of pre-clearing samples, an anti-
collagen IV antibody was used each time.  All antibodies were mixed in a 1:10 ratio 
with Sepharose beads that were pre-washed using lysis buffer.  Antibody-bead 
complexes were incubated for 1 hour with constant rotation at 4°C and then washed 
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in equal volumes of IP wash buffer, before centrifuging to pellet the antibody-bead 
complex, and repeating the wash step twice more. 
Cross-linking of the anti-!cR and anti-EPOR antibodies to Sepharose beads was 
performed using 20mM dimethyl pimelimidate (DMP) in 0.2M sodium borate (pH 
9.0) in a 1:1 ratio with the pre-mixed antibody-bead complexes.  The antibody-bead 
complex was returned to constant rotation at 4°C for 1 hour, before the cross-linking 
reaction was quenched using 1ml of 0.2M ethanolamine (pH 8.0).  The cross-linked 
antibody-bead complex was centrifuged and the supernatant removed.  To ensure all 
residual DMP was neutralised, a further 1 ml of 0.2M ethanolamine (pH 8.0) was 
added before the cross-linked antibody-bead complex was washed 3 times, as 
described above with IP wash buffer. 
Pre-clearing samples 
Following preparation of the pre-clearing antibody-Sepharose bead complex, the 
supernatant from tissue homogenisation was applied and the whole sample incubated 
at 4°C with rotation for 1 hour.  The sample was centrifuged, and the supernatant 
removed with care taken not to aspirate any of the bead pellet.  The supernatant was 
then divided in two, and applied to either the anti-!cR or anti-EPOR Sepharose bead 
cross-linked pellet.  Samples were incubated at 4°C with constant rotation for 1 hour.  
Each sample was then divided in two in order to be washed with IP wash buffer of 
either 150mM (low stringency) or 500mM (high stringency) NaCl concentration.  5 
washes in total were performed, before samples were resuspended in LDS-sample 
buffer, heated at 95°C for 5 minutes, centrifuged to pellet the beads, and the 
supernatant used for SDS-PAGE Western blot analysis to confirm the presence of the 
receptor that was immunoprecipitated, as well as the presence of the co-
immunoprecipitated protein. 
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3.4 Results 
Table 3.1 shows analysis of clinical and demographic data from all CLI and control 
donors.  Analysis revealed no significant difference in the prevalence of all major risk 
factors for PAD between the two sample groups.  There was also no significant 
difference in age or cardiovascular risk factor treatment between the two groups.  3 
patients in total were receiving ESA therapy, however these samples were only used 
for tissue analysis, and not isolation of human myoblasts. 
ABPI was the only clinical indicator in which there was a significant difference 
(P<0.0002, Mann-Whitney test, n=17 CLI, n=15 control group) between CLI and 
control patients. 
Table 3.1: Clinical and demographic summary of study participants 
 CLI Control 
Age 73 ± 18.5 62 ± 10.5 
Male:Female 11:6 11:4 
ABPI 0.2925 ± 0.1929 0.9974 ± 0.0656 
Diabetes Mellitus 6 5 
Ischaemic Heart Disease 13 15 
Hypertension 15 11 
Smoking History 12 10 
Aspirin Therapy 11 9 
Statin Therapy 13 13 
ESA Therapy 2 1 
CLI: Critical limb ischaemia, ABPI: ankle-brachial pressure index, ESA: erythropoiesis 
stimulating agent. 
 
3.4.1 Expression of the tissue protective receptor in human skeletal muscle 
3.4.1.1 Multiple EPOR antibodies can detect EPOR expression 
Using the same CLI and control sample muscle homogenates two different EPOR 
antibodies, produced commercially from two separate companies were compared.  
Both antibodies were capable of detecting a protein band at approximately 60 kDa, 
and showed a similar pattern of protein expression between identical Western blots 
performed with CLI and control samples (figure 3.1).   
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Muscle homogenates from all CLI and control patient samples were used to 
demonstrate the expression of both components of the tissue protective heteroreceptor 
complex.  Western blot analysis of CLI and control samples revealed a distinct 
increase in expression of the EPOR and !cR  (figure 3.2A).  Densitometric analysis 
of the detected protein bands showed expression of both receptors to be significantly 
upregulated in CLI muscle samples in comparison to controls (CLI: n=17, Control: 
n=15; P<0.001) (figure 3.2B). 
Using RNA isolated from 12 of the patients, qRT-PCR analysis for the !cR and 
EPOR genes showed significantly upregulated gene activity in CLI samples, 
correlating with the observed increase in protein expression (CLI: n=6, Control: n=6; 
!cR: P<0.030; EPOR: P<0.0173).  Figure 3.3 A and B show the normalised gene 
expression levels in whole muscle RNA from CLI and control samples. 
 
 
Figure 3.1: Expression of EPOR using 2 antibodies 
Western blot analysis was performed to compare two commercially available anti-
EPOR antibodies.  Both antibodies demonstrated similar expression profiles of 
identical CLI and control samples.  
EPOR 
(SC-697) 
EPOR 
(ab56310) 
CLI    Control 
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Figure 3.2: Expression of !cR and EPOR in human muscle lysate 
A: A representative Western blot of human skeletal muscle from CLI and control 
samples demonstrated increased expression of both !cR and EPOR (both antibodies 
from Abcam) in CLI muscle.  B: This was confirmed using densitometric analysis of 
all Western blots performed on all CLI (n=17) and control (n=15) samples, which 
concluded an increase in expression of both receptors in CLI muscle (*P<0.001, 
Mann-Whitney test).  Data are expressed as mean ± SEM. 
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Figure 3.3: !cR and EPOR gene expression in human skeletal muscle 
Differences in !cR and EPOR between CLI and control muscle shows a marked 
increase in gene expression in CLI muscle samples.  (*P<0.05; **P<0.01, both 
Mann-Whitney test, n=6 both CLI and control groups).  Data are expressed as mean 
± SEM.  NTC: non-template control. 
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3.4.2 Interaction of the EPOR and !cR in human skeletal muscle 
Following co-immunoprecipitation of our sample with an antibody for each protein of 
interest, subsequent Western blot analysis demonstrated that the !cR co-precipitated 
when anti-EPOR antibody was used to immunoprecipitate proteins of interest from a 
muscle lysate sample.  The same finding was observed when a sample was 
immunoprecipitated for using an anti-!cR antibody, where it was subsequently 
possible to detect the co-precipitated EPOR (figure 3.4).   
 
Figure 3.4: Co-immunoprecipitation of !cR and EPOR in human skeletal muscle 
A: Co-immunoprecipitation using an anti-!cR antibody to perform 
immunoprecipitation pull-down.  B: Co-immunoprecipitation performed using anti-
EPOR antibody to pull-down.  Subsequent Western blot analysis for both !cR and 
EPOR demonstrated the co-immunoprecipitation of both receptors in each sample. 
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3.4.3 Distribution of the tissue protective receptor 
To explore the location of both !cR and EPOR within muscle sections 
immunostaining was performed.  Figure 3.5A shows representative immunostaining 
of the !cR: a markedly diffuse distribution of staining throughout the cytoplasm of 
muscle fibres.  In comparison, in figure 3.5B, representative immunostaining for the 
EPOR showed more discrete staining, mainly localised to the periphery of fibres.  
Double-staining for both !cR and EPOR (both antibodies from Abcam) using the 
chromagen alkaline phosphatase to stain for the !cR and DAB to display the EPOR, 
identified areas where the two receptors co-localise with one another (figure 3.5C).  
An IgG Isotype control for both antibodies was also prepared (figure 3.5D).   
Co-localisation of the two receptors in human skeletal muscle sections was more 
clearly demonstrated using direct immunofluorescence for !cR and EPOR (both 
antibodies from Santa Cruz Biotechnology).  The presence of both receptors co-
localising in CLI and control human skeletal muscle was demonstrated.  Co-
localisation of the two receptors was mainly limited to the muscle fibre membrane 
(figure 3.6). 
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Figure 3.5: Tissue-protective heteroreceptor expression in human skeletal 
muscle 
A: !cR can be found distributed quite ubiquitously throughout the muscle fibre, but 
greater membrane staining.  B: EPOR expression is located discretely around the 
membrane of muscle fibres.  C: Double-staining for the presence of both !cR 
(alkaline phosphatase, red) and EPOR (DAB, brown) shows co-localisation (black 
arrows) of the two receptors in human muscle sections.  D: IgG isotype (rabbit and 
mouse) control.  Scale bar = 50µm. 
A B 
D C 
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Figure 3.6: Immunofluorescence co-localisation of !cR and EPOR in human 
skeletal muscle 
Double staining for the presence of !cR (red) and EPOR (green) shows co-
localisation of the two receptors (orange) in human muscle sections of CLI and 
control samples.  An IgG isotype control (rabbit) was also included. 
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3.4.4 Regenerative potential of human skeletal muscle in CLI 
Western blot analysis of human skeletal muscle lysates for the satellite cell marker 
Pax7 demonstrated significantly increased expression of Pax7 in CLI samples (lanes 
1 – 5) compared to controls (P<0.05, Mann-Whitney test, n=5 both CLI and control) 
(figure 3.7A).   
Immunostaining of human skeletal muscle sections identified Pax7 positive nuclei in 
both CLI and control muscle sections.  However, in concordance with Western blot 
results, CLI muscle sections had a greater number of Pax7 positive nuclei per field of 
view, compared to control muscle (figure 3.7B).   The number of positive nuclei 
observed in CLI muscle was approximately 3 times greater than that observed in 
control samples – CLI mean=18.29, control mean=6.11, n=5 per group.  The 
proportion of Pax7 positive nuclei observed within control sections was comparable 
to the 2–7% reported in the literature [299].  An IgG isotype and non-muscle tissue 
(tonsil) control was also included to ensure specificity of the anti-Pax7 antibody. 
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Figure 3.7: Myogenic potential in human skeletal muscle 
A: Human skeletal muscle homogenates were assessed using Western blot analysis 
for the satellite cell marker Pax7.  CLI muscle samples (lanes 1–5) demonstrated 
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approximately 5-fold greater expression of Pax7 compared to control muscle samples 
(lanes 6–10; *P<0.05, Mann-Whitney test, n=5 both CLI and control groups).          
B: Immunohistochemistry performed on skeletal muscle sections from CLI and 
control samples demonstrated increased expression of Pax7 positive nuclei in CLI 
muscle sections compared to control.  Quantification of the number of Pax7-positive 
nuclei per muscle fibre demonstrated approximately 3-fold greater numbers of Pax7 
positive nuclei in CLI muscle samples (***P<0.0003, Mann-Whitney test n=5 both 
CLI and control groups).  An IgG Isotype specific and non-muscle tissue control were 
used to ensure specificity of the anti-Pax7 antibody.  Scale bar = 100µm 
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3.5 Discussion 
In this chapter, the presence of the tissue protective receptor, described in chapter 1, 
has been examined in more detail.  Although EPOR expression has been 
demonstrated in various tissue types beyond erythrocyte precursors in the bone 
marrow, less literature exists describing its presence in human skeletal muscle.  Those 
reports that do describe the presence of EPOR in muscle have utilised either murine 
cell lines (C2C12) [172] or skeletal muscle from healthy volunteer subjects [169-
171].  Further, expression of the !cR within human skeletal has not been 
demonstrated previously.   
Observation of the presence of the EPOR in human skeletal muscle is in keeping with 
work by other groups [169, 171].  Previous studies assessing the efficacy of EPO in a 
setting of ischaemic stroke has demonstrated the presence of EPOR and an 
upregulation in receptor expression following ischaemic insult, in both pre-clinical, 
animal models, as well as in human study subjects [300-302].  A similar pattern of 
expression was observed in our CLI muscle samples when compared to control 
samples, when gene expression levels were assessed.  Whilst there is likely to be a 
multitude of factors interplaying to result in the increased presence of EPOR 
observed, one possibility is the hypoxic environment found in CLI muscle initiates 
HIFs which then respond by upregulating various genes and signalling cascades 
designed to counteract the hypoxic stimulus, including increasing EPOR expression – 
similar to the scenario with red blood cells.  Another possible explanation for the 
upregulation of EPOR observed is the role of the innate immune system and its 
response to pathogen invasion – a common cause of prolonged colonisation of 
ischaemic ulcers and or gangrene often seen in CLI patients.  In order to prevent 
spread of an infection, the innate immune response is initiated and employs pro-
inflammatory cytokines of the type I superfamily to isolate and remove any 
pathogens.  Members of the pro-inflammatory cytokine superfamily include TNF-", 
one of a number of genes responsible for the upregulation of EPOR expression in the 
innate immune response [303].  The roles of the EPOR and TNF-" are antagonistic to 
one another.  Upregulation of EPOR expression is required to regulate the extent of 
the response mounted by the pro-inflammatory arm by salvaging cells from pro-
inflammatory cytokine-induced cell death.  This mechanism is designed to ensure 
 109 
excessive collateral damage is prevented.  Therefore the presence of infection and 
inflammatory stimuli could be another additional reason for the increase in EPOR 
expression observed in CLI muscle.   
Indeed, the importance of the EPOR in embryonic development as well as in 
mediating tissue-protection has already been investigated, and been shown to play a 
pivotal role in both of these areas.  Firstly, EPOR knockout mice die at around 
embryonic day 13.5, due mainly to the failure of erythropoiesis, but additionally due 
to ventricular hypoplasia that is also observed between embryonic day 12-13, likely 
as a consequence of the general hypoxic state [304].  In addition, the fundamental 
role of EPOR in mediating tissue-protection has also been demonstrated in models of 
ischaemic stroke.  In these models, upregulation of the EPOR as well as 
endogenously produced EPO has been observed, and shown to reduce infarct size as a 
consequence.  However addition of a soluble EPOR abolishes this reduction in infarct 
size by competing for available EPO-ligand leading to greater infarct volume and 
worse behavioural outcomes [305, 306].  The same outcome can also be observed 
when an EPOR conditional knockout strain is used, and knockout of EPOR is 
introduced after initiation of stroke [307]. 
The presence and distribution of the !cR in human skeletal muscle was also revealed.  
Due to its nature as a multi-faceted, common receptor subunit, it is not surprising that 
it was present in skeletal muscle.  However, the effect of ischaemia on its expression 
has not been previously described.  The results proceeded to show elevated 
expression of the !cR in human CLI muscle.  Following a similar pattern of 
expression as the EPOR gene, RNA analysis of muscle isolates for expression of the 
!cR gene mirrored the increased expression seen in CLI samples.  This result was 
consistently seen on gene as well as protein analysis in all samples analysed.  
Previous examples of hypoxia inducing expression of the !cR have not been 
described, and within the current literature, stimuli of !cR mainly revolves around 
pro-inflammatory cytokines – IFN-" and TNF [308, 309].  Considering the role of IL-
3, IL-5 and GM-CSF in regulating key players of the haematopoietic system, 
including eosinophils, basophils, monocytes and macrophages, it is not surprising that 
inflammatory cytokines are capable of mediating their upregulation, in order to more 
effectively mount and maintain an immune response.  A proposed mechanism for 
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upregulation of the !cR in human CLI muscle could be the possibility of increased 
infection in patients with CLI, as also described for the increase in EPOR. 
Although reports exist in the literature with regards to specificity of certain 
commercially available antibodies, by comparing two antibodies – one from Santa 
Cruz biotechnology, previously queried in the publication by Elliot et al [292] – and a 
second antibody produced by Abcam Ltd, we were able to detect very similar results 
with both antibodies on Western blot analysis.  Both antibodies detected increased 
expression of the EPOR in CLI samples.  The comparable nature of results yielded 
may not be true for immunohistochemistry where this antibody was not trialled.  The 
use of this antibody for co-localisation of the EPOR with expression of the !cR by 
immunofluorescence yielded discrete, membranous staining, comparable to the 
expression of EPOR demonstrated by the Abcam EPOR antibody on 
immunohistochemistry.  Close examination of the publication by Elliot et al clearly 
reveals that the anti-EPOR (C-20) antibody is capable of specifically detecting EPOR 
expression in cell lines known to positively express EPOR by Western blot analysis, 
and queries only the specificity of the antibody for immunohistochemical techniques.  
Using direct immunofluorescence, co-localisation of the two receptors was revealed 
in both CLI and control samples more clearly than with immunohistochemistry. 
Association, or co-localisation of the two receptors has previously been demonstrated 
in spinal cord neurons and cardiomyocytes only [228].  Demonstrating this putative 
tissue protective receptor complex co-localising and physically interacting in human 
skeletal muscle gives credence to the idea of EPO mediating tissue protection via a 
novel receptor isoform, distinct from the EPOR homodimer required for 
haematopoiesis.  In addition, it encourages the future development of therapeutic 
EPO and EPO-derivatives and their use in a setting of tissue-protection following 
ischaemic injury. 
The findings of this study provide a greater platform of evidence into the role of 
tissue-protective signalling via the !cR and EPOR in ischaemia.  It complements 
previous reports describing the presence and co-localisation of these receptors and by 
demonstrating the heteroreceptor complex, as well as its upregulation in ischaemic 
tissue, it suggests a key role for tissue-protection. 
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The behaviour and response of myogenic precursors following chronic ischaemic 
muscle injury is poorly understood.  The observed increase in satellite cells in CLI 
muscle suggests an attempt at repair and regeneration in response to ischaemic 
muscle injury, as would be expected following muscle injury or damage in the normal 
physiological setting.  However this does not appear to translate into a clinical benefit 
for CLI patients, who have indubitable muscle atrophy and weakness.  The 3-fold 
increase in Pax7 positive nuclei may, in part, be explained by another well-recognised 
phenomenon that contemporaneously exists in CLI muscle.  There is an 
acknowledged histomorphological change in muscle fibres, with a shift towards the 
more oxidative, type 1-muscle fibres [114-116].  In addition there have been several 
reports published identifying a difference in the proportion of satellite cells in relation 
to type 1 and 2 muscle fibres, with type 1 muscle fibres demonstrating between 4-5 
fold greater numbers of associated satellite cells [310-314].  Taken in conjunction, the 
alteration in proportion of type 1-muscle fibres may provide a partial explanation for 
the increased number of satellite cells demonstrated in CLI muscle.   The presence of 
Pax7 positive nuclei in association with blood vessels may be explained by their 
common embryological origin, which forms the foundation of much work looking 
into the ability of blood vessels and other tissues to provide myogenic cells for 
muscle regeneration [310].  However, it has not yet been demonstrated that 
endothelial-derived myogenic precursors are capable of becoming quiescent satellite 
cells, and opposing views suggest that satellite cells instead share a common origin 
with myoblasts [310, 315, 316].  
Whilst it has not been demonstrated that there is a subsequent increased regenerative 
drive in patients with CLI, these results do suggest that the normal downstream 
processes of myogenic commitment, differentiation into myoblasts and fusion with 
existing myofibres to allow terminal differentiation are more susceptible to ischaemic 
injury, causing deviations from the physiological muscle repair pathway, rather than a 
lack of contribution from satellite cells in the first instance.  The presence of satellite 
cells in patients with CLI may therefore provide suitable target to focus future 
therapies, aimed at improving muscle function to prevent the muscle atrophy 
frequently observed in CLI patients [109].   
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3.6 Summary 
In conclusion, we have described the presence of the !cR and the EPOR in human 
skeletal muscle.  We report a striking difference in expression of both receptors 
within human skeletal muscle, at both a protein, as well as transcriptional level 
between CLI and control muscle.  It provides compelling evidence for the role of the 
EPOR and !cR in mediating a response to ischaemic injury.  Thus we propose that 
the presence, and upregulation of the tissue-protective receptor could be utilised by 
EPO and EPO-derivatives to mediate tissue-protection as a therapeutic adjunct in an 
ischaemic setting. 
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CHAPTER 4  
Effect of ARA-290 on C2C12 myoblasts and 
myotubes in vitro 
4.1 Introduction 
One of the most common and persistent progressive features in patients with PAD is 
a decline in functional independence and ability to perform activities of daily living 
due to pain and muscle weakness [114].  Often this is attributed to the lack of 
perfusion to the affected limb.  However, in spite of successful revascularisation 
many patients will still describe significant functional deficit and morbidity at levels 
comparable to their pre-operative state [88-92].  The majority of studies assessing 
novel therapeutics in patients with CLI focus on the aspect of arterial insufficiency, 
and catalysing angiogenesis in an attempt to improve perfusion to the limb.  Although 
this is likely to partially ameliorate those complications mentioned above, and 
improve viability of the limb, the effect on functional outcome and underlying 
detriment to skeletal muscle is less clear. 
The musculopathy that exists in PAD has been detailed to involve multiple cellular 
ultrastructural components and their functioning.  This includes changes in muscle 
fibre type, as well as aberrant mitochondrial function, neither of which demonstrated 
benefit following successful revascularisation.  There is a growing body of evidence 
supporting the existence of underlying muscle pathology and dysfunction in patients 
with PAD, which should also be addressed in order to improve functional deficit in 
patients.  Currently, supervised exercise-training programmes have led to 
improvement in patients’ functional ability to an extent. 
In vitro models provide a useful platform for the initial assessment of novel 
hypotheses and therapeutics.  C2C12 skeletal-myoblast cells represent a heavily 
utilised, and therefore extensively characterised, mouse myoblast-derived cell line.  
They are often used in the study of muscle cell growth, differentiation and function 
due to similarities in character and behaviour to isolated human cells [317-320].  
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A novel in vitro model system for simulated ischaemia of C2C12 skeletal myotubes 
has previously been described.  The simulated ischaemia model was capable of 
reproducing many of the physiological parameters known to be abnormal in 
ischaemic CLI muscle, including pH, partial pressure of oxygen and carbon dioxide 
[238].  Downstream consequences following simulated ischaemia include increased 
apoptosis, lactate dehydrogenase, IL-6 and TNF-" release.  
EPO has previously demonstrated utility in numerous settings of ischaemic tissue 
injury, including models of ischaemic stroke and MI [305, 307].  Its protective role in 
ischaemia or trauma induced injury on skeletal muscle has also been reported [321-
325].  In these scenarios, a combination of increased capillary perfusion and 
proliferation of satellite cells as well as reduced apoptosis of muscle fibres led to 
favourable results.  In keeping with observations of EPO treatment in clinical 
scenarios, there was a dose-dependent effect over which increasing doses became 
detrimental.  This was due to EPO-mediated side effects on haematocrit. 
The development of EPO-derivatives that have removed the haematopoietic 
capabilities but retained tissue-protective functions has reignited an interest in the 
potential of EPO and EPO-derivatives to provide tissue-protection.  ARA-290 has 
been assessed in several pre-clinical in vitro and in vivo models, for a number of 
conditions, including renal ischaemia, neuropathic pain, myocardial infarction and 
stroke.  In both in vitro and in vivo assessment ARA-290 did not demonstrate any 
haematopoietic or angiogenic potential, whilst improving cellular and whole-tissue 
survival outcomes. 
The mechanisms through which EPO and ARA-290 are capable of driving cell 
survival are incompletely understood.  Much of the current knowledge on EPO-
mediated tissue survival has been derived from studies assessing EPO-mediated red 
blood cell survival.  As yet, it is unclear how the signalling pathways involved in 
EPO-mediated red blood cell survival translate into the general cytoprotective 
domain.   
4.2 Aims 
In this chapter, using the in vitro model of simulated ischaemia on the C2C12 cell 
line, we aim to assess the effect of simulated ischaemia on both the progenitor 
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myoblast cell, as well as differentiated myotubes.  In addition, the potential role of 
ARA-290 and EPO in mediating cytoprotection during simulated ischaemia will be 
investigated.  Further investigation aims to identify the importance of potential 
signalling pathways in mediating cytoprotection. 
4.3 Methods 
Culture of C2C12 myoblasts and differentiation into myotubes has been described in 
detail in chapter 2.4.  Briefly, culture of myoblasts was always performed using 
C2C12 myoblast growth medium, consisting of DMEM GlutaMAX™ supplemented 
with 10% FCS, 100 units/ml penicillin and 100µg/ml streptomycin.  When required, 
C2C12 myoblasts were seeded onto 6, 24 or 96 well plates at a cell density of 25,000 
cells/ml.   
Under particular conditions of serum removal C2C12 myoblasts will spontaneously 
differentiate to produce a reliable source of skeletal myotubes [238, 326].  Therefore, 
when required, C2C12 myoblasts at suitable confluence (70–80%) were cultured in 
differentiation media consisting of DMEM GlutaMAX™ supplemented with 2% HS, 
100 units/ml penicillin and 100µg/ml streptomycin.   
The effect of simulated ischaemia on C2C12 myoblast and myotubes survival was 
assessed using Western blot analysis for the apoptotic marker cleaved caspase-3.  
MTT and crystal violet assays were performed to investigate the effect of simulated 
ischaemia on C2C12 myoblast proliferation, and scratch-wound migration assays 
were performed to investigate the effect of ischaemia on myoblast migration.  
Subsequently, the addition of EPO or ARA-290 prior to simulated ischaemia was also 
investigated to identify their potential actions on myoblast survival, proliferation and 
migration.  Comprehensive methods of each of these techniques can be found in 
chapter 2.5.2.   
The potential roles of known mediators of erythrocyte precursor survival were 
interrogated for their role in mediating cytoprotection following simulated ischaemic 
injury.  This included addition of inhibitors against JAK2/STAT3, PI3k/Akt and 
NF#B activation following pre-treatment with ARA-290 or EPO and prior to 
simulated ischaemia.  
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4.4 Results 
4.4.1 Effect of ischaemia on C2C12 myoblast apoptosis, proliferation and 
migration in ischaemia 
Apoptosis 
Pooled data from repeated simulated ischaemia procedures on C2C12 myoblasts were 
assessed using western blot analysis performed looking for the apoptotic marker 
cleaved caspase-3.  Figure 4.1 demonstrates the upregulation of cleaved caspase-3 in 
ischaemic samples compared to parallel samples left in ‘normal’ conditions 
(humidified incubator at 37°C and 5% CO2). 
Proliferation 
Assessment of proliferative potential using MTT reagent as a marker of cell number 
demonstrated an increase in proliferation in cells placed under normoxic conditions.  
In comparison, cells subjected to simulated ischaemia demonstrated significantly 
reduced proliferative potential (P<0.0001, Mann-Whitney test, n=12 in both 
conditions; Figure 4.2A).  Subsequent analysis using crystal violet protocol 
demonstrated similar pattern of results to the MTT assay.  A significant reduction in 
proliferative potential occurred in myoblasts subjected to ischaemia (P<0.0001, 
Mann-Whitney test, n=15 in both conditions; Figure 4.2B).  Due to the comparable 
detection of proliferation by MTT and crystal violet assays, subsequent analysis of 
C2C12 myoblast proliferation employed both assays interchangeably. 
Migration 
Scratch-wound assays to assess migratory potential of myoblasts under normoxic and 
simulated ischaemic conditions demonstrated an increased ability of myoblasts to 
promote migration in normoxic conditions.  Assessment of the positive control wells 
(no mitomycin-C (MMC) added) demonstrated the ability of myoblasts to obtain 
greater than 80% closure in normoxic conditions, and greater than 70% closure in 
ischaemic conditions, utilising both proliferation and migration (Figure 4.3 A and B).  
However, inhibition of proliferation using 7.5µg/ml MMC, as a negative control 
comparison, displayed an average of 10% closure of the scratch-wound by migration 
alone in both normoxic and hypoxic conditions (Figure 4.3 C and D).    
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Figure 4.1: C2C12 myoblast apoptosis following simulated ischaemia 
A significant difference (*P<0.05, Mann-Whitney test) was evident in cleaved 
caspase-3 protein expression from C2C12 myoblast lysates following exposure to 
simulated ischaemia.  Representative Western blot and pooled data from 3 
independent simulated ischaemia experiments (n=6).  Summary data is expressed as 
mean ± SEM. 
 
Figure 4.2: Effect of simulated ischaemia on proliferation of C2C12 myoblasts 
Analysis of both MTT (A) and crystal violet (B) assay displayed a significant 
reduction in C2C12 myoblast proliferation following ischaemic injury (both 
***P<0.0001, Mann-Whitney test, MTT assay n=12 per group, Crystal Violet n=15 
per group). 
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Figure 4.3: Migratory potential of C2C12 myoblasts following simulated 
ischaemia 
Representative phase-contrast images of myoblasts 24 hours after scratch-wound.  
Myoblasts demonstrated ability to close a scratch-wound through proliferation and 
migration (A and B) in both normoxic and hypoxic conditions.  Addition of the anti-
proliferative agent MMC to isolate only migratory effects demonstrated severely 
reduced closure of the scratch-wound at 24 hours, under both normoxic and hypoxic 
conditions (C and D). 
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4.4.2 EPO and ARA-290 mediated reduction in C2C12 myoblast apoptosis 
Addition of EPO 12-hours prior to induction of simulated ischaemia demonstrated 
partial effect on reducing the detection of cleaved caspase-3.  Levels of cleaved 
caspase-3 were approximately half of the levels detected in parallel un-treated 
ischaemic samples.  A similar effect was observed when myoblasts were pre-treated 
with ARA-290 (figure 4.4). 
 
Figure 4.4: Effect of EPO and ARA-290 pre-treatment on C2C12 myoblasts 
apoptosis following simulated ischaemia 
Representative Western blot demonstrating significant anti-apoptotic effects of EPO 
and ARA-290 pre-treatment on C2C12 myoblasts prior to simulated ischaemia.  EPO 
and ARA-290 significantly reduced expression of cleaved caspase-3 compared to the 
ischaemic control (both ***P<0.0001, one-way ANOVA n=6 per group).  No 
significant difference compared to the normoxic samples occurred. 
 
4.4.3 Effect of EPO and ARA-290 on C2C12 myoblast proliferation 
Following initial assessment of the effect of ischaemia on myoblast proliferation, 
EPO and ARA-290 were investigated for their ability to ameliorate the ischaemia-
induced difference in proliferation.  Under normoxic conditions, addition of either 
compound had no significant effect upon proliferation compared to control.  EPO, as 
the traditional cytoprotective agent, demonstrated slight, but non-significant, 
improvement of proliferative capacity compared to untreated cells in ischaemia.  
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ARA-290 pre-treatment of myoblasts however, displayed significantly improved 
proliferative capability compared to untreated cells in ischaemia (P=0.0005, one-way 
ANOVA, n=15; figure 4.5). 
 
Figure 4.5: Ability of EPO and ARA-290 to improve ischaemia-induced deficit in 
proliferation 
Myoblasts subjected to simulated ischaemia displayed a significantly diminshed 
proliferative capacity compared to parallel myoblasts in normoxic conditions 
(P<0.0001, one-way ANOVA, n=7 per group).  Under normoxic conditions, pre-
treatment with EPO or ARA-290 did not alter proliferative capabilities compared to 
untreated control (P>0.95).  EPO pre-treated myoblasts subjected to ischaemia 
demonstrated increased proliferation compared to the ischaemic control, however 
this did not attain significance (P=0.0698, n=15).  Pre-treatment with ARA-290 prior 
to ischaemic injury was able to ameliorate proliferation differences.  ARA-290 
treated myoblasts demonstrated a significantly improved proliferation potential 
(P=0.001, one-way ANOVA, n=15). 
 
4.4.4 Effect of EPO and ARA-290 on C2C12 myoblast migration 
Following initial assessment of the effect of ischaemia on myoblast migration, EPO 
and ARA-290 were investigated for their ability to ameliorate the ischaemia-induced 
differences in migration.  Under normoxic conditions, addition of either compound 
was capable of significantly improving the migration of C2C12 myoblasts greater 
than the negative control myoblasts which were treated with MMC only.   Addition 
of EPO or ARA-290 led to a 50–70% increase in the number of cells observed to 
move into the scratch-wound area (figure 4.6).  
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Figure 4.6: Effect of ARA-290 and EPO pre-treatment on C2C12 myoblast 
migration 
ARA-290 (A and B) and EPO (C and D) pre-treatment resulted in increased myoblast 
migration compared to the negative control samples (1%FCS and MMC only). 
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4.4.5 Involvement of the Jak2, PI3k/Akt and NFkB signalling pathway 
Inactivation of JAK2/STAT3 using the inhibitor SD-1029, PI3k/Akt using the broad-
spectrum irreversible inhibitor wortmannin and NF#B using the NF#B inhibitor of 
activation demonstrated severe reduction in the ability of ARA-290 and EPO to 
improve myoblast migration in either normoxic or simulated ischaemic conditions.  
Inhibition using wortmannin or NF#B inhibitor of activation demonstrated the 
greatest effect upon ARA-290 or EPO mediated myoblast migration (Figure 4.7 B 
and D, respectively).  Inhibition of JAK2/STAT3 also displayed reduced migration of 
myoblasts, but the difference was not significant in either normoxic or hypoxic 
conditions (Figure 4.7A). 
The broad-spectrum reversible inhibitor LY294002, displayed greater effect upon 
inhibition of EPO mediated myoblast migration than ARA-290 (Figure 4.7 C).  
Migration of myoblasts treated with ARA-290 and LY294002 achieved 
approximately 30% cell migration into the scratch to attain closure of the scratch 
wound (approximately half the closure achieved by treatment with ARA-290 alone).  
As with ARA-290 treatment alone, a greater percentage of cell movement was 
observed under hypoxic conditions.  Conversely treatment with EPO and LY294002 
did not demonstrate any movement greater than that observed in the negative control 
samples.  This highlights the possible divergence in signalling molecules utilised by 
EPO and ARA-290 to direct their cytoprotective potential. 
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Figure 4.7: Inhibition of signalling molecules on C2C12 myoblast migration 
Selective inhibition of (A) JAK2/STAT3, (B and C) PI3k/Akt and (D) NF"B was 
performed to identify potential molecules utilised by ARA-290 and EPO.  Both ARA-
290 and EPO treated samples demonstrated significant improvement of myoblast 
migration compared to negative control samples (1% FCS + MMC only) (P<0.0001, 
one-way ANOVA, n=6 per group).  Subsequent inhibition with any inhibitor 
demonstrated significant removal of ARA-290 and EPO potentiated myoblast 
migration, to levels similar to negative control  (P<0.0001 ARA-290 vs any inhibitor 
and EPO vs any inhibitor, one-way ANOVA, n=6 per group).  Interestingly, 
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LY294002 inhibition of ARA-290 pre-treated myoblasts displayed significantly less 
reduction in migration compared to remaining inhibitors (P<0.0023, one-way 
ANOVA, n=6 per group).  Figure 4.7 E and F summarise myoblast migration for 
ARA-290 and EPO pre-treated samples respectively. 
 
4.4.6 Effect of ischaemia on C2C12 myotube apoptosis 
C2C12 myotubes subjected to simulated ischaemia demonstrated increased protein 
expression of cleaved caspase-3 compared to parallel normoxic controls.  This 
finding indicates greater susceptibility of C2C12 myotubes to ischaemia-induced 
apoptosis (Figure 4.8 A and B). 
4.4.7 Effects of EPO and ARA-290 on C2C12 myotube apoptosis  
Addition of EPO or ARA-290 24-hours prior to induction of simulated ischaemia 
demonstrated a significant reduction of cleaved caspase-3 expression.  The role of 
phosphorylated-Akt was also investigated and demonstrated increased 
phosphorylated protein in EPO and ARA-290 treated lysates compared to normoxic 
or ischaemic controls (Figure 4.8 A and B).   
4.4.8 Involvement of the Jak2, PI3k/Akt and NFkB signalling pathway 
Molecules known to play a role in EPO-mediated erythrocyte precursor survival were 
interrogated for their role in abolishing the previously observed EPO or ARA-290 
mediated cytoprotection in C2C12 myotubes.  As phosphorylated-Akt demonstrated a 
correlation with cleaved caspase-3 expression in early studies, the effect of inhibition 
of various known upstream and downstream signalling partners on Akt 
phosphorylation was also analysed.  Figure 4.8A demonstrates the effect of EPO 
(60ng/ml) pre-treatment on C2C12 myotubes, followed by subsequent inhibition of 
JAK2/STAT3, PI3k/Akt, and NF#B, prior to simulated ischaemia exposure.  The 
effect of EPO pre-treatment on reducing the levels of cleaved caspase-3 expression is 
abolished upon addition of all inhibitors to a comparable extent.  Inhibition of 
JAK2/STAT3 using SD-1029 also resulted in increased apoptosis with parallel 
decrease of phosphorylated-Akt.  The effect of PI3k/Akt inhibition with wortmannin 
or LY294002 upon EPO pre-treated myotubes resulted in increased expression of 
cleaved caspase-3 and decreased expression of phosphorylated-Akt.  The effect of 
LY294002 on ARA-290 pre-treated myotubes was not as apparent.  Inhibition of 
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NK#B activation also resulted in an abolishment of EPO mediated cytoprotection and 
phosphorylated-Akt decrease.   
The effect of the above inhibitors upon ARA-290 pre-treated cells followed a similar 
pattern of results, with abolishment of anti-apoptotic effects of ARA-290 pre-
treatment on C2C12 myotubes undergoing ischaemic injury, with the exception of 
addition of LY294002.  LY294002 is a reversible PI3k/Akt inhibitor.  Similar to its 
effects on C2C12 myoblast migration, addition of LY294002 displayed the least 
abolishment of ARA-290 effect on ischaemia-induced apoptosis.  Though expression 
of phosphorylated-Akt was also diminished, expression was still apparent, suggestive 
of incomplete occupation of all relevant ATP-binding domains.  In contrast, 
wortmannin, an irreversible PI3k/Akt inhibitor, caused apoptosis to similar levels 
observed in the ischaemic, untreated controls, with an additional decrease in 
phosphorylated-Akt.  
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Figure 4.8: Analysis of ARA-290 and EPO pre-treatment on apoptosis in C2C12 
myotubes 
Representative Western blot of (A) EPO and (B) ARA-290 pre-treated myotubes 
subjected to simulated ischaemia.  Potential pathways utilised by EPO and ARA-290 
for mediating cell survival were dissected by inhibiting JAK2/STAT3 (SD-1029), 
PI3k/Akt (Wortmannin and LY294002) and NK"B activation.  Addition of any of these 
inhibitors in conjunction with ARA-290 or EPO abolished the prior decrease in 
cleaved caspase-3 expression observed following simulated ischaemia.   !
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4.5 Discussion 
In this study, the effect of simulated ischaemia on several cellular and physiological 
outcomes of the C2C12 murine myoblast cell line has been investigated.  Alterations 
in apoptosis, migration and proliferation in response to simulated ischaemia were 
identified.  Most poignant was the detrimental effect of ischaemia upon myoblast 
function and survival, as well as myotube survival, features which may contribute to 
muscle pathology in PAD.   
Interestingly, several groups investigating the effect of low oxygen tension on 
satellite cells have a identified a beneficial effect of low, or physiological, oxygen 
concentrations, compared to the 5% CO2 95% air, which contains approximately 20% 
oxygen.  This includes increased rates of proliferation, chemotaxis and survival, as 
well as maintenance of satellite cells in their quiescent state with replenishment of the 
self-renewal population [327-330].   Future work may need to be conducted to 
identify this balancing phenomenon between beneficial and destructive qualities of 
decreasing oxygen concentrations. 
The in vitro model of skeletal muscle ischaemia used in this work has also been 
invaluable in highlighting potential aspects of myoblast function which are most 
affected following ischaemic insult, suggestive of the underlying pathology in human 
disease.  Evidence from the study also demonstrated the potential of novel therapeutic 
agents to improve a number of features that occur following ischaemic injury.   
Treatment with EPO and ARA-290 demonstrated an ability to ‘rescue’ myoblasts and 
myotubes from the detrimental effects propagated by ischaemia.  Both agents resulted 
in similarly effective and significant ability to prevent myoblast and myotube 
apoptosis.  Identification of critical mediators involved in delivering ARA-290 and 
EPO-mediated tissue protection were explored by inhibition of discrete molecules 
known to play a role in EPO-mediated erythrocyte precursor survival.  Addition of 
inhibitors in combination with EPO or ARA-290 pre-treated cultures resulted in 
impedance of previously observed anti-apoptotic effects of both ARA-290 and EPO.  
Although the signalling cascades involved in EPO-mediated erythrocyte precursor 
survival has been extensively investigated, less knowledge is available on signalling 
pathways through the tissue-protective heteroreceptor complex.  Interrogating known 
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molecules to illuminate their role in tissue-protective pathways identified the 
importance of JAK2, PI3k/Akt, and NF#B. 
JAK2, via crystallographic studies, is in direct interaction with the EPOR, and known 
to be required to mediate the phosphorylation of itself, and several other tyrosine 
kinases to propagate signalling cascades.  Downstream molecules known to interact 
with JAK2 following EPO-ligand binding include STAT3 and STAT5.  The inhibitor 
SD-1029 (JAK2/STAT3) resulted in reduced migration and increased apoptosis, 
although the extent of these features suggested incomplete blockade of all 
downstream signalling pathways.  Literature has shown that SD-1029 targets 
phosphorylation of STAT3 by JAK2 [331-333].  Although the observed effects of 
inhibition suggest a crucial role of STAT3 in mediating tissue protection, it is likely 
that some alternative signalling may also occur via other interacting molecules.  
The disparity in inhibition between the two broad-spectrum PI3k/Akt inhibitors, 
wortmannin and LY294002 on ARA-290 treated samples highlights possible 
deviations in the tissue-protective signalling cascade from those known to be 
involved in EPO dependent erythrocyte precursor survival and maturation.  
Differences in the effect of PI3k/Akt inhibition using both inhibitors have also been 
identified and include differences in cell growth and apoptosis, intracellular calcium 
homeostasis and action potentials and nitric oxide production [334-337].  A plausible 
explanation for these observed differences is that although both inhibitors rely upon 
competitive ATP-binding, LY294002 will bind via a reversible hydrogen bond, 
whereas wortmannin binding results in an irreversible covalent complex [338, 339].  
This study provides compelling evidence of a negative effect of ischaemia on skeletal 
muscle tissue.  The observed decrease in migration and proliferation as well as the 
increase in apoptosis under ischaemic conditions are all features relevant to human 
CLI, and support the idea of the occurrence of musculopathy in patients with CLI.  
Currently, a large focus of CLI treatment aims to target the diminished vascular 
supply.  Understanding and acceptance of underlying muscle pathology is not widely 
established, providing a vast arena to target for therapeutic benefit.   
Functional deficit associated with CLI is a leading cause of morbidity for the majority 
of patients.  Despite successful revascularisation, a corresponding improvement in 
functional outcomes is often not described.  The contribution of myoblasts to the 
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pathogenesis of musculopathy and functional decline in CLI is uncertain but likely to 
play a role considering the vast bulk of tissue in the hindlimb is composed of skeletal 
muscle.  In addition, the increased vulnerability of skeletal muscle to ischaemia 
compared to other components of the limb increases the likelihood that there will be a 
consequent modulation in myoblast and myotubes behaviour [340].  The ability to 
observe the behaviour of skeletal muscle cells, including in their precursor state, is 
highly relevant in this study. 
 
4.6 Summary 
In this study, the deleterious effects of ischaemia on a murine skeletal muscle 
immortal cell line were seen.  This suggests the muscle pathology observed in PAD 
patients may be as a consequence of the chronic ischaemic conditions found in CLI 
limbs.  The cytoprotective properties of EPO and ARA-290 were also demonstrated 
as evidenced by their ability to reduce ischaemia-induced injury in the C2C12 
skeletal muscle in vitro model.  In conjunction, these results highlight the 
susceptibility of C2C12 skeletal myoblasts and myotubes to ischaemic injury as well 
as the possibility of “rescuing” cells from ischaemic injury using novel therapeutic 
agents. 
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CHAPTER 5  
Effect of ARA-290 on human myoblasts and 
myotubes in vitro 
5.1 Introduction 
Cell lines represent an invaluable tool in the in vitro modelling of human disease 
pathogenesis.  The majority of cell lines provide a domain that is easy to handle, and 
well established, making the results generated easier to replicate and also more 
acceptable due to their extensive characterisation.  In the assessment of skeletal 
muscle, the C2C12 cell line retains all these features, and in addition allows for a 
degree of standardisation through its use across investigating communities.  However, 
whilst cell lines provide a reliable and replicable source of immortalised cells, they 
are often quite removed from the clinical scenario of interest.  Phenotypical 
differences that have been recognised between the C2C12 cell line and primary 
human skeletal muscle myoblasts include cell size, growth rate, formation of 
sarcomeres and the substrates required for optimal growth [341, 342], all of which 
may have an impact upon different fields of study.    
A logical progression, following the use of immortalised cell lines in the study of 
human disease, is the use of primary cell lines to more closely mimic human cellular 
behaviour, or pre-clinical in vivo models to replicate the entire disease process.  In 
this chapter, the use of human primary myoblasts isolated from patients with CLI, as 
well as control individuals – for comparison, provides a more pertinent experimental 
model to assess the underlying human disease pathology.   
Isolation of myoblasts from CLI patients has not previously been reported in the 
literature.  Very little knowledge is therefore available on the behaviour of CLI 
myoblast explants.  To counteract possible confounding results, myoblasts were also 
isolated from control donors to better identify phenotypical differences that may exist 
as a result of the ischaemic niche present in the CLI limb. 
The experimental data from the previous chapter indicated differences in myoblast 
behaviour as a result of simulated ischaemia.  In addition, C2C12 myotubes showed 
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sensitivity to ischaemia-induced apoptosis.  Pre-treatment with EPO or ARA-290 
demonstrated potential to provide protection to C2C12 myoblast and myotubes 
against injury as a result of simulated ischaemia.  The response of CLI and control 
myoblasts and myotubes to simulated ischaemia is uncertain.  The effect of ARA-290 
on human skeletal myoblasts has also not been established, however work in the field 
of ischaemic cardiac myocytes may provide evidence for possible therapeutic benefit 
of EPO and ARA-290.  Therefore the cytoprotective effects of ARA-290 on skeletal 
myoblasts and myotubes were explored.  Key signalling molecules of EPO-mediated 
red blood cell survival, identified in the previous chapter, were subsequently assessed 
in this study. 
5.2 Aims 
This study aimed to develop an in vitro simulated ischaemia model using myoblasts 
and myotubes isolated from CLI and control samples which would allow the 
identification of differences in the functional characteristics of myoblasts from the 
CLI and control donor populations, as well as their response to simulated ischaemia.   
In addition, the therapeutic potential of EPO and ARA-290 to provide cytoprotection 
against ischaemia-induced apoptosis was investigated.   
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5.3 Methods 
In this study, the effect of simulated ischaemia on primary human skeletal myoblasts 
and myotubes was investigated.  Myoblasts were isolated from biopsies of our 
disease group of interest – CLI patients.  In order to allow comparison of myoblasts 
and myotubes, isolation of myoblasts from the control group was also performed.  
Isolation of human myoblasts from skeletal muscle biopsies, and their subsequent 
culture and differentiation into myotubes have been described in detail in chapter 2.5.  
Briefly, all muscle biopsies from both CLI and control sample biopsies were isolated 
using the same standard operating procedure.  Isolated myoblasts were maintained in 
specialised skeletal myoblast growth medium (PromoCell) supplemented PromoCell 
skeletal muscle SupplementMix, 10% FCS (Gibco®), 1x GlutaMAX™ (Gibco®, UK), 
100 units/ml penicillin and 100µg/ml streptomycin.  When required, human 
myoblasts were seeded onto 6, 24 or 96 well plates at a cell density of 30,000 
cells/ml.  
Under particular conditions of serum removal human myoblasts will spontaneously 
differentiate to produce a reliable source of skeletal myotubes.  Therefore, when 
required, human myoblasts at suitable confluence (70–80%) were cultured in 
differentiation media consisting of DMEM GlutaMAX™ supplemented with 2% HS, 
100 units/ml penicillin and 100µg/ml streptomycin.   
Myoblast characterisation 
Cultures of primary human myoblasts were inspected using a phase-contrast 
microscope to confirm typical myoblast morphology.  Subsequent characterisation of 
human myoblasts involved immunocytochemistry/immunofluorescence for the 
muscle-specific marker desmin, to ensure homogeneous myoblast populations.  To 
ensure myoblast differentiation into myotubes, cell lysates were assessed for the 
myogenic-regulatory factor, myogenin, using western blot analysis.  
Apoptosis 
Quantitative assessment of apoptosis in human myoblast and myotubes following 
simulated ischaemia was performed in order to correlate significant findings from 
western blot analysis.  The luminescent Caspase-Glo® 3/7 Assay (Promega, UK) was 
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used according to manufacturer’s protocol.  Briefly, cells of interest were plated at 
25,000 cells/ml, in a white-walled 96-well sterile, tissue-culture plate (100µl/well), 
and allowed to adhere for 4 hours prior to initiation of 8 hours of simulated 
ischaemia, with a parallel plate left in normoxic conditions.  Subsequently, both 
plates were allowed to equilibrate to room temperature, during which time the 
Caspase-Glo® 3/7 buffer and substrate were mixed in 1:1 volume.  100µl/well of 
Caspase-Glo® 3/7 mixed reagents was added to each well, the plates gently shaken, 
and allowed to equilibrate for 1 hour at room temperature.  Luminescence of each 
plate was then read using a microplate reader (Mithras LB940 microplate reader).   
Proliferation 
Differences in proliferative capabilities of CLI and control myoblast were 
investigated using established assays, as well as newer, commercial options. 
Proliferation assays have been described in detail in chapter 2.5.   
All proliferation assays were performed on cells seeded at 30,000 cells/ml into 96-
well plates (100µl/well).  Every primary cell line was seeded at least in duplicate, and 
identical plates were seeded for assessment of proliferative differences under both 
normoxic and simulated ischaemic conditions, using all three assays, to ensure 
passage number did not affect proliferation (6 plates in total).  MTT assay relies on 
the relationship between mitochondrial activity and cell number to provide an 
estimate of proliferation potential.  The crystal violet and CyQUANT assays use 
agents which will intercalate with DNA to give a proportional representation of cell 
number.  These assays were used in conjunction to identify similarities and potential 
differences between CLI and control myoblasts. 
Migration 
Migration of myoblasts to areas of injury is an important feature of tissue repair.  
Investigation into potential underlying phenotypic differences in migratory ability of 
CLI and control myoblasts was performed by introducing a scratch-wound into a 
monolayer of CLI or control myoblasts. 
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Contraction 
Skeletal muscle has many functions, including mobilisation and movement, through 
coordinated skeletal muscle group contraction and relaxation.  In addition, cell 
contraction plays an important role in overall cell migration, especially in a co-
ordinated response to tissue injury, in order to facilitate repair.  To further identify 
potential causes for alterations in CLI myoblast migration in the above assay, as well 
as aberrant skeletal muscle repair in CLI patients, contractile ability was investigated 
using floating type I collagen gel lattices. 
Human myotube in vitro model 
The lack of oxygen during ischaemia causes consequent alterations in a number of 
genes encoding proteins designed to counteract the local hypoxia.  These genes often 
share a common mode of regulation that involves activation of the HIF family of 
transcription factors, and in particular, HIF-1".  HIF-1", a cellular detector of low 
oxygen tension becomes stabilised by hypoxia, and promotes transcription of several 
factors to counteract the low oxygen concentrations.  Although upregulation of HIF-
1" has previously been demonstrated in C2C12 myobtubes undergoing ischaemic 
injury [238], this finding was revalidated in the human myotubes in vitro model using 
both control and CLI myotubes.  Following simulated ischaemia, cell lysates were 
assessed for the expression of HIF-1", compared to paired normoxic lysates using 
western blot analysis. 
Previously, using the C2C12 cell line, EPO and ARA-290 demonstrated an ability to 
reduce ischaemia-induced apoptosis.  In addition, key signalling molecules involved 
in EPO or ARA-290 mediated reduction of apoptosis were identified.  Using these 
identified molecules, investigation of their role in human primary cells was 
performed.  This included pre-treatment of human myotubes with EPO or ARA290 
and the use of inhibitors against JAK2/STAT3 (SD-1029), PI3k/Akt (wortmannin and 
LY294002) and NF#B (NF#B inhibitor of activation IV). 
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5.4 Results 
5.4.1 Analysis and differentiation of primary human myoblasts 
Characterisation 
Due to the composition of skeletal muscle (endothelial cells, fibroblast and 
myoblasts), purity of myoblast populations was investigated to ensure homogeneous 
myoblast population.  Obtaining pure myoblast cultures was of greater difficulty in 
biopsies from CLI patients, and is likely due to the more fibrotic nature of their 
muscle tissue.  To assess the purity of myoblast populations immunocytochemistry 
was performed using the muscle-specific marker desmin.  Figure 5.1 provides 
representative phase-contrast images of myoblasts in culture following isolation from 
muscle biopsy at day 3 (A), 7 (B) and 14 (C), as well as myoblasts that have 
differentiated, fused and aligned to become myotubes (D).  Figure 5.1E shows a 
representative image of myoblasts with positive desmin staining confirming muscle-
derived cells.  Desmin staining was performed on all isolated human cultures, and at 
each passage used, to ensure that the derived population had less than 5% 
contamination with other cell types when used experimentally. 
Confirmation of myoblast differentiation was also achieved by assessment of 
myoblast and myotubes cell lysates for the myogenic regulatory factor myogenin. 
Figure 5.2 shows a representative Western blot of myoblast and myotubes lysates, 
assessed for expression myogenin.  Cell lysates, from myotubes, that have undergone 
myogenic differentiation show an increase in myogenin protein expression.   
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Figure 5.1: Isolation of human myoblasts 
Representative phase-contrast photomicrographs of primary skeletal myoblasts at 
day 3 (A, 100x magnification), 10 (B), and 14 (C) following isolation.  Myoblasts 
were also induced to differentiate (D), and stained with desmin antibody to confirm 
cell type (E).  Phase-contrast magnification = x20 unless otherwise stated.  Scale 
bar=20 µm.  
 
Figure 5.2: Analysis of human myoblast differentiation 
Representative Western blot of paired myoblast and myotubes cell lysates assessing 
differentiation of myoblasts by probing for myogenin expression.  Myotube samples 
demonstrated increased expression of myogenin (lanes 1, 3 and 5) compared to 
parallel myoblasts (lanes 2, 4 and 6). 
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5.4.2 Effect of ischaemia on myoblast function 
Apoptosis 
Myoblasts isolated from CLI and control donors subjected to simulated ischaemia 
were assessed for caspase-3/7 activity following ischaemic exposure.  Under 
normoxic conditions, myoblasts from CLI and control did not display a significant 
difference in caspase activity.  Parallel samples of myoblasts evaluated following 
exposure to simulated ischaemia displayed a significant increase in caspase-3/7 
activity compared to normoxic controls.  Interestingly, caspase-3/7 activity was 
approximately 2-fold greater in myoblasts isolated from control samples compared to 
myoblasts from CLI patients under ischaemic conditions, indicative of underlying 
physiological differences in response to hypoxic injury, likely as a response of their 
native environment (figure 5.3). 
Figure 5.3: Differences in myoblast apoptosis in response to simulated ischaemia 
Quantification of apoptotic activity using Caspase-3/7 assay revealed reduced 
sensitivity of CLI myoblasts to ischaemia induced apoptosis.  Control myoblasts 
showed 2-fold greater caspase-3/7 activity, indicating increased apoptosis, as a 
result of simulated ischaemia (P<0.0001, one-way ANOVA, n=6 for CLI myoblasts, 
n=5 for control myoblasts). 
 
Proliferation 
Proliferative potential of human myoblasts was evaluated using multiple 
complementary assays.  Whilst all three proliferation assays were able to detect a 
significant proliferative difference between CLI and control myoblasts, different 
assays demonstrated different sensitivities for the proliferation capacity of CLI and 
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control myoblasts under different oxygen tension conditions.  Figure 5.4 represents 
the pooled data from a series of proliferation assays using all three reagents.   
Crystal violet assay of CLI and control myoblasts in normoxic and simulated 
ischaemic conditions highlighted significant differences between their respective 
proliferative capabilities.  Even in normoxic conditions, CLI myoblasts demonstrated 
a significantly greater (over 1.5-fold greater) proliferative capacity compared to 
control myoblasts in the same conditions (P<0.0001, one-way ANOVA, n=6 for CLI 
myoblasts; n=5 for control myoblasts).  A significant decrease was observed in CLI 
and control myoblasts that were subjected to an ischaemic period, compared to their 
normoxic parallel counterparts.  Interestingly, even following simulated ischaemia, 
CLI myoblasts still retained greater proliferative potential than control myoblasts, 
subjected to either normoxic or ischaemic periods (P<0.0001, one-way ANOVA). 
The commercial CyQUANT assay yielded similar patterns of proliferation 
capabilities between CLI and control myoblasts.  There was a greater difference 
under normoxic conditions, approximately 2-fold, between proliferation observed in 
CLI versus control myoblasts.  Similarly to the crystal violet assay, CLI myoblasts, 
even after an ischaemic period, still demonstrated a significantly higher proliferative 
potential compared to control myoblasts under any condition.  To note however, 
following simulated ischaemia there was no significant decrease in proliferation 
observed compared to parallel control myoblasts. 
The MTT assay revealed the least difference between CLI and control myoblasts 
following simulated ischaemia: with no significant difference detected between CLI 
myoblasts subjected to simulated ischaemia compared to their normoxic counterparts, 
as the previous two assays suggested.  In addition, no significant difference was 
observed between CLI myoblasts and control myoblasts in normoxic conditions – a 
significant difference detected by both the previous assays.   
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Figure 5.4: Multiple assessment of proliferative capacity of human CLI and 
control myoblasts 
Myoblasts from CLI donors demonstrated significantly greater proliferative potential 
in crystal violet and CyQUANT assays compared to control myoblasts.  This finding 
was still present after simulated ischaemia (P<0.0001, one-way ANOVA, n=6 CLI 
myoblasts, n=5 control myoblasts).  The MTT assay demonstrated a significantly 
greater proliferative capacity of CLI myoblasts compared with control myoblasts, but 
was less sensitive at detecting proliferative differences under simulated ischaemic 
conditions.  
CLI Control
0.0
0.5
1.0
1.5
2.0
Human myoblasts
C
ry
sta
l V
io
let
 A
bs
or
ba
nc
e 5
50
(r
at
io
 o
f c
on
tr
ol
)
Crystal Violet Assay
***
*
CLI Control
0.0
0.5
1.0
1.5
Human myoblasts
M
T
T
 P
ro
lif
er
at
io
n
(r
at
io
 o
f c
on
tr
ol
)
MTT Assay
ns
***
CLI Control
0.0
0.5
1.0
1.5
2.0
2.5
Human myoblasts
C
yQ
U
A
N
T
 ce
ll 
pr
ol
ife
ra
tio
n
(r
at
io
 o
f c
on
tr
ol
)
CyQUANT® Assay
ns
***
Normoxia
Ischaemia
 140 
Migration 
Scratch-wound assays to assess migratory potential of human CLI and control 
myoblasts under normoxic and simulated ischaemic conditions demonstrated a 
diminished ability of CLI myoblasts to promote migration alone in hypoxic 
conditions when the anti-proliferative agent MMC, was added as a negative control 
comparison.  On average CLI myoblasts displayed an average of 16.6 and 5.8% 
closure of the scratch-wound by migration alone, in normoxic and hypoxic conditions 
respectively, compared to control myoblasts which achieved 16.3 and 15.9% closure 
of the scratch-wound under the same respective conditions (Figure 5.5).    
 
Figure 5.5: Migratory potential of CLI and control myoblasts following 
simulated ischaemia 
Myoblasts from CLI donors demonstrated a diminished ability to migrate into a 
scratch made in a monolayer of cells compared to control myoblasts.  This finding 
was further exaggerated when myoblasts were subjected to simulated ischaemia. 
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Contractility and migration 
Data from a series of independent contraction assays using type I collagen gel lattices 
outlined an important, aberrant functional effect of the CLI phenotype, similar to the 
diminished migratory potential observed above.  Figure 5.6 shows contraction assays 
from myoblasts isolated from CLI patients, compared with controls. Myoblasts from 
CLI patients were unable to promote the same degree of contraction of the collagen 
gel lattice as healthy control myoblasts, suggestive of dysfunctional contractile 
apparatus affecting myoblast migration. 
 
Figure 5.6: Enhanced contraction of collagen gel lattices by control myoblasts 
Representative image demonstrating the diminished ability of CLI myoblasts to 
contract type I collagen gel lattices compared to control myoblasts (P<0.0001, one-
way ANOVA, n=5 for both CLI and control myoblasts).  There was no significant 
difference in contractile ability when subjected to simulated ischaemia. 
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5.4.3 EPO and ARA-290 improvement of human myoblast migration 
Treatment of myoblast cultures with EPO or ARA-290 at the time of scratch-wound 
demonstrated positive effects of both agents on promoting myoblast migration 
(Figure 5.7).  Both EPO and ARA-290 were capable of improving CLI and control 
myoblast migration, to similar levels.  The migration observed in both CLI and 
control treated samples was significantly higher than migration observed in MMC-
only (negative control) wells, under both normoxic and simulated ischaemic 
conditions. 
 
Figure 5.7: Pro-migratory effect of EPO and ARA-290 on human myoblast 
Pre-treatment of human myoblasts with EPO or ARA-290 resulted in an increased 
migration of myoblasts into the scratch wound compared with the negative control 
scratch-assays (1%FCS and MMC only) 
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5.4.4 Involvement of the JAK2, PI3k/Akt and NFkB signalling pathway in 
myoblast migration 
Inhibition of EPO treated samples using inhibitors against JAK2/STAT3, PI3k/Akt or 
NF#B resulted in marked decrease in myoblast migration into the scratch-wound.  
Under normoxic conditions there was an observable reduction in both CLI and 
control myoblast migration, but the difference was not significant.  However, 
inhibition of EPO effect using SD-1029, wortmannin, LY294002 or NF#B inhibitor 
of activation was consistently more prominent on myoblasts subjected to simulated 
ischaemia, whether from either CLI or control samples (figure 5.8). 
Inhibition of JAK2/STAT3, PI3k/Akt using wortmannin and NF#B demonstrated 
severe reduction in the ability of ARA-290 to improve either CLI or control myoblast 
migration in either normoxic or simulated ischaemic conditions.  All three inhibitors 
caused significant reduction in ARA-290 mediated migration.  The reduction in 
migration following inhibition ranged between approximately 7 – 50% of migration 
observed when treated with ARA-290 and MMC alone.  Simulated ischaemia did not 
demonstrate any compounding effect on myoblast migration of ARA-290 with 
inhibitor-treated wells.  The broad-spectrum reversible inhibitor LY294002, similar 
to previous results, did not entirely abolish improvements in migratory potential of 
either CLI or control myoblasts.  CLI and control myoblasts treated with ARA-290 
and LY294002 still achieved greater than 70% migration of ARA-290 only treated 
samples.  This is in comparison to wortmannin-induced PI3k inhibition samples, and 
those treated with EPO where LY294002 had greater inhibitory effect.   
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Figure 5.8: Inhibition of EPO and ARA-290 mediated migratory effects 
EPO (A) and ARA-290 (B) treated scratch-wounds were concomitantly treated with 
inhibitors against JAK2/STAT3, PI3k/Akt and NF"B to assess potential signalling 
cascades in mediating the migratory effects of both compounds.  Addition of any 
inhibitor caused a significant reduction in EPO or ARA-290 mediated improvements 
in CLI or control myoblast migration (P<0.05, one-way ANOVA, n=5 both CLI and 
control). 
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5.4.5 Effect of ischaemia on human myotube apoptosis and cell death 
Western blot analysis of parallel samples of CLI and control myoblasts harvested 
from normoxic conditions, or following exposure to simulated ischaemia 
demonstrated an increase in HIF-1" expression in ischaemic samples from both CLI 
and control myotubes samples (figure 5.9).  
Observation of myotubes isolated from CLI and control patients when subjected to 
simulated ischaemia repeatedly demonstrated lower signal intensity of cleaved 
caspase-3 in ischaemic samples from CLI myotubes, compared to control myotubes.  
To quantitatively assess the difference in response to ischaemia of CLI and control 
myotubes two further techniques were utilised.    
Control and CLI myotubes were assessed for caspase-3 and 7 activity using the 
caspase GLO assay as described above.  CLI and control myoblasts in normoxic 
conditions did not demonstrate any significant difference in levels of apoptosis, as 
represented by caspase-3/7 activity.  Following conditions of simulated ischaemia, 
both CLI and control myotubes demonstrated a significant increase in caspase-3/7 
activity (figure 5.10 A).  However, the rise in caspase-3/7 activity between CLI and 
control myotubes was also significantly dissimilar.  CLI myotubes subjected to 
ischaemia demonstrated approximately 3-fold difference in caspase-3/7 activity 
compared to normoxic control.  On the other hand, control myotubes, following 
simulated ischaemia, demonstrated approximately 6.75-fold increase in caspase-3/7 
activity compared to normoxic control (over 2-fold increase in caspase-3/7 activity 
compared to CLI myotubes also subjected to ischaemia) (figure 5.10A). 
Further assessment of apoptosis and cell death in human myotubes was performed 
using immunocytochemistry/immunofluorescence techniques.  Samples of both CLI 
and control myotubes subjected to ischaemia were stained for using an anti-annexin 
V antibodies, in conjunction with propidium iodide (PI) (figure 5.10B). 
Control myoblasts exposed to simulated ischaemia demonstrated a greater number of 
cells positively stained for annexin V – indicating a greater degree of apoptosis in 
comparison to CLI myotubes under identical conditions.  Annexin V staining was 
most intense in the nuclei, but could also be demonstrated in the cytoplasm.  
Counterstaining myotubes with PI was used to determine permeability of the plasma 
membrane to small molecules, indicative of a cell undergoing secondary necrosis.  
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Similarly to annexin V expression, PI was only detectable in the nuclei of control 
myotubes following simulated ischaemia.  In comparison, CLI myotubes subjected to 
ischaemia displayed very little nuclear or cytoplasmic annexin V or PI staining, 
suggesting resilience in apoptotic response to ischaemic injury (figure 5.10 B). 
 
Figure 5.9: HIF-1" expression following simulated ischaemia in human 
myotubes 
Representative Western blot of HIF-1# expression in human cell lysates subjected to 
ischaemia (lanes 7 – 12), and their parallel normoxic counterparts (lanes 1 – 6).  A 
significant upregulation in HIF-1# expression was observed in ischaemic myotubes.  
There was no significant difference in HIF-1# expression between myotubes from CLI 
(lanes 1 – 3 and 7 – 9) or control (lanes 4 – 6 and 10 – 12). 
  
Lane 
!–tubulin 
(50 kDa) 
HIF-1! 
(100 kDa) 
1    2    3    4    5    6    7    8    9  10  11  12 
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Figure 5.10: Effect of ischaemia on human myotube apoptosis 
(A): Quantification of caspase-3/7 activity in CLI and control myotubes demonstrated 
a significantly reduced susceptibility of CLI myotubes to caspase-mediated apoptosis.  
Apoptosis was more than 2-fold increased in ischaemic control myotubes, compared 
to ischaemic CLI myotubes. (P<0.0001 one-way ANOVA, n=6 CLI, n=6 control 
myotubes) 
(B) Immunocytochemistry/immunofluorescence for the apoptotic marker annexin V 
and PI demonstrated increased apoptosis in control myoblasts.  Further there was 
increased signal of PI suggesting later stages of apoptosis in control myotubes.  CLI 
myoblasts had reduced signal of annexin V staining, and did not counterstain with PI 
– indicating an intact nuclear membrane. 
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5.4.6 EPO and ARA-290 mediated reduction in human myotube ischaemia-
induced apoptosis and IL-6 release 
Pre-treatment of human myotubes with EPO or ARA-290 24-hours prior to induction 
of simulated ischaemia demonstrated a significant reduction in cleaved caspase-3 
expression.  The role of phosphorylated-Akt was also investigated and demonstrated 
increased phosphorylated protein in EPO and ARA-290 treated lysates compared to 
normoxic or ischaemic controls (Figure 5.11 A and B). 
ELISA assessment of cell culture supernatants for release of the cytokine IL-6, 
demonstrated an increased secretion of IL-6 into supernatant of samples subjected to 
ischaemia compared to parallel normoxic controls.  Pre-treatment with EPO or ARA-
290 prior to simulated ischaemia caused a significant decrease in IL-6 concentration 
compared to ischaemic control samples.   A similar trend in IL-6 secretion by either 
CLI or control myoblasts was detected (Figure 5.12). 
5.4.7 Involvement of the JAK2, PI3k/Akt and NFkB signalling pathway 
Following EPO pre-treatment a reduction in cleaved caspase-3 expression was 
observed.  Subsequent inhibition using LY294002, wortmannin, SD-1029 or NF#B 
inhibitor of activation IV demonstrated a significant abolishment of EPO-mediated 
reduction of apoptosis.  As a consequence of inhibition of any of the above molecules 
there was an increase in cleaved caspase-3 expression above that of the simulated 
ischaemia control (figure 5.11A).  
Following ARA-290 pre-treatment, a reduction in cleaved caspase-3 expression was 
also observed.  Likewise, subsequent inhibition using the above-mentioned inhibitors 
also caused a decrease in ARA-290 mediated prevention of apoptosis.  Similarly to 
previous findings, inhibition of ARA-290 effect using LY294002 consistently 
demonstrated less inhibition of PI3k/Akt, coinciding with a reduction in cleaved 
caspase-3 expression. 
The findings described above were consistently found in our human myotube cell 
lines isolated from CLI or control samples.  However, as mentioned earlier, detection 
of cleaved caspase-3 in CLI lysates required almost 3 times the total quantity of 
protein to be loaded to adequately detect expression. 
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Supernatant collected after human myotubes were subjected to simulated ischaemia, 
prior to myotubes lysis, were assessed for release of the inflammatory cytokine IL-6.  
Simulated ischaemia caused a significant increase in IL-6 release compared to 
normoxic controls for each primary human cell line.   Pre-treatment of myotubes with 
EPO or ARA-290 lead to a decrease in IL-6 secretion into cell media as a result of 
simulated ischaemia.  This reduction in IL-6 secretion could be removed when 
inhibitors against JAK2/STAT3, PI3k/Akt and NF#B were applied to cells prior to 
simulated ischaemia (Figure 5.12).  
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Figure 5.11: EPO and ARA-290 effect on ischaemia-induced apoptosis 
Representative Western blots of EPO pre treated human myotubes demonstrating 
increase expression of cleaved caspase-3 when human myotubes were subjected to 
ischaemia.  Pre-treatment with EPO or ARA-290 cause a reduction in cleaved 
caspase-3 levels, similar to levels observed in samples not exposed to ischaemia.  
Further identification of important signalling pathways used by EPO and ARA-290 to 
mediate myotubes protection revealed important roles of JAK2/STAT3, PI3k/Akt and 
NF"B, as evidenced by their ability to abolish EPO or ARA-290 mediated 
improvements in apoptosis. 
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Figure 5.12: ELISA quantification of IL-6 secretion into media following 
simulated ischaemia, and pre-treatment with EPO or ARA-290. 
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Simulated ischaemia caused a significant increase in IL-6 production compared to 
normoxic samples in both CLI and control samples.  Pre-treatment with EPO or 
ARA-290 demonstrated a sustained ability to suppress IL-6 secretion during 
simulated ischaemia.  However, inhibition of JAK2/STAT3, PI3k/Akt or NF"B 
resulted in a rise in IL-6 secretion.  
(N=Control myotubes, I=CLI myotubes, A=ARA-290, E=EPO, SD=SD-1029, 
W=wortmannin, LY=LY294002, NF"B=NF"B inhibitor of activation IV) 
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5.5 Discussion 
In this study the effect of simulated ischaemia on myoblasts and myotubes from CLI 
and control patients was investigated.  There are no previous reports in the literature 
of primary isolation of CLI myoblasts – the closest comparison being isolation of 
myoblasts of healthy individuals after intensive exercise.  Therefore, very little 
investigation has been performed on the fundamental building block of muscle tissue 
– myoblasts and myotubes – and potential phenotypic alterations as a result of 
prolonged exposure to ischaemia. 
Myoblasts from CLI and control donors demonstrated important functional 
differences under both normoxic and simulated ischaemia conditions.  Leading on 
from this, differentiated CLI myotubes also demonstrated subtle differences 
culminating in resistance to simulated ischaemia. 
5.5.1 Functional differences in human myoblasts from controls and CLI 
Though MTT is often used as a proliferative assay, it relies upon the correlation 
between cell number and metabolic activity.  However metabolic activity within a 
cell can be influenced by a number of variables – including their response to 
ischaemic injury – which may account for the lower sensitivity and specificity 
observed using MTT to highlight potential proliferative differences between human 
primary myoblasts.   
It is a well-recognised fact that skeletal muscle has the ability to repair and regenerate 
new muscle fibres in response to a variety of injuries (biological, chemical or 
mechanical) or as a consequence of disease.  The processes of repair and regeneration 
requires the activation of a pool of quiescent muscle stem cells, known as satellite 
cells, which in response to injury, start to proliferate, and differentiate.  Myoblasts are 
a differentiated form of satellite cells, which in response to myogenic regulatory 
factors, commit themselves to a myogenic lineage, and then fuse to form myotubes.  
The differentiation of satellite cells into myoblasts, and their ability to travel to sites 
of injury is therefore key in the repair and regeneration cycle.  Assessment of human 
skeletal muscle has previously demonstrated an upregulation of satellite cells in CLI 
muscle, providing evidence of regenerative attempts in response to ischaemic injury 
[298].  This highlights the possibility that the underlying myopathy observed in CLI 
 155 
patients is not as a result of a defect in the self-renewal properties of muscle precursor 
cells, but of later attempts to repair muscle at sites of injury.  
Impaired migration and contractile ability of CLI-isolated myoblasts compared to 
control myoblasts was another significant finding.  Though the reasons for this 
decreased contractile ability in CLI myoblasts are likely to be manifold, a plausible 
explanation is the reduced mitochondrial activity previously described in CLI patients 
[118].  Mitochondrial dysfunction has been identified in the skeletal muscle of CLI 
patients.  In addition, defective electron transport chain complexes (mainly ETC I and 
III) cause increased reactive oxygen species damage to the skeletal muscle [124].  
Muscle, under aerobic and anaerobic conditions, has an absolute requirement for ATP 
in order to contract.  In combination, this leads to the idea that CLI myoblasts are 
likely to exhibit a deficit in myoblast contraction due to their impaired mitochondrial 
activity leading not only to less forceful contractions but also earlier fatigue and 
fewer contractions [343, 344].  Another well-known clinical scenario where 
ischaemia is responsible for impaired functional contractility is myocardial infarction.  
In this scenario, following the ischaemic period, the infarct becomes invaded with 
inflammatory cells, and then subsequently myofibroblasts colonise the wounded 
infarct area and remodelling occurs, creating a stable, but immobile and less 
contractile scar.  CLI muscle at the time of biopsy harvest is macroscopically more 
fibrotic than healthy non-ischaemic muscle.  This is also likely to account for the 
discrepancy between myoblast purity following isolation between CLI and control 
myoblasts.  However the work conducted above did not specifically focus on 
myofibril contraction typically associated with muscle function, which would require 
the differentiated form of myotubes, and is often observed in vitro as myofibril 
twitching, or analysed using techniques which are capable of transducing and 
measuring a contraction force, such as isometric and eccentric force generated. 
A relevant phenomenon is the conferred resistance to ischaemic injury as a result of 
previous exposure to ischaemia – known as ischaemic pre-conditioning [345, 346].  
In those situations, although the exposure to ischaemia is usually for an acute period, 
the underlying mechanisms may be applicable.  The increased resistance of CLI 
myoblasts and myotubes to simulated ischaemia was a repeated finding in this 
chapter, and quantification of caspase-3/7 activity and annexin V staining resulted in 
clear indications of significant difference between the response of CLI and control 
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myoblasts to ischaemia.  Through survival in a chronically ischaemic niche, it is 
possible that CLI myoblasts have been pre-conditioned, or that additionally they have 
developed pertinent adaptations which allow them to better withstand a second 
ischaemic insult. 
5.5.2 EPO and ARA-290 influence on human myoblasts and myotubes 
Treatment of CLI or control myoblasts and myotubes with EPO or ARA-290 resulted 
in improvement of observed detrimental responses to simulated ischaemia.   This 
included improved migration of myoblasts, and reduced susceptibility of myotubes to 
ischaemia-induced apoptosis and subsequent secretion of the pro-inflammatory 
cytokine IL-6.   
The influence of different signalling molecules on EPO and ARA-290 mediated 
cytoprotection was examined by investigating a number of molecules known to 
facilitate EPO-mediated erythrocyte precursor survival.  In the previous chapter, 
inhibitors of JAK2/STAT3, PI3k/Akt and NF#B demonstrated a significant inhibitory 
effect on EPO and ARA-290 cytoprotective effects.  Their impact on human 
myoblasts and myotubes was similarly valid.  In both CLI and control myoblasts and 
myotubes, addition of any of the above inhibitors to EPO or ARA-290 pre-treated 
samples resulted in reduced migration and increased apoptosis.  This identifies key 
roles of JAK2/STAT3, PI3k/Akt and NF#B in human cell signalling, as well as 
murine cells.  However, the effect of ischaemia on cellular mechanisms is not limited 
to these molecules only, and recent observations of the JAK1, STAT5, MAPK and 
TLR signalling cascades are just a handful of other important molecules within the 
deluge of interacting molecules arbitrating the effects of ischaemia. EPO is known to 
have interactions with most of these molecules, and therefore the potential interaction 
with ARA-290 remains to be investigated. 
The ability of both EPO and ARA-290 to dampen the secretion of IL-6 may account 
for their ability to attenuate secondary injury by removing the noxious pro-
inflammatory damage often triggered by the primary tissue injury.  EPO has already 
been explored in this role, and evidence has shown its antagonistic effects to TNF-" – 
a well-known pro-inflammatory cytokine – in order to limit collateral injury [347].  
The opposing roles of EPO and TNF-" in inflammation have been identified in other 
human disease pathologies including rheumatoid arthritis and myelodysplastic 
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syndromes [348, 349].  Recent studies assessing ARA-290’s ability to reduce 
inflammatory cytokines has also identified efficacy at reducing levels of IL-6, TNF-" 
and other cytokines (IL-1!, IL-8 and MCP-1) following injury [249, 260, 350]. 
Although in vitro models do not fully recapitulate the in vivo environment, the rapid 
and high-throughput screening of target molecules, oligonucleotides and novel 
hypotheses and strategies can be easily assessed by cell-culture systems, prior to more 
extensive validation in animal models, which possess both time and cost implications. 
The main drawbacks of using in vitro human explant primary cell cultures is their 
limited proliferative capacity, behavioural heterogeneity due to donor age and genetic 
composition, and their variation in phenotype as culture and passage progress [351-
353].  However, they often yield more valid results than immortal cell lines, and 
therefore provide a useful bridge to clinical assessment [354, 355]. 
5.6 Summary 
Isolation of human myoblasts from our clinical group of interest provided insight into 
fundamental adaptations they have accumulated due to a chronically ischaemic 
environment.  Both CLI and control myoblasts offered suitable alternatives to the 
C2C12 skeletal muscle in vitro model, allowing repeated observations of their 
function and responses to simulated ischaemia. 
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CHAPTER 6  
Effect of ARA-290 in vivo in a murine model of 
hindlimb ischaemia 
6.1 Introduction 
Whilst there is an evident utility of in vitro methods for its amenability to the high-
throughput analysis and testing of novel hypotheses and therapies, as well as the 
ability to finely control numerous parameters, assessment of many diseases is often 
more complex than the majority of single or co-cultured experimental offerings.  An 
in vivo model is also often a pre-requisite to establishing novel therapies before their 
permitted use in human clinical trials.  In vivo models, though not usually performed 
on the end-target species, do provide a more relevant platform for analysis, by 
incorporating many of the multiple organ-systems, molecular and cellular interactions 
and associated signalling pathways, and complexities, making it more representative 
of the human disease pathology being investigated when an appropriate and relevant 
model is used.  In this project, the use of a murine hindlimb ischaemia model as a 
pre-clinical model of CLI provided a useful means of assessing the potential 
therapeutic capability of EPO and ARA-290. 
In the previous chapters, the cytoprotective potential of EPO and ARA-290 was 
demonstrated first in an established murine myoblasts – myotubes cell line, and then 
in a novel in vitro model of human myoblasts – myotubes using cells derived from 
both CLI and control patients.  In both models, EPO and ARA-290 demonstrated an 
ability to prevent ischaemia-induced apoptosis in these single cell-type cultures.  
Despite its promising role in mediating cytoprotection in vitro this needs to be 
translated into a model that encompasses the multiple aspects often found in 
occlusive arterial diseases, such as PAD.  This includes the response of the occluded 
vasculature, as well as the impact upon surrounding muscle, which forms the primary 
bulk of tissue found in the limb and is reported as being the most sensitive and 
vulnerable tissue in the limb to ischaemia [340].  
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6.1.1 Severity of hindlimb ischaemia model 
A model of CLI was first described in 1953, achieved by injecting thrombin and a 
sclerosant into the femoral artery of a rabbit hindlimb [356, 357]. Since then, a 
number of different methods for inducing ischaemia in the hindlimb, both surgical 
and newer endovascular techniques have been described, each manifesting in slight, 
but distinct, modifications in terms of vascular injury and potential regeneration as 
well as consequent surrounding tissue injury observed in the model [285, 358-364]. 
Most commonly, hindlimb ischaemia is induced by surgical ligation or interruption of 
the arterial (inflow) vessels of the lower limb.  However, there is no standardised 
method for inducing hindlimb ischaemia, and this may be due, in part, to the relative 
endpoint being examined by different users.  In addition, considering the 
heterogeneous nature of PAD manifestations, it is desirable to have a model that can 
likewise, be manipulated to represent all the different pathological features of PAD.  
The hindlimb ischaemia model is used, in various forms, to assess a variety of 
different therapeutic options, including angiogenesis, arteriogenesis, and tissue 
protection potential of different agents, and therefore slight modifications in the 
protocol make the model more relevant to each area of PAD study.  For example, a 
single ligation of the femoral artery, just distal to the origin of the profunda femoris, 
without excision will result in milder ischaemia, more comparable to intermittent 
claudication than CLI [365].  With this model, collaterals are left viable and intact 
and as a consequence, blood flow to the limb is usually completely restored within 7 
days [358]. 
Alternatively, using a double ligation method, placing the proximal ligature just 
proximal to the bifurcation that gives rise to the profunda femoris at the inguinal 
ligament, and excising the intervening segment until the distal ligature, which is 
placed just proximal to the bifurcation of the popliteal artery around the knee joint, a 
model of hindlimb ischaemia which is more severe than single ligation is created.  
This is due to the disruption and removal of much of the collateral bed, which results 
in far reduced blood flow that is prolonged for up to 28 days [358]. 
In comparison, a ligature can be placed far more proximally, in the region of the 
external iliac artery with ligation of all distal branches until the level of the popliteal 
artery.  The region of vessel between the two ligations (external iliac to popliteal 
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artery) is excised, resulting in a very severe model of ischaemia, which very rapidly 
leads to necrosis and auto-amputation of the affected limb.  This model is at the most 
severe end of the spectrum, and is not often utilised as a representative model CLI 
[361]. 
6.1.2 Modifications of the hindlimb ischaemia model 
In addition to alterations in surgical technique, it is possible to influence the severity 
of the hindlimb ischaemia model by selecting certain laboratory mice strains, using 
transgenic strains to mimic known risk-factors or co-morbidities associated with 
disease and aging animals. 
Inter-strain variability 
Two of the most commonly used mice strains – BALB/c and C57BL/6 – have vastly 
different responses in natural recovery to hindlimb ischaemia.  This is due to 
differences in distribution of collateral arteries and the response of the collateral 
circulation as a result of obstruction to arterial flow.  BALB/c strains have reduced 
native collaterals compared with C57BL/6 and therefore show slower recovery after 
induction of hindlimb ischaemia, providing a larger window of assessment [366, 
367]. 
Co-morbidities 
Patients with PAD typically suffer from multiple co-morbidities including diabetes 
mellitus, hypercholesterolaemia and hypertension.  All of these factors have been 
extensively investigated and are known to contribute to the pathology of PAD 
through inflammation, endothelial dysfunction and oxidative stress.  However 
transgenic strains modelling the majority of human diseases now exist, and can be 
used in conjunction with the hindlimb ischaemia model to more accurately mimic the 
PAD state. 
Age 
The prevalence of PAD increases with age, whereas the majority of hindlimb 
ischaemia studies will use mice aged 8-12 weeks.  A mouse would need to be aged 
for approximately 2' years to age-match a 75-year-old human.  This involves 
considerable cost implications to house and age mice for such a period.  
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6.2 Aims 
Since the first study of hindlimb ischaemia was published there has been a multitude 
of different techniques described to induce hindlimb ischaemia.  It is important to 
select a model which will result in an adequate degree of ischaemia for the purpose of 
the study as well as ensuring the period of hindlimb ischaemia is appropriate for the 
time-course studied, and representative of the disease being modelled. 
A preliminary aim was therefore to establish a suitable model of hindlimb ischaemia 
by assessing a variety of different levels of the double ligation model, commonly 
used strains, and also the age of animals used and the consequent outcomes.  The 
quantification of the hindlimb ischaemia model was assessed by conventional 
techniques including LDPI and H&E microscopic assessment of the hindlimb 
muscles – gastrocnemius and tibialis anterior.  In addition to disruption in blood flow, 
measured by LDPI, it was vital to produce a model of hindlimb ischaemia which was 
relevant to CLI, and which mimicked characteristic alterations in muscle pathology 
observed in human disease.  
The greater objective of this chapter aims to assess the therapeutic potential of ARA-
290 in a pre-clinical CLI model, and compare its tissue-protective potential with EPO  
which has previously demonstrated tissue-protective functions in other settings of 
ischaemic injury.  Tissue protective capabilities was assessed by outcomes including 
functional ability, return of blood flow using LDPI, and histological evaluation of 
ischaemic and inflammatory damage to muscle and attempts at regeneration.   
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6.3 Methods 
All animal studies described in this chapter were licensed under the UK Home Office 
Animals (Scientific Procedures) Act 1986, project license number 70/7087. 
Experimental procedures were designed, first to assess the feasibility of different 
hindlimb ischaemia models to provide an adequate and representative pre-clinical 
model of CLI, and secondly to assess the therapeutic potential of a novel synthetic 
peptide – ARA-290. 
6.3.1 Establishing parameters for a model of hindlimb ischaemia 
Variations in surgical technique 
Two models of hindlimb ischaemia were evaluated.  Surgically, both involved double 
ligation of the arterial inflow supply, but differed in terms of the location of the 
proximal ligature. Briefly, a 1 cm incision was made in the groin area in both 
scenarios to gain exposure of the femoral artery around the level of the inguinal 
ligament.  In the less severe hindlimb ischaemia model the femoral artery was ligated 
just distal to the bifurcation of the profunda femoris and just proximally to the 
bifurcation of the popliteal artery.  The intervening segment (approximately 10 mm) 
was also excised.  In the more severe model, the proximal ligature was placed just 
proximally to the bifurcation of the profunda femoris, and the distal ligature again 
placed just proximally to the bifurcation of the popliteal artery.  The intervening 
segment was also excised (approximately 12 mm).  In both operative procedures, care 
was taken to avoid damage to surrounding structures (vein and nerve) and the skin 
was closed using 6-0 vicryl sutures.  Both surgical procedures were performed on the 
C57BL/6 background strain, with mice aged 8 weeks. 
Common laboratory mice strain 
The two commonest strains of mice used for assessing hindlimb ischaemia are 
BALB/c and C57BL/6.  Mice from each strain, obtained in-house from UCL 
comparative biological unit, at 9 weeks of age, were assessed for their ability to 
provide an acceptable model of hindlimb ischaemia.  The more severe hindlimb 
ischaemia technique discussed above was introduced in animals of each strain, and 
assessed over a time-course of 21 days. 
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Age of mice 
Incidence of PAD rises sharply with age in human subjects, therefore investigation 
into the effects of aged mice and the resultant influence on the model was 
investigated.  The hindlimb ischaemia model was performed on aged mice (16 weeks 
of age) and compared with young animals (6 weeks of age).  Both young and old 
animals were sourced from the BALB/c strain.  There is however a trade-off that 
needs to be made between the costs required to house and age animals and 
advantages in replication of a disease mainly prevalent in older members of the 
species. 
6.3.2 Assessment of ARA-290 in an in vivo hindlimb ischaemia model 
Immediately following induction of hindlimb ischaemia, animals were randomised to 
receive either saline vehicle control (n=4), Eprex® (3000IU/kg; n=6), low-dose 
ARA-290 (30µg/kg; n=6), or high-dose ARA-290 (60µg/kg; n=6), all via intra-
peritoneal injection.  Mice received subsequent doses on days 2, 4, 6, 8 and 15 
postoperatively until the relevant endpoint.  Sham operated animals followed the 
same anaesthetic and operative procedure but did not undergo ligation of femoral 
artery.  In addition, they received the same post-operative analgesic care, but no 
subsequent interventions until the relevant endpoint. 
At the relevant endpoints, animals were first transferred to an open field for 
assessment of functional outcomes as described in chapter 2.5.4, then anaesthetised 
using Avertin for assessment of paw perfusion using LDPI, collection of whole 
blood, and collection of hindlimb muscles for histological analysis. 
Histological analysis of mouse hindlimb muscle included routine H&E stain to assess 
tissue morphology following ischaemic injury and assessment of C:F ratio using 
endothelial cell markers (CD34).  To investigate the effects of ARA-290 on 
ameliorating ischaemia-induced tissue injury, images were recorded of the stained 
sections.  2 high-powered fields of view were taken of both the gastrocnemius and 
tibialis anterior muscles of the operated limb and 1 high-powered field of view for 
both the gastrocnemius and tibialis anterior muscles of the non-operated limb for 
comparison.   Scoring of the muscle sections was conducted in a blinded fashion by 5 
assessors for H&E sections, and 3 assessors for all other staining.  Assessment of 
proliferative index was performed using immunohistochemistry to detect the Ki-67 
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protein – known to be strictly associated with cell proliferation.  Using sections 
stained for Ki-67 all images were analysed using ImageJ software, and the ‘cell-
counter’ plug-in (v1.47, http://rsbweb.nih.gov/ij).  Ratios of proliferative (positive 
staining): resting  (no staining) cells were calculated and assessed. 
 !
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6.4 Results 
6.4.1 Initial assessment of hindlimb ischaemia model 
In the preliminary study, a number of different permutations of animal, age and 
surgical technique were explored, yielding quite varied impact upon the duration of 
flow disruption, and muscle fibre injury, as evidenced by histological analysis, as 
detailed below. 
Surgical technique 
With the less severe model, analysis of LDPI results demonstrated resolution of blood 
flow disruption to almost 75% or normal, or full, flow by day 7.  By day 21 blood 
flow had achieved 95% in the ligated limb, compared to the contralateral un-operated 
limb.  In comparison, using the modified, more severe hindlimb ischaemia model, by 
day 7, blood flow had returned to only 40% of full flow, and 80% of full flow by day 
21 (Figure 6.1). 
Histological analysis of FFPE sections, stained with H&E, demonstrated slight 
variation in muscle fibre damage observed in each operative technique.  In the less 
severe model at day 7 tissue architecture looks normal, and at day 21 there is some 
muscle fibre size variation but nuclei still reside around the periphery of each fibre.  
In comparison, in the more severe ligation, tissue architecture looks abnormal.  At 
day 7, there is evidence of inflammation and muscle fibre necrosis, in addition to loss 
of peripheral nuclei.  By day 21, tissue structure remains abnormal, a number of 
fibres have centrally located nuclei, indicative of muscle fibres attempting 
regeneration (figure 6.2). 
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Figure 6.1: Recovery of paw perfusion following different severity of hindlimb 
ischaemia 
Paw perfusion appears to recover faster and to a greater extent in the less severe 
femoral artery ligation model compared to the more severe ligation (n= 2 per group 
and at each time point). 
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Figure 6.2: Muscle injury following different severity of hindlimb ischaemia 
A and B: Representative H&E sections from less severe hindlimb ischaemia model at 
day 7 (A) and 21 (B). Tissue architecture maintains features of normal skeletal 
muscle at both the early and late time points, with little evidence of muscle injury. C 
and D: Representative H&E sections from a more severe hindlimb ischaemia model 
at day 7 (C) and day 21 (D).  Muscle sections show features of muscle injury at both 
early and late time points including variation in fibre size and sarcoplasmic 
destruction.  Scale bars = 50µm. 
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Background strain of mouse 
Comparison of LDPI results between the BALB/c and the C57BL/6 strains at day 7 
demonstrated a significant difference in the perfusion ratio between ischaemic and 
non-ischaemic limbs, with the BALB/c strain showing less resolution of perfusion.  
The C57BL/6 strain demonstrated approximately 20% greater perfusion ratio 
compared to BALB/c mice at the day 7 (Figure 6.3).  This finding was sustained, and 
the difference in perfusion ratio between the two strains increased to 30% greater 
perfusion in C57BL/6 animals at the day 21 endpoint. The BALB/c animals 
demonstrated 68% perfusion in the operated limb in comparison to the non-operated 
limb at day 21. 
In both strains of mice histological analysis using routine H&E of samples displayed 
typical feature of skeletal muscle injury in muscles isolated from the operated limb.  
These features included signs of necrosis with gross infiltrating inflammatory cells 
and sarcoplasmic destruction as well as variation in muscle fibre size.  There was 
however, some difference in the severity of the muscle injury displayed.  Animals 
from the BALB/c strain showed diffuse inflammatory infiltrate in comparison to 
C57BL/6 mice, which showed little, or very discrete areas of inflammation, at any 
time point.  The BALB/c animals also showed greater susceptibility to muscle 
necrosis, observed as large pyknotic nuclear clumps.  Progression of ischaemic injury 
in the BALB/c mice also lead to adipogenic and fatty connective tissue areas, 
whereas the C57BL/6 strain did not demonstrate such features (figure 6.4).   
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Figure 6.3: Natural recovery of paw perfusion in different strains of laboratory 
mice 
Paw perfusion appears to recover faster and to a greater extent in the less severe 
femoral artery ligation model compared to the more severe ligation (n= 2 per group 
and at each time point). 
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Figure 6.4: Effect of common laboratory strains of mice on hindlimb ischaemia 
model 
A and B: Representative H&E sections from C57BL/6 hindlimb muscle at day 7 (A) 
and 21 (B). Tissue retains structural architecture, with evidence of muscle injury 
including sarcoplasmic destruction and variation in fibre size. C and D: 
Representative H&E sections from BALB/c hindlimb muscle at day 7 (C) and day 21 
(D).  Muscle sections show features of muscle injury at both early and late time 
points including gross inflammatory infiltrates, variation in fibre size and 
replacement of muscle fibres by fibrotic fatty tissue.  Scale bars = 50µm. 
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Age of mice 
Analysis of the hindlimb ischaemia model in 6 weeks old mice (young) compared to 
18 weeks old mice (old) displayed markedly prolonged disruption in re-perfusion in 
the older animals.  At day 7, a 20% difference in perfusion ratio was observed 
between the young and older mice.  This finding was persistent and increased at the 
day 21 endpoint, when the difference in perfusion ratio between the young and old 
animals increased to 36%, with the older animals achieving only 48% perfusion in the 
operated limb, compared to the non-operated limb (Figure 6.5). 
Figure 6.6 shows observations following H&E staining of muscle sections from the 
operated limb.  Younger animals had milder signs of muscle injury, both in the early 
and late phases analysed.  It was only possible to detect very defined regions of 
muscle regeneration (Figure 6.6A), or infiltration of inflammatory cells (Figure 6.6 
B), and at all time points observed, the majority of each muscle area did not display 
overt features of ischaemic injury.  In contrast, observations of the older animals 
following hindlimb femoral artery ligation showed gross tissue abnormalities which 
became more severe with progression of time.  In the initial stage following ligation, 
there was evidence of muscle fibre necrosis as seen by pyknotic nuclear clumps and 
infiltration of muscle tissue by inflammatory cells (Figure 6.6C).  The muscle damage 
observed progressed into fibrotic changes towards day 21, and those areas where 
muscle fibres remained showed attempts at regeneration (Figure 6.6D). 
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Figure 6.5: Natural recovery of paw perfusion following hindlimb ischaemia 
induction in mice of different ages 
Paw perfusion appears to recover faster and to a greater extent in younger mice (6 
weeks of age) compared to older (16 weeks of age) mice (n=2 per group and at each 
time point). 
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Figure 6.6: Effect of animal age on hindlimb ischaemia model 
A and B: Representative H&E sections from young mice hindlimb muscle at day 7 (A) 
and 21 (B). A: Tissue retains structural architecture, and demonstrates little evidence 
of muscle besides a small number of fibres with central nuclei.  Even at later stages 
(B), a small degree of localised inflammatory infiltrate can be observed. C and D: 
Representative H&E sections from older mice hindlimb muscle at day 7 (C) and day 
21 (D).  Muscle sections show features of severe inflammatory infiltrate and necrosis 
of muscle fibres in the early stages (C), which appears to lead to muscle fibre 
necrosis and replacement of extensive areas with fibrotic fatty tissue.  Scale bar = 
50µm. 
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Summary of hindlimb ischaemia model development 
Comparison of LDPI perfusion images identified the more severe ligation technique, 
BALB/c strain and older mice as demonstrating the most prolonged period of 
perfusion mis-match between left and right limbs (Figure 6.7).  A similarly increased 
degree of muscle tissue damage was also evident on comparison of H&E sections 
from the various hindlimb groups.  Therefore for subsequent experiments, the severe 
ischaemia model on 12 weeks old BALB/c strain was used. 
 
 
Figure 6.7: Comparison of paw perfusion following variations in hindlimb 
ischaemia model 
Summary graph of all preliminary studies assessing variability in the hindlimb 
ischaemia model through alterations in technique, animal strain and age (n=2 per 
group and at each time point).  The more severe surgical ligation provided a more 
suitable model of hindlimb ischaemia.  In subsequent comparisons between mice 
strain and age the more severe ligation was used.   
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6.4.1.1 Applicability of hindlimb ischaemia model to human disease 
The relationship between human PAD and the murine hindlimb ischaemia model was 
assessed to ensure a robust model was used that replicated classical features of the 
disease of interest.  The comparisons relied on histological techniques to assess 
muscle morphology (routine H&E stain) as well as connective tissue fibrosis – a 
histopathological feature of more chronic and severe disease – using picro-sirius red 
stain. 
Figure 6.8 A, B and C shows representative images of human skeletal muscle taken 
from control patients and patients with different stages of PAD.  This can be 
compared to skeletal muscle samples taken from the BALB/c hindlimb ischaemia 
model, which shows normal muscle from the non-operated limb, as well as muscle 
from a middle and late time point (Figure 6.8 D, E and F).  Characteristic features in 
early stage of disease observed by H&E analysis include infiltration of inflammatory 
cells, attempts of muscle fibres to regenerate as well as evidence of past regeneration 
(central nuclei) and muscle fibre size heterogeneity.  At terminal stages of disease, 
replacement of muscle fibres with fatty, fibrotic tissue can be observed, as well as 
loss of peripheral nuclei, and centrally located nuclei as muscle fibres attempt to 
regenerate. 
Following observations of fibrotic regions in CLI muscle, human skeletal muscle 
sections were assessed for collagen deposition in both control and CLI disease 
patients, using picro-sirius red staining.  Analysis of sections under brightfield, and 
subsequent polarised light microscopy confirmed little collagen present around 
muscle fibres of control samples but increased deposition of collagen in CLI muscle.  
In brightfield images, collagen around the muscle fibres was stained red, which when 
viewed under polarised light, demonstrates both larger collagen fibres (orange and 
yellow staining) as well as smaller reticular fibres (green staining).  Analysis of 
mouse hindlimb ischaemia sections demonstrated similar features of endomysial 
fibrosis previously observed in human CLI sections. 
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Figure 6.8: Comparison of human and mouse skeletal muscle following 
prolonged ischaemia 
A and D: Representative H&E sections from adult, non-ischaemic human (A) and 
mouse (D) gastrocnemius.  Structure of the muscle tissue is composed of a mosaic of 
muscle fibres in contact with one another.  Each fibre has a peripherally located 
nucleus.  B and E demonstrates muscle injury in the early ischaemic period, with 
characteristic sarcoplasmic destruction and variation in fibre size.  C and F 
demonstrate severe muscle injury following chronic ischaemia, with loss of muscle 
fibre and replacement with adipocytic connective tissue.  Analysis of connective 
tissue seen in later stages of PAD (G and H), and the hindlimb ischaemia model (I 
A B C 
D E F 
G H 
I J 
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and J) using picro-sirius red staining identified the endomysial and perimysial 
distribution of collagen. 
6.4.2 ARA-290 treatment improves functional and physiological outcomes in 
the murine hindlimb ischaemia model 
Following induction of unilateral hindlimb ischaemia in 12-week old BALB/c female 
mice, daily monitoring revealed mice that were less active in comparison to sham-
operated animals in the days immediately after hindlimb ischaemia was induced.  
This decrease in movement and activity was only evident for three to four days post 
operation, after which all animals were observed to be freely moving around. 
Qualitative assessment of functional (Tarlov and modified BMS) and ischaemia-
related (ischaemia and modified ischaemia) scoring systems was therefore performed 
to identify differences in physiological outcomes between the different animals.   
All scoring platforms identified operated mice as being less ambulatory, and 
demonstrating features of ischaemic injury in the first 3 days post operation compared 
to sham operated mice.  Natural recovery of all physiological outcomes was also 
observed to an extent by the vehicle-control treated animals by day 21  (Figure 6.9).   
High-dose ARA-290–treated mice showed significantly accelerated improvement in 
comparison to vehicle-control mice, in all scoring systems as early as day 10 
(P=0.0075 Tarlov score; P=0.0052 Ischaemia score; P=0.0002 modified ischaemia 
score; P=0.0121 modified BMS score, all by one-way ANOVA, post-hoc Tukey’s 
test, n=6 mice/group).  These observations were prolonged until day 21, compared 
with vehicle-control mice in all scoring systems except the ischaemia score.  A 
similar pattern of improved physiological scores was exhibited in low-dose ARA-
290–treated mice by day 21 in the Tarlov, modified ischaemia and BMS scoring 
systems only.   Improvement in physiological scores were also observed following 
EPO treatment however the trend was not significant, and was also less pronounced 
in comparison to ARA-290 treated animals.  Representative images of both normal 
and ligated paws showing nail and digital necrosis can be seen in figure 6.10. 
Animals were also assessed for changes in weight, which may affect recovery.  All 
animals were weighed pre-operatively and on days 3, 10 and 21, before anaesthesia 
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was administered.  There were no significant changes in weight between the animals 
at any time point (figure 6.11).   
 
 
Figure 6.9: Assessment of functional outcomes following hindlimb ischaemia 
Analysis of functional scoring systems demonstrated variation in extent of recovery 
following hindlimb ischaemia.  Vehicle-control treated animals recovered the least 
across all scoring platforms.  In comparison, ARA-290 treated animals receiving 
either low or high-dose treatment showed significantly improved functional and 
ischaemia-related scores.   Summary data is expressed as mean ± SEM. 
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Figure 6.10: Hindlimb paws following induction of hindlimb ischaemia 
Representative image of normal paw (A), ischaemic ‘dusky’ paw (B) and nail and 
digit necrosis (C). 
 
Figure 6.11: Assessment of weight pre and post-operatively in all animals 
All animals were weighed prior to ligation of femoral artery, and also prior to  the 
relevant end-point.  There was no significant alterations in weight in any treatment or 
control group nor at different time points. 
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6.4.3 Effect of ARA-290 on blood flow 
The effect of EPO and EPO-derivative administration on limb perfusion following 
surgical induction of hindlimb ischaemia was measured over 21 days.  Vehicle-
control treated animals demonstrated natural recovery of blood flow to the affected 
limb of approximately 50% compared to the unaffected limb by day 21.  The degree 
of paw perfusion was still significantly reduced compared to sham operated animals 
(Figure 6.11).   
In comparison, at day 21, animals treated with either EPO or ARA-290 demonstrated 
significantly greater improvements of paw perfusion, compared to vehicle-control 
treated animals (P=0.0009 EPO-treated; P=0.0001 low-dose ARA treated; P=0.0003 
high-dose ARA-290 treated, all by one-way ANOVA, n=6 mice/group).  Treatment 
with either low or high-dose ARA-290 demonstrated accelerated recovery of limb 
perfusion, as early as day 10.  At this time, paw perfusion in both groups was not 
significantly different to sham operated animals (P>0.55 both ARA-290 treatment 
groups, one-way ANOVA).  In addition the improvement in paw perfusion was 
significantly attenuated compared to vehicle-control mice (P=0.042 low-dose ARA; 
P<0.0001 high-dose ARA, one-way ANOVA). 
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Figure 6.12: Recovery of hindlimb ischaemia following EPO and ARA-290 
treatment 
(A) Analysis of recovery in paw perfusion forllowing hindlimb ischaemia. (B) 
Representative Laser Doppler images of paw perfusion at all time points and 
intervention groups.  Summary data are expressed as mean ± SEM. 
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6.4.4 Effect of ARA-290 on muscle injury 
The effect of hindlimb ischaemia on muscle damage was assessed using H&E 
analysis of muscles harvested from the hindlimb.  The pre-defined grading system, 
which takes into account characteristic features of muscle injury and its evolution, 
clearly displayed a detrimental effect of hindlimb ischaemia on skeletal muscle at day 
3.  Typical features seen in the affected limb of all operated animals at day 3 include 
infiltration by inflammatory cells, centrally located nuclei, muscle fibre shrinkage and 
variation in fibre size (Figure 6.13).  Vehicle-control treated animals tended to 
progress towards greater severity of muscle damage, which was prolonged until 
experimental end-point (Figure 6.12).   
In comparison, treatment with low-dose ARA-290 maintained a similar level of 
muscle injury observed at day 3, across all time points.  Treatment with high-dose 
ARA-290 did not appear to have as great a benefit on preventing the natural 
progression of muscle damage at day 10, especially in the more distal tibialis anterior 
muscle, but subsequently, ameliorated the progression of disease by day 21.  
Treatment with EPO similarly, did not show initial benefit in counteracting 
ischaemia-induced muscle injury evolution at day 10.  However, tissue-protective 
properties were demonstrated, by day 21, when the level of muscle injury observed 
was comparably lower.  Protracted treatment with EPO caused slight muscle damage 
in the contra-lateral, non-operated limb in 1 animal from the EPO-treatment group 
(n=6).  This finding may be consistent with known thrombotic side effects of high-
dose EPO treatment. 
Figure 6.13 exhibits representative H&E images of characteristic features observed in 
the progression of ischaemic-muscle injury.  Muscle sections from the non-operated 
limb all displayed normal architecture, with single peripherally located nuclei (A).  At 
day 3 post-operative hindlimb ischaemia the operated limb had inflammatory cell 
infiltration (B).  Progression of muscle injury was variable across the different 
treatment groups, but other characteristic features of muscle injury observed included 
muscle fibre diameter shrinkage, variation in fibres size, denervation and loss of 
peripheral nuclei (C), attempts at muscle regeneration and centrally located nuclei (D 
and E), muscle necrosis and pyknotic nuclear clumps, with replacement of muscle 
fibres with adipogenic tissue (E and F). 
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Figure 6.13: Evaluation of muscle injury following hindlimb ischaemia 
Analysis of blinded scores of muscle H&E sections for all animals and timepoints 
revealed an increase in mean muscle injury score in vehicle-control treated animals 
at day 21.  EPO treated animals demonstrated worsening muscle injury scores, 
comparable to saline-treated animals at day 10.  Resolution in muscle injury 
occurred towards day 21.  ARA-290 treated animals demonstrated less severe muscle 
injury, and significantly improved muscle injury scores by day 21.  Summary data is 
expressed as mean ± SEM. 
 
Figure 6.14: Features of ischaemic muscle injury 
Representative images of H&E stained muscle sections showing normal (A) and 
pathological muscle tissue (B-F).  In the early ischaemic period there is an increased 
infiltration of inflammatory cells (B).  Loss of myofibre innervation, peripheral nuclei 
and variations in size also occur (C).  Attempts by muscle to regenerate are 
characterised by centrally located nuclei (D).  Necrosis of vast numbers of muscle 
fibres leads to pyknotic nuclear clump (E) and replacement of normal myofibres with 
adipogenic and fibrous connective tissue (E and F). 
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6.4.5 Effect of ARA-290 on myofibre proliferation 
Assessment of muscle fibre nuclei for the proliferative marker Ki-67 revealed EPO 
and ARA-290 treatment groups had accelerated induction of proliferation – 
evidenced by the increased percentage of Ki-67+ nuclei – at day 3.  There was a 
significantly higher percentage – greater than two-fold higher – of positive nuclei in 
the EPO and ARA-290 treated groups at this early time point (figure 6.14 and 6.15).  
The vehicle-control treated group demonstrated an increase in positively stained cells 
between day 3 and 10, to a comparable level observed in the EPO and ARA-290 
treated groups.  By day 21 all treatment groups had less than 20% positively stained 
cells, with no significant difference between vehicle and EPO or ARA-290 treated 
groups.  All treatment groups demonstrated significantly increased proliferation 
compared to the contralateral limb, as well as sham operated animals, at all time 
points. 
 
Figure 6.15: Analysis of proliferation index following hindlimb ischaemia 
ImageJ analysis of muscle sections stained for Ki-67 demonstrated an increase in 
proliferation positive cells in animals subjected to hindlimb ischaemia.  There is an 
initial increase in proliferative nuclei, which during our time course peaked at day 
10, followed by a steady decline.  EPO and ARA-290 treated animals demonstrated 
an accelerated increase in positive cells, followed by a steady decline.  Summary data 
is expressed as mean ± SEM.  
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Figure 6.16: Histological analysis of proliferation following hindlimb ischaemia 
Representative images used for cell counting of both positively and negatively stained 
Ki-67 nuclei (in brown (DAB)) to assess proliferative index.  Arrow indicates Ki-67 
positive nucleus.  Scale bars = 20µm. 
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6.4.6 Effect of ARA-290 on ischaemia-induced angiogenesis 
Analysis of C:F ratio over the time-course of the experiment demonstrated a slight 
decrease in the C:F ratio in all operated animals compared to sham operated animals 
at day 3.  Observation of vehicle-treated animals as an indication of natural recovery 
demonstrated an increase in C:F ratio to approximately 1.5-fold greater than sham 
operated animals, indicating a degree of neoangiogenesis occurred following 
hindlimb ischaemia.  Treatment with either low or high-dose ARA-290 demonstrated 
a similar reduction in C:F ratio at day 3, followed by an increase to approximately 1.1 
by day 10, after which a plateau was observed (Figure 6.16).   
EPO treated animals demonstrated a greater than 3-fold increase in C:F ratio between 
day 3 and 10.  A further, slight, increase in C:F ratio was observed at day 21 (Figure 
6.16).  This finding is in keeping with known observations of the angiogenic 
capabilities of EPO. 
Representative images of CD34 staining for assessment of C:F ratio are shown in 
Figure 6.13.  An increase in CD34 staining can be seen in operated animals at day 10 
and 21. EPO-treated animals display a far greater proportion of CD34 positive stained 
cells, indicating an increase in the number of capillaries present.  This increase in 
CD34 staining is prolonged until day 21 (Figure 6.16). 
 
Figure 6.17: Evaluation of capillary : fibre ratio following hindlimb ischaemia 
A gradual increase in C:F ratio is observed in ischaemic muscle as perfusion 
recovers.  EPO-treated animals demonstrate greater increase C:F ratio by day 10, 
which is sustained until the experiment end-point.  Summary data is expressed as 
mean ± SEM. 
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Figure 6.18: CD34 immunohistochemistry for C:F assessment 
Representative images of CD34 immunohistochemistry performed on muscle from the 
ischaemic hindlimb, used to calculate the C:F ratio in the different treatment groups 
at different time points.  Arrow demonstrates a capillary.  Scale bars = 50µm. 
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6.5 Discussion 
In this study, establishing a murine model of hindlimb ischaemia which closely 
mimics characteristic features of human CLI and PAD was made possible through 
modulation of a number of common variables of the technique and animals used.  
Variation in the surgical technique, mouse strain and age all had consequent effects 
on the severity of the hindlimb ischaemia produced.   Developing a robust pre-clinical 
model was a pre-requisite in order to test the novel EPO-derivative, ARA-290, as a 
potential tissue-protective agent following ischaemic injury to the hindlimb.   
6.5.1 Establishing a suitable model of hindlimb ischaemia 
Initiation of hindlimb ischaemia model: Severity of hindlimb ischaemia 
The mouse hindlimb is known to have an extensive innate collateral system, and for 
this reason, is remarkably resistant to ischaemia, with models utilising single ligation 
of the femoral artery often documenting no severe ischaemic change, and resolution 
to normal parameters within 7–28 days [358, 368, 369].  For this reason, development 
of a chronic ischaemia model will often employ techniques involving double ligation, 
or gradual occlusion of the femoral artery – using balloon dilation devices – to 
induce, and maintain a prolonged ischaemic period.  In this study, we varied the 
length of femoral artery ligated to increase the severity of ischaemia induced.  As 
expected, the more severe surgery resulted in a hindlimb that showed greater 
evidence of ischaemia, including more pronounced reduction in paw perfusion, and 
histological features suggestive of more severe ischaemic injury.  In comparison, the 
less severe technique failed to provide a prolonged window of reduced paw perfusion, 
with resolution in perfusion achieving 75% of the non-ischaemic limb within 7 days.  
Histological analysis demonstrated only mild features of muscle injury in localised 
areas, with the majority of muscle not overtly dissimilar in appearance to muscle 
from the contralateral, normal limb.   
Initiation of hindlimb ischaemia model: C57BL/6 vs. BALB/c strains 
Comparison of two common laboratory mice strains – C57BL/6 and BALB/c were 
also considered for the innate ability to recuperate following femoral artery ligation to 
render the limb ischaemic.  Following interruption or occlusion to arterial inflow, 
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there is significant variation in the response of the collateral circulation between these 
strains.  Analysis of the animals after surgery displayed considerable variation in the 
natural response to hindlimb ischaemia.  BALB/c animals demonstrated a greater 
susceptibility to ischaemic injury following surgery, as evidenced by a prolonged 
period of reduced paw perfusion in the affected limb, and more pronounced 
histological features of muscle inflammation, injury, attempted regeneration, and 
necrosis, with subsequent fibrotic fatty tissue replacement.  C57BL/6 animals, in 
comparison, also demonstrated sensitivity to hindlimb ischaemia, but a greater 
propensity for recovery of both paw perfusion and muscle tissue injury, within a 
shorter timeframe.  This could be due, in part to previous observations that C57BL/6 
mice have a large repository of native collaterals compared to BALB/c mice [370, 
371].  As a consequence, the recovery times of C57BL/6 mice tends to be 
significantly reduced whereas BALB/c mice exhibit a prolonged recovery period – a 
potentially desirable feature, providing a greater period for analysis of interventions 
[372].  Both strains are highly inbred with minimal genetic heterogeneity within each 
strain.  In addition, a vast number of knockout mice are based on a background 
utilising one of these strains, making them ideal to devise appropriate, replicable pre-
clinical models of hindlimb ischaemia.   
Initiation of hindlimb ischaemia model: Age 
A key feature of PAD is its increased prevalence with age.  The majority of patients 
with PAD are elderly, with impaired regenerative capacity and dynamic response to 
everyday stimuli and mechanical or other trauma.  The effect of mouse age on natural 
recovery rates in the hindlimb ischaemia model was assessed.  Young mice (6 weeks 
old) displayed a remarkable capacity to withstand and recover from ischaemic injury.  
Histological analysis demonstrated very mild features of muscle damage in very 
localised areas.  In contrast the older mice (16 weeks of age), although not 
comparable in age to a typical 70-year-old human PAD sufferer, displayed many of 
the characteristic features of muscle injury, and attempted regeneration, as well as 
muscle tissue death.  The significance of aging mice, for more accurate representation 
of clinical disease features needs to be balanced with cost-effectiveness of achieving 
characteristics.  To produce a 75 year old human ‘age-matched’ mouse the mouse 
would need to be 2' years old, which has significant housing and maintenance costs 
implications.  Analysis of young and old mice responses to ischaemia emphasised the 
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significantly slower recovery rates observed in the older animals.  Other studies 
looking at the effects of aging in the hindlimb ischaemia model, using mice that show 
typical age-related phenotype (Klotho mutant mice) also reported impaired recovery 
of the ischaemic limb [373]. 
6.5.2 Effect of ARA-290 on recovery following hindlimb ischaemia 
Erythropoietin has previously demonstrated its utility as a multi-tissue-protective 
agent.  Unfortunately, its routine use in chronic diseases other than the treatment of 
anaemia cannot be justified due to the side effects of repeated administration, 
including effects on haematocrit, platelets, and blood pressure [374-376].  
Assessment of the novel EPO-derivative, ARA-290, was therefore trialled for 
potential tissue-protective effects in vivo following induction of hindlimb ischaemia. 
Treatment of mice following induction of hindlimb ischaemia with ARA-290 
significantly improved the natural recovery of blood flow, functional and histological 
outcomes within the ischaemic limb over 21 days.  The mechanisms underlying these 
observations are likely due to the contribution and complex interaction between each 
of these factors, amongst a multitude of others. 
Recovery of blood flow demonstrated improvement when treated with ARA-290.  
Indeed, treatment with high dose ARA-290, at twice the dose given to the low-dosed 
animals resulted in accelerated recovery in the early to mid-phase, which normalised 
and equalled the blood flow recovery observed in the low-dose ARA-290 treated 
animals by the day 21 endpoint.   Interestingly, though there was an increase in blood 
flow recovery in EPO treated animals, the difference was not as significant compared 
to ARA-290 mice.  Analysis of angiogenic potential of EPO and the EPO-derivative 
revealed significantly enhanced C:F ratio, indicative of angiogenesis in the EPO 
treated group only.  This explains, in part, the increased improvement in blood flow 
recovery observed in the EPO treated group, but does not account for the increased 
and faster recovery seen in ARA-290 treated groups, neither of which displayed 
capillary fibre ratios above that observed in saline, vehicle-control treated animals.  
This finding is in keeping with other functional studies of EPO and ARA-290.  EPO 
is known to possess angiogenic potential [377-380], but the design of ARA-290 
intentionally focused on harnessing only the tissue-protective potential of the EPO-
molecule and discarding all other haematopoiesis-related attributes [245].  
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Assessment of angiogenic potential in vitro, assessing capillary tube formation, 
demonstrated treatment with ARA-290 did not positively influence angiogenic 
outcomes [381].  EPO is also capable of promoting blood vessel outgrowth by 
influencing other cells.  Examples of such actions include the role of EPO on 
stimulating endothelial progenitor cells to mobilise to ischaemic tissue and promote 
new blood vessel formation [382-384].  In addition EPO has demonstrated an effect 
upon regulation of nitric oxide, another molecule known to promote angiogenesis in 
addition to vasodilation [385, 386].  
Functionally, all treatment groups demonstrated enhanced recovery of ambulation 
compared to vehicle-control group with high-dose ARA-290 treated animals 
improving earlier (by day 10) than low-dose ARA-290 treated animals.  Although it 
might be expected that EPO treated animals, following increased C:F ratio may 
demonstrate the greatest functional outcomes, this was not the case, and conversely, 
analysis of functional scores for EPO-treated animals did not reach statistical 
significance in comparison to vehicle-control.  A similar pattern of results was 
observed when animals were assessed for physiological improvements.  ARA-290 
treated animals showed statistically significant improvement towards the end of the 
experimental period in the modified ischaemia score only.   
Inter-related with blood flow and functional outcomes is the effect of hindlimb 
ischaemia on the skeletal muscle which, much like in humans, in mice, also makes up 
the bulk of the hindlimb.  Histological assessment of the effect of ischaemia on the 
muscle tissue identified many characteristic features of the various stages of muscle 
injury.  As expected, all EPO and ARA-290 treatment groups demonstrated 
improvement in histological appearance at day 21, and at all time points compared to 
the saline, vehicle-control treated animals.  Interestingly, EPO and high-dose ARA-
290 treated animals, similarly to the vehicle control animals showed a progression in 
muscle damage between day 3 and 10, which begin to show resolution after day 10.  
Such progression of muscle damage was not observed in low-dose ARA-290 animals 
On a macroscopic level, it is logical to assume that an improvement in blood flow 
would impact upon the degree of muscle injury observed, which in turn alters 
functional and physiological outcomes, and underpinning a greater resolution of 
perfusion deficit could be the ability to develop greater numbers of collateral vessels 
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to improve the perfusion to the ischaemic area.  Whilst this may be true for the EPO-
treated animals, only a relatively modest increase in C:F ratio was observed in both 
ARA-290 treatment groups.  The C:F ratio observed was also below the levels 
observed in vehicle-control treated animals, who fared significantly worse on all 
functional and physiological scores in comparison to ARA-290 treated animals.  
What is known, is that the ischaemia induced following surgical ligation of the 
femoral artery to create the hindlimb ischaemia model, catalyses a complex cascade 
of events including muscle damage, and in response to the hypoxic environment that 
is created, a degree of angiogenesis to reperfuse the limb.  In addition, treatment with 
EPO or ARA-290 appears to have differential effects on ameliorating muscle 
damage, angiogenic potential of the muscle and as a consequence the functional 
benefit observed.   
Another possible explanation for the improved functional outcomes observed in EPO 
and EPO-derivative treated animals is the effect these agents had upon proliferative 
index following hindlimb ischaemia.  In the early period following surgery, EPO and 
ARA-290 treated animals displayed significantly higher proportion of proliferative 
nuclei when analysed using immunohistochemistry for the proliferative marker Ki-
67, indicative of a regenerative phenotype.  Though this higher proliferative index 
was not maintained across all time points, it is possible that the accelerated initial 
proliferation might ‘kick-start’ the regenerative potential of the muscle tissues, hence 
why the observed staining in each group is not prolonged. 
Limitations of the hindlimb ischaemia model 
In initialising a hindlimb ischaemia model, a number of factors were considered, 
besides how closely the model mimicked the human disease of interest.  Age of 
disease sufferers has previously been mentioned, and was assessed as above.  Other 
underlying mechanisms that contribute to PAD, aside from increased age, include 
hypertension, hypercholesterolaemia and diabetes mellitus.  Numerous animal models 
mimicking each of these diseases exist, and the additive effect of each or any of these 
factors on the hindlimb ischaemia model has been reported in the literature [386-392].   
In diabetic models of hindlimb ischaemia, there is impairment in ischaemia-induced 
vascular remodelling as well as dysregulation of the inflammatory response.  The 
aberrations in vascular remodelling affect both arteriogenesis and angiogenesis due to 
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inhibition of mobilisation and integration of bone marrow progenitor cells into the 
endothelium and impaired signalling of VEGF ligand, respectively [387, 393, 394]. 
A number of methods exist for producing dyslipidaemic and atherosclerotic animals, 
including changing their feed to a high-fat diet, but more commonly an ApoE-
knockout or a low-density lipoprotein (LDL) receptor knockout mice can be used. 
These animals get characteristic atherosclerotic lesions in major vessels, including the 
aorta, carotid, femoral and popliteal arteries.  Literature suggests that the 
dyslipidaemic state affects inflammatory responses [388]. 
Animal models have constant and undeniable utility and important roles in helping to 
answer clinical questions, as well as identifying potentially efficacious future 
therapies.  However, no model is capable of exactly replicating the highly evolved 
and multifaceted disease of interest, and often a scenario will dictate the optimum 
permutations of factors to use in order to get the most representative disease model.  
Although not ideal for standardising results and assessments, such is the nature of 
human disease pathology. 
6.6 Summary 
The changes seen in human skeletal muscle of patients with CLI can be reproduced 
using the murine model of hindlimb ischaemia.  The model therefore provides a 
suitable platform to assess the potential therapeutic effects of novel agents.  
Administration of EPO or ARA-290 resulted in improved functional, histological and 
perfusion outcomes following induction of hindlimb ischaemia. 
  
 194 
CHAPTER 7  
General discussion and Future studies 
7.1 General discussion 
PAD is a syndrome with multiple aetiologies.  This complex interaction between 
several disease pathologies makes the management of individuals with PAD equally 
as complex.  Much of the current clinical research for patients with “no option” CLI 
has focused on therapeutic angiogenesis – in an attempt to stimulate the development 
of new blood vessels, and replenish blood flow, and therefore oxygen and key 
nutrients to ischaemic tissue.  Though this represents a promising novel treatment in 
individuals with CLI, therapeutic angiogenesis has been of interest to investigators 
since the 1970’s, and clinical breakthroughs have remained somewhat elusive, with 
limited success in phase II and III clinical trials [372].  In addition, there are many 
facets of CLI that therapeutic angiogenesis does not directly address, and therefore 
there remains a large scope to develop novel adjunctive therapies.  
In the treatment of CLI patients, several recent studies have identified that despite 
successful revascularisation patients do not always report a return to their pre-morbid 
functionality.  In these cases, it hints at the possibility of additional pathologies 
affecting CLI individuals, preventing recovery.  Study of CLI muscle has indicated a 
number of changes that occur in the skeletal muscle of CLI patients, which do not 
appear reversible despite successful revascularisation [88, 90, 118, 124].  Many of the 
described changes centre on the largest organ supported by the network of arteries in 
the lower limb – muscle. 
This thesis has investigated EPO and the EPO-derivative, ARA-290, in order to 
determine their potential muscle-protective properties.   
7.1.1 Tissue-protective receptor in CLI 
The initial aim of the study was to identify the presence of the tissue-protective 
receptor in human skeletal muscle, especially CLI sample muscle, as the clinical 
group of interest.  This was essential due to recent publications suggesting incorrect 
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localisation of the EPOR to a number of tissues [292, 395-397].  In addition, 
expression of the !cR in human skeletal muscle has not been previously described.   
Multiple EPOR and !cR antibodies were initially assessed for their ability to 
accurately detect the presence of both receptors in human whole-muscle 
homogenates.  Following the demonstration of EPOR and !cR protein expression by 
Western blot analysis in human muscle samples, RNA expression was also 
demonstrated using qRT-PCR techniques.  However, having demonstrated the 
presence of the receptors individually, determining the nature of their physical 
interaction was achieved using a combination of techniques.  This included co-
localisation techniques by immunohistochemistry and immunofluorescence, as well 
as protein-protein interaction using co-immunoprecipitation.  Co-localisation of the 
EPOR and !cR as well as positive co-immunoprecipitation results suggests these two 
receptors likely form heteroreceptors in human skeletal muscle. 
Assessment of Western blot and qRT-PCR analysis established an increase in 
expression of both EPOR and !cR in CLI muscle.  The underlying reason for this 
observed increase in expression of both receptors is likely due to their location within 
an ischaemic niche.  Previous work has described an increase in EPOR expression in 
skeletal muscle following intensive exercise-induced ischaemia in healthy 
individuals, although this is an acute ischaemic period [169].  In addition, increase in 
EPOR expression has also been described in other organs following ischaemic injury 
including the brain, nervous system, eye and heart [300, 301, 398-400]. 
A limitation of this study was the need to use antibodies previously suggested to be 
non-specific (anti-EPOR (C-20) from Santa Cruz biotechnology), due to the range of 
applications required to assess the presence and interactions of the EPOR and !cR in 
human skeletal muscle.  However, careful study of the literature and initial 
comparison between multiple EPOR antibodies provided evidence of satisfactory 
specificity of the C-20 EPOR antibody.  Its use in co-immunoprecipitation was 
further validated by subsequent Western blot analysis using a second EPOR antibody 
to demonstrate the presence of the pull-down product. 
The use of EPO in humans is reserved for the treatment of anaemia of chronic 
disease.  In addition, the tissue-protective capacity of EPO has been recognised for 
some time, but therapeutic side-effects of EPO’s native role have often precluded its 
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use in a clinical setting.  Investigation into potential arenas for EPO tissue-protective 
settings have included cerebral ischaemia (stroke), cardiac and renal ischaemia.  Due 
to haematopoietic side-effects, the search for EPO-derivatives which retain 
cytoprotective properties, without causing haematopoiesis, has seen great advances, 
and in addition to developing EPO-derivatives, has identified potential receptors and 
signalling pathways utilised by tissue-protective EPO-derivatives to mediate their 
beneficial effects.  Identifying the presence of the tissue-protective receptor in human 
skeletal muscle is an important step towards demonstrating the future potential use of 
EPO-derivatives in the management of CLI patients.   
In order to study the presence of the tissue-protective receptor in human tissue, and 
isolate primary skeletal muscle cells for in vitro analysis of the effect of simulated 
ischaemia, patients undergoing amputations and CABG were recruited.  Access to the 
lower limb was gained through surgical exposure.  The surgical procedure therefore 
dictated the exact site and timing of sample collections.  In samples collected from 
patients undergoing lower limb amputation, there is a longer acute ischaemic time.  
This is the time between the vessels (usually the femoral or popliteal artery and vein) 
to the lower limb extremities being clamped and the lower limb removed, and the 
remnant passed for research – between 5 and 20 minutes.  In contrast, during harvest 
of the saphenous vein for CABG all branches are ligated, but arterial supply to the 
muscle is not disrupted.  Once the saphenous vein has been removed, a much shorter 
period of time elapses between muscle biopsy harvest and processing for research – 
typically less than 5 minutes.  An assumption was therefore made that the second, 
acute, ischaemic period when collecting samples from CLI patients would not be 
significant, compared with the chronic ischaemia in the limb.  Due to natural 
variation in muscle fibre composition within different muscle groups, a standardised 
technique was employed when collecting biopsies from CLI or control patients.  
Biopsies were always collected from the deep belly of the gastrocnemius muscle in 
order to reduce the confounding effect of natural fibre composition. 
An alternative source of control muscle is the proximal muscles in CLI patients.   
However, as mentioned already, variations occur in fibre composition depending on 
location, making direct comparison more challenging.  In addition, proximal muscle 
from CLI patients, which may still be clinically viable is unlikely to be entirely 
normal due to the systemic effect of pathological changes in the distal muscle, such 
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as the release of endogenous ligands affecting the proximal muscles.  Obtaining 
muscle biopsies from control patients without objectively proven PAD provided a 
more reliable source of ‘normal’ control tissue. 
7.1.2 In vitro assessment of EPO and ARA-290 cytoprotective function 
In vitro assessment of the tissue-protective capacity of EPO and ARA-290 was made 
possible through a previously described in vitro simulated ischaemia C2C12 skeletal 
muscle model [238].  Pre-treatment of C2C12 myotubes with EPO or ARA-290 
demonstrated a distinct ability of both to reduce ischaemia-induced apoptosis of 
myotubes.  Importantly, the functionality of phosphorylated Akt in mediating 
cytoprotection was also identified.  In addition, inhibition of potential signalling 
molecules involved in cytoprotection, JAK2/STAT3, PI3k/Akt and NF#B 
demonstrated a dampening effect of EPO or ARA-290 mediated reduction of 
apoptosis.  Whilst these molecules had quite severe effect upon EPO and ARA-290 
cytoprotective ability it is likely there are many more potential signalling cascades 
that will need to be interrogated to fully appreciate the complex tissue-protective 
pathways utilised by both agents, and also to propagate further development of tissue-
protective therapies.  Based on observations in the literature of signalling pathways 
required for EPO-mediated red blood cell survival, it is likely that following JAK2 
phosphorylation STAT 1 and 5, MAPK and protein kinase C may also be activated to 
promote tissue-protection.  The diversity of molecules regulated by STAT 1, 3 and 5, 
as well as the cross-talk between MAPK, PI3k/Akt and NF#B will likely be 
investigated in the future to assess their contribution to EPO and ARA-290 mediated 
cytoprotection.   
Besides the effect of EPO and ARA-290 on rescuing myotubes from ischaemia-
induced apoptosis, both had positive effects on C2C12 myoblasts and ischaemia-
induced aberrations in function.  These effects included improving C2C12 myoblast 
migration, proliferation and apoptosis.  These observations are supported by other 
studies that have noted similar functional benefit in alternative cell types, as well as 
myoblasts, following administration of EPO [172, 401-404]. 
Following the observation of promising results in the C2C12 myoblast and myotubes 
model of skeletal muscle, this thesis attempted to produce more clinically relevant 
results by assessing the utility of EPO and ARA-290 on skeletal myoblasts isolated 
 198 
from our disease group of interest.  As with all disease entities, usually there are 
several cellular attributes that, in becoming abnormal, lead to the disease state.  In 
order to compare therefore, myoblasts were also isolated from control donors who did 
not demonstrate arterial pathology of the lower limbs. 
Primary isolated human myoblasts and myotubes yielded a suitable model of skeletal 
muscle, showing characteristic features when subjected to simulated ischaemia, such 
as differentiation of myoblasts, as evidenced by increased expression of myogenin, 
and upregulation of the hypoxia responsive protein HIF-1".  Both CLI and control 
myotubes demonstrated these features.  However, observation of their behaviour in 
culture and during simulated ischaemia provided novel insights into potential 
functional differences between CLI and control myoblasts and myotubes. 
7.1.3 Functional differences between CLI and control myoblasts 
Myoblasts from patients with CLI demonstrated enhanced proliferative activity 
compared with myoblasts from control individuals.  However, myoblasts from CLI 
patients also demonstrated suppressed migratory activity, and reduced ability to 
contract collagen gel lattices in vitro.  In conjunction, these results identify cellular 
mechanisms that are differentially affected as a result of chronic exposure to 
ischaemia. 
The increased proliferative activity of myoblasts from CLI patients in both normoxia 
and simulated ischaemia is likely due to the increased requirement of muscle repair 
and regeneration in CLI patients due to the loss of muscle tissue under chronically 
hypoxic conditions.  In addition, patients with CLI often have concomitant infection 
in the lower limb extremities, and inflammation and infection, through TNF-", IFN-( 
and downstream effects on IGF-1 are known to cause an increase in myofibre 
regeneration.  This was also evident when human skeletal muscle was probed for the 
expression of myogenic precursors.  There was significantly increased expression of 
Pax7 on Western blot and immunohistochemical examination.  Although the process 
of myogenic repair and regeneration in CLI is incompletely understood the results 
assessing prevalence of myogenic precursors yields promising results that the 
underlying defect is not attributable to a dysfunction in proliferative potential of 
satellite cells or myoblasts. 
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The impaired migratory and contractile activity of myoblasts from patients with CLI 
may provide some insight into the functional impairment often described by CLI 
patients, even after successful revascularisation.  These findings suggest that 
underlying alterations in cellular apparatus responsible for myofibre contraction and 
migration occur when muscle is subjected to chronic periods of ischaemia.  Even 
after isolation of myoblasts, and their prolonged culture under normoxic conditions, 
those alterations, are not amenable to improvement.  Interestingly, control myoblasts 
subjected to simulated ischaemia maintained superior migratory and contractile 
ability compared to CLI myoblasts, although ischaemia caused slightly diminished 
migratory potential. 
Differences observed between CLI and control myoblasts and their response to 
simulated ischaemia highlights the key role ischaemia plays in inducing lasting 
pathology.  Understanding the cellular mechanisms that govern muscle regeneration 
during and after ischaemia will improve treatment alternatives for those individuals 
who are unsuitable for revascularisation, and help those who do not benefit 
functionally after successful revascularisation. 
The effect of EPO and ARA-290 pre-treatment on human myoblasts and myotubes 
demonstrated similar findings to those observed in C2C12 myoblasts and myotubes.  
EPO and ARA-290 were able to reduce ischaemia-induced apoptosis in both CLI and 
control myotubes.  Inactivation of JAK2/STAT3, PI3k/Akt and NF#B signalling 
molecules demonstrated their key roles in mediating the beneficial effects of EPO and 
ARA-290 treatment against apoptosis, as well as release of the inflammatory cytokine 
IL-6.  CLI and control myotubes subjected to simulated ischaemia demonstrated a 
significant release of IL-6 into the medium, compared to normoxic controls, as 
assessed by ELISA methods.  The response of CLI and control myotubes to EPO and 
ARA-290 treatment however was less uniform, and is likely due to subtle differences 
in the susceptibility of myotubes to EPO and ARA-290 effect, as well as the initial 
injurious ischaemic period.  Although only small numbers were assessed in each 
disease group, there was no correlation between disease versus control, gender or 
other co-morbidities and effect of EPO or ARA-290 treatment on IL-6 release.  
Absolute concentration of IL-6 secretion was also variable, and it is likely that all of 
these observations are due to the natural heterogeneity between individuals. 
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The combination of observations, including the ability of EPO and ARA-290 to 
reduce apoptosis and inflammatory cytokine secretion add to the understanding of 
their mechanisms of action.  It is important to remember however, that muscle 
damage as a result of ischaemia is a culmination of myofibre injury, oxidative stress 
and inflammation.  It is therefore important that therapeutic strategies are developed 
that aim to treat more than one aspect of the disease pathology and support the 
regenerative potential of myofibres. 
7.1.4 In vivo hindlimb ischaemia model 
Having observed the potential of EPO and ARA-290 to improve skeletal myoblast 
and myotube function following ischaemia-induced dysfunction, it was important to 
assess their role in a pre-clinical assay, and as such, the hindlimb ischaemia model 
was selected.  Preliminary studies with small numbers of animals were performed to 
identify a suitable technique that would provide a significant degree of muscle 
damage, akin to changes observed in CLI muscle biopsies.  This involved assessing 
the effect of age, strain and surgical technique on variation in the resultant severity 
and period of hindlimb ischaemia.  
The hindlimb ischaemia model identified the ability of EPO and ARA-290 to 
improve functional outcomes, perfusion and proliferation of muscle fibres.   In 
animals treated with EPO, this was likely due to the angiogenic potential of EPO, as 
evidenced by the increased capillary:fibre ratio.  ARA-290 did not demonstrate an 
increase in C:F ratio, and therefore the underlying mechanism for observed 
improvements needs to be further interrogated in order to validate the potential use of 
ARA-290 for use in human subjects.  However, considering the safety of ARA-290 
prescription in both healthy individuals and those with sarcoidosis has already been 
reported [252], confirming ARA-290 mechanism of therapeutic benefit in a setting of 
ischaemic injury will endorse its clinical application for patients with CLI.   
The majority of pre-clinical models for CLI induce hindlimb ischaemia by ligation of 
lower limb vessels.  It is important to realise however, that there are several 
limitations to the use of this model, and therefore, care needs to be taken in making 
direct comparison with human clinical benefit.  Most importantly, the hindlimb 
ischaemia model does not adequately take into account the natural progression of 
PAD, and the complex interaction between multiple co-morbidities.  In patients with 
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PAD, atherosclerotic lesions tend to develop over time, in multiple locations, giving 
rise to diffuse lesions, and a more insidious onset of ischaemia, with greater 
opportunity for the limb to develop a collateral circulation.  Most animal models of 
CLI fail to mimic these features.  In addition all surgical ligation models of hindlimb 
ischaemia represent more of an acute ischaemic insult due to the sudden loss of 
arterial supply to the limb.  This partly explains the extensive inflammatory response 
observed.  Other techniques exist to mimic CLI in hindlimb ischaemia model.  This 
includes slow occlusion of the vessel with constrictors or balloon dilation, which is 
less reproducible, with high-costs associated with the constrictor and the prolonged 
period of experimental intervention.  Other techniques include double ligation of the 
femoral artery twice, separated by approximately 12 weeks to produce a more chronic 
hindlimb ischaemia.  Assessment of muscle injury is not widely available in these 
alternative models however, and would therefore need to be assessed in greater detail 
to explore their relevance as a model to mimic the muscle pathology observed in 
human CLI disease.  PAD patients also tend to have multiple co-morbidities, which 
influence disease state and progression.  Although transgenic strains for the majority 
of co-morbidities found in PAD patients exists, little work has been done assessing 
the hindlimb ischaemia model with transgenic animals to assess the resultant effect 
on muscle. 
Laser Doppler measurement of ‘perfusion’ is a reliable and easily reproducible 
technique for assessment of recovery of ischaemia, and is often complemented with 
histological analysis of C:F ratio.  However, LDPI assesses blood flux rather than 
true tissue perfusion, and relies on the standardisation of ambient conditions, 
including the temperature of the animal and surroundings.  
In addition, much information can be accrued by observing other aspects in the field 
of muscle biology.  The investigation of muscle degeneration and weakness, both age 
or disease related is likely to highlight many potential dysregulated pathways 
applicable to muscle dysfunction in CLI.  An example of this is the IGF-1 axis, which 
has for sometime been known to play a role in cancer cachexia and muscle wasting, 
as well as driving muscle regeneration [405, 406].  Recently, components of the IGF 
axis have been associated with both the presence and severity of PAD, identifying it 
to have an underlying pathophysiological role [407]. 
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In summary, the work contained in this thesis has attempted to assess the protective 
functions of EPO and ARA-290 for the application in CLI.  In order to do this, human 
myoblasts were isolated from both our disease group of interest and control donors.  
Comparison of their behaviour and function identified significant differences between 
them.  This study also sought to identify a clinically relevant hindlimb ischaemia 
model which mimicked features of muscle pathology found in human patients in 
order to test potential tissue-protective hypotheses and therapies.  Cumulatively, this 
work has been able to provide evidence of the tissue-protective capabilities of EPO 
and ARA-290 in vitro and in vivo in settings of ischaemic injury. 
7.2 Future studies 
The potential use of ARA-290 in mediating tissue protection in a setting of ischaemic 
injury is an exciting observation of this work.  Further studies need to be conducted to 
address some of the limitations of this thesis. 
Though a tissue protective receptor has been suggested, there is yet to be confirmed 
analysis of ARA-290 binding to the suggested tissue-protective receptor.  In addition, 
the possibility of alternative receptors needs to be explored, in conjunction with 
identification of additional signalling cascades.  This work has demonstrated the 
ability of EPO and ARA-290 to provide numerous beneficial effects against 
ischaemia, including apoptosis, migration and proliferation.   It is therefore likely that 
there are multiple signalling cascades at interplay, and delineating those pathways 
may provide useful insight into aberrations in the CLI disease state. 
The functional differences in myoblasts isolated from CLI and control patients have 
not previously been described.  Although they provide useful insight into the 
responses of myoblasts to chronic ischaemia, potential mechanisms underlying the 
observed differences need further interrogation, for the purposes of improving 
understanding of the deficit in muscle function often described by individuals with 
CLI.  In addition, manipulation of the differences in CLI myoblast behaviour may 
provide a cornerstone for the future management of individuals with CLI.  Whilst 
isolated myoblasts were able to survive, proliferate and differentiate ex vivo, further 
analysis will need to be conducted to evaluate in detail the observations made in this 
work with regard to functional differences in CLI myoblast function.  It is important 
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to understand whether these observed difference were due to their ‘pre-conditioning’ 
in an ischaemic niche, or whether the exposure to chronic ischaemia had a resultant 
effect on intrinsic myoblast function, giving rise to the differences in myoblast 
function, and ultimately the muscle symptoms described in PAD patients.  It is clear 
that CLI myoblasts, in their native in vivo conditions are incapable of physiologically 
normal muscle repair and regeneration.  However, it is not clear whether the 
underlying deficit is due to the hypoxic conditions or the myoblast itself. 
Elucidating the trail that leads to muscle injury and inadequate repair following 
chronic exposure to ischaemia is essential to combat the musculopathy observed in 
CLI patients.  Recent attempts at cell-based therapies to transplant myogenic stem 
cells have yielded promising results.  However, if an ischaemic niche is responsible 
for alterations in myoblast function, the benefit from introduction of new myogenic 
stem cells is likely to be short-lived.  Dual introduction of myogenic and 
haematopoietic stem cells to improve muscle function and perfusion may ultimately 
be required, with simultaneous revascularisation to alleviate the local ischaemic niche 
sufficiently for the newly introduced stem cells to become integrated. 
Though this study has examined the differences in human myoblasts between CLI 
and control, future work could focus on the main muscle progenitor – satellite cells.  
Observations made in this work have suggested that the satellite cell population 
becomes activated in CLI muscle, but their regenerative and reparative function and 
ability to differentiate into valuable myoblasts and myotubes is uncertain. 
The hindlimb ischaemia model also demonstrated the promising ability of ARA-290 
to ameliorate ischaemia-induced injury to muscles of the hindlimb.  However, though 
the hindlimb ischaemia model is able to recapitulate the effects of ischaemia, it does 
not take into account the co-morbidities commonly present in patients with CLI, such 
as diabetes, hypertension and hyperlipidaemia, which can affect not only muscle 
regeneration and repair [341, 408-410], but also other factors, such as release of 
inflammatory cytokines and dampening of endothelial cell proliferation that may 
hinder improvements in CLI patients [411-413].  The use of transgenic and knockout 
animals allows investigators to address those risk factors known to be important in 
human disease.  This may aid in the identification of novel therapies that will be 
equally as efficacious at the bedside as they are at the bench.  In addition to 
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longitudinal assessment of perfusion using LDPI, many novel imaging techniques are 
in constant development, and their resolution and use in small animals is 
continuously improving.  Imaging modalities such as micro and photoacoustic CT 
and dynamic contrast-enhanced MRI would allow evaluation of collateral formation 
in the ischaemic hindlimb.  In addition, evaluating mitochondrial activity, which 
often becomes pathological following ischaemic injury could, indirectly assess 
muscle viability and function as a result of hindlimb ischaemia and any subsequent 
intervention.  
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Appendix 
A 1: Patient information and consent form 
Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON  
Address for Correspondence:  
University Department of Surgery 
Royal Free Campus 
The Royal Free Hospital  
Pond Street, 
London NW3 2QG 
Telephone: 020 77940500 
Facsimile: 02074726711 
PATIENT INFORMATION SHEET  
Study Title: A study of muscle injury in peripheral vascular disease 
You are invited to participate in a research study. This information sheet explains why 
we are conducting this study and how it is being done. Please take some time to read the 
information carefully and to decide whether you would like to take part or not. Please 
discuss it with your family and friends as you wish and ask us if you have any questions.  
What is the purpose of this study?  
The aim of this project is to study some aspects of peripheral vascular disease which are 
not well understood. Peripheral vascular disease is a common condition where the blood 
supply to the legs is impaired and the leg muscles are damaged. At present, treatment 
includes bypass surgery to improve the circulation. We aim to study the mechanisms that 
are involved in causing muscle damage secondary to peripheral vascular disease. A 
better understanding of these mechanisms may improve treatment for this disease in the 
future.  
Why have I been chosen?  
You have been invited to take part either because you suffer from peripheral vascular 
disease or because the operation you will be undergoing is similar in many ways to that 
done for peripheral vascular disease. This allows us to collect suitable samples for 
analyses and make appropriate comparisons.  
Do I have to take part?  
You do not have to take part in this study if you do not want to. If you decide to take 
part you may withdraw at any time without giving a reason. Your decision to take part 
or not will not affect your care in any way.  
What will happen to me if I take part?  
Up to 2 calf muscle samples, each the size of a small pea, will be taken during the 
operation. These are for the study and not part of the treatment. None of these should 
cause any ill effect or additional discomfort and will not affect your recovery from 
your operation.  
What do I have to do?  
You do not have to do anything more than you need to for your operation.  
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Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON  
Address for Correspondence:  
University Department of Surgery 
Royal Free Campus 
The Royal Free Hospital  
Pond Street, 
London NW3 2QG 
Telephone: 020 77940500 
Facsimile: 02074726711 
Date: 25 Sept 2008  
What are the possible disadvantages and risks in taking part?  
You will have small samples of your calf muscle taken. However, these will be done during 
the operation when you are asleep and so will not cause any discomfort. Your treatment and 
recovery will not be affected.  
What are the possible benefits of taking part?  
This study will help us improve treatment for this condition in the future. However, at this 
stage, there will be no immediate benefits to you.  
What if something goes wrong?  
This study does not involve any extra treatment or any high-risk procedures so nothing is 
likely to go wrong. However, if you wish to complain about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms may be available to you.  
Will taking part in this study be kept confidential?  
Any information collected about you during the course of the research will be kept strictly 
confidential.  
What happens to the results of the research study?  
Results from this study will be published in a medical journal in approximately a year's 
time. However you will not be identified in any report or publication. If you wish to know 
the outcome of the study, you can do so by contacting us.  
Who is organising and funding the research?  
This study is organised and funded by the Vascular Unit of the Department of Surgery.  
Who has reviewed the study?  
The Research Ethics Committee of the Royal Free Hospital has reviewed this study.  
If you have any questions or queries at any stage, please contact: 
  
Miss Janice Tsui 
University Department of Surgery 
Royal Free Hospital 
Pond Street 
London NW3 2QG 
Tel: 020-7794-0500 Ext 33938  
You will be given a copy of the information sheet and a signed consent form to 
keep. Thank you very much for taking part in this study.  
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Royal Free and University College Medical School 
UNIVERSITY COLLEGE LONDON  
Address for Correspondence:  
University Department of Surgery 
Royal Free Campus 
The Royal Free Hospital  
Pond Street, 
London NW3 2QG 
Telephone: 020 77940500 
Facsimile: 02074726711 
 
 
 
Consent Form 
 
Project Title: Study of Muscle Injury in Peripheral Vascular Disease 
 
Researcher: Miss Janice Tsui & _______________________ 
 
1. I confirm that I have read and understood the information sheet provided for 
the above study and have had the opportunity to ask questions. 
 
 ! 
2. I confirm that I have had sufficient time to consider whether or not I want to 
be included with the study. 
 
 ! 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reasons, without my medical care 
or legal rights being affected. 
 
 ! 
4. I understand that sections of my medical notes may be looked at by 
responsible individuals from NHS or from regulatory authorities where it is 
relevant to my taking part in the research. I understand that samples of my 
muscle may be kept up to 6 months for other studies. 
 
 ! 
5. I agree to take part in the above study. 
 
 
 
 ! 
   
Name of patient 
 
 
 
Date Signature 
   
Name of person taking 
consent 
Date Signature 
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A 2: Awards, presentations and publications arising from 
this work 
Awards 
1. JSPS-British Council Summer fellowship – Japan, Summer 2012 
2. Richard Wood Memorial prize, Vascular Society UK Annual General Meeting – 
Manchester, UK, November 2013 
Presentations 
1. Tissue-protective effects of EPO and EPO-derivative in isolated human 
myoblasts. 
Society of Academic and Research Surgery Annual Conference 2012 (oral 
presentation) 
2. Role of PI3k/Akt Pathway in the Cytoprotective Effects of Erythropoietin and 
Derivatives in Ischemic Human Myotubes 
Society for Vascular Surgery Annual Conference 2012 (poster presentation) 
3. Differential Proliferative and Migratory Activity of Human Myoblasts Isolated 
from CLI and Control Patients 
Society for Vascular Surgery Annual Conference 2013 (poster presentation) 
4. Signalling Pathways Involved in the Tissue-protective Effects of Erythropoietin 
and Erythropoietin-derivatives in Ischemic Human Myotubes 
Society for Vascular Surgery Annual Conference 2013 (poster presentation) 
5. Enhanced proliferative and migratory differences in human myoblasts isolated 
from CLI and control patients 
European Society for Vascular Surgery Spring Meeting 2013 (oral presentation) 
6. Tissue-protective effects of an erythropoietin-derivative in a model of hindlimb 
ischaemia  
Vascular Society UK Annual General Meeting 2013 (oral presentation) 
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Publications and published abstracts 
1. Potential of Novel EPO Derivatives in Limb Ischemia.  
Cardiology research and practice, 2012. 2012: p. 213785. Joshi D, Tsui J, Yu R, 
Shiwen X, Selvakumar S, Abraham D. J. Baker, D. M. 
2. Tissue protective effects of EPO and EPO-derivative in isolated human 
myoblasts (2012) 
British Journal of Surgery, 99, 7-123 
3. Role of PI3k/Akt Pathway in the Cytoprotective Effects of Erythropoietin and 
Derivatives in Ischemic Human Myotubes (2012) 
Journal of Vascular Surgery, 55, 76-76 
4. Differential Proliferative and Migratory Activity of Human Myoblasts Isolated 
from CLI and Control Patients (2013) 
Journal of Vascular Surgery, 57, 81S – 82S 
5. Signalling Pathways Involved in the Tissue-protective Effects of Erythropoietin 
and Erythropoietin-derivatives in Ischemic Human Myotubes (2013) 
Journal of Vascular Surgery, 57, 78S – 78S 
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